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CHAPTER 1 BACKGROUND 
1.1 SCIENCE OF PAIN  
Pain is a sensation that people have long feared, as it typically signals that something is wrong. 
However, this perception of pain also forces us to seek medical care, thereby ironically protecting 
us.  In many ways, this natural phenomenon was man's earliest warning system. Pain is a subjective 
measure, yet no equipment or device is able measure it. Individuals experience pain differently; 
some describe it as the worst thing they have ever experienced in their life, requiring analgesia for 
its relief, while others can tolerate it and even manage it using non-pharmacological methods such 
as meditation.  
For many years, scientists have studied this normal physiological reaction that informs us of 
underlying pathology, in the hope of preventing or controlling pain. Pain occurs when our body 
and the nervous system alert our brain about actual or potential harm to the tissue. Musculoskeletal 
pain is one of the common causes of pain. It may involve any structure in the body, and for this 
reason, it can have a varied presentation and affect individual's lives in different ways.   
Painful stimuli activate special receptors in the tissues called nociceptors, which then transduce 
this information into an electrical impulse carried by axons into the central nervous system (CNS).  
Nociceptors are the free nerve endings of nerve fibers. There are two main types: A-delta fibers, 
which are myelinated, and C fibers, which are unmyelinated. The types of pain and the speed at 
which pain is conducted along these fibers differ. These characteristics are summarized in Table 





Fiber type  Að- fibers (myelinated)  C fibers (unmyelinated)  
Fiber diameter 2-5 µm < 2 µm 
Conducting velocity 5-15 m/second  0.5-2 m/second  
Distribution Body surface, muscle, joint Most tissue  
Pain sensation Rapid, pricking, well-localized  Slow, diffuse, dull, aching  
Position of synapses within the 
dorsal horn of the spinal cord 
Laminae I and V  Laminae II (substantia gelatinosa)  
Table 1. Type of fibers. Extracted from Charlotte E Steeds et al.2008 (1) 
There are two types of nociceptors, high-threshold mechanoreceptors (HTM) and polymodal 
nociceptors (PMN), each of which respond to a different painful stimulus. HTM responds to a 
mechanical stimulus whereas PMN responds to various endogenous inflammatory mediators that 
immerse, activate and sensitize the nociceptors following different pathways. For instance, 
adenosine triphosphate (ATP) and protons (H+) bind to receptor molecules found in the membrane 
of the nerve ending, thereby activating them; ATP activates nociceptors by binding to purinoceptor 
3 (P2X3) receptor molecule while H+ bind to both transient receptor potential vanilloid 1 (TRPV1) 
and acid-sensing ion channels (ASICs) (1, 2).  
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Chronic pain occurs due to an influx of nervous impulses from muscle nociceptors into the spinal 
cord, which increases the excitability of dorsal horn neurons to a greater extent than the input from 
cutaneous nociceptors. This spread of excitation is due, in part, to an overexcitability of sensory 
neurons of the spinal cord. The overexcitability of nociceptor neurons in the CNS is considered 
the leading cause of allodynia and hyperalgesia in patients with chronic muscle pain. Patients with 
chronic muscle pain are challenging to treat because the CNS's functional and structural changes 
require time to regress (2, 3). It is important to note that pain arising in muscles is more likely to 
cause referred pain patterns and be confused with dermatomal pain, which will affect diagnosis 
and treatment. Referred pain is pain that is not only felt at the site of origin but at another spot, 
which is sometimes distant from the site of pain (1-4). Patients will often complain of pain at one 
area although the origin of the pain is somewhere else; such is the case of patients who present 
with plantar heel pain (PHP), whereby treatment of the gastrocnemius, tibialis posterior, and other 
muscles leads to pain relief, according to Janet Travell (5).  To quote one of the pioneers of 









1.2 EPIDEMIOLOGY  
The incidence and prevalence of PHP are uncertain, although it is the most common type of pain 
affecting the lower extremity treated by health care providers (7-9). However, it is estimated that 
10% of the population may suffer from this condition (7, 10). Although there are few high-quality 
epidemiological studies available, a study conducted in the United States between 1995 and 2000 
found that consultations for PHP equaled approximately one million visits to physicians per year 
(11). In the United States, PHP affects about 2 million Americans each year, and as much as 10% 
of the population will be affected throughout their lifetime (7, 8, 12). It is estimated that 7% of 
people aged over 65 years in the US report tenderness at the heel site (13).   
1.3 PLANTAR HEEL PAIN DIAGNOSIS 
Despite PHP being a common cause of pain and affecting a person's activities of daily living and 
thus the quality of life, muscles are poorly understood and often neglected as a potential source of 
pain. This situation translates to a limited number of treatment modalities available to patients. 
Suffering PHP can substantially affect a patient's quality of life (7, 8, 12-16). PHP is an umbrella 
term used to describe several clinical conditions with overlapping features (17, 18) and different 
diagnostic labels. One example is "plantar fasciitis," although there is a move away from this term 
towards "plantar fasciosis," which means degeneration of the plantar fascia, and "plantar 
fasciopathy," which simply means pathology of the plantar fascia. Current imaging studies 
demonstrate that the condition spreads beyond the fascia or the heel bone and surrounding tissue, 
therefore the more general term, PHP, is considered more appropriate (9, 19). 
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PHP causes tenderness and pain in the foot, sometimes extending to the medial arch of the foot (9) 
and in many cases, the only part of the foot that is affected is the heel. This condition affects both 
athletic and sedentary people and does not seem to be influenced by gender. The diagnosis is 
mainly clinical, as there are no definitive confirmatory studies available, and as such, it is based 
on the patient's history and physical examination, emphasizing pain during the first steps in the 
morning or after prolonged rest and pain during prolonged standing or walking (7, 12, 16). The 
proper identification of the cause of the pain can be difficult as it is often multifactorial (14). The 
similarities between the overlapping conditions and the lack of definitive investigations pose a 
diagnostic challenge. 
There are some differences between the different diagnosed conditions, and it is crucial to be able 
to distinguish one from the other as it will have an impact on treatment: 
- Plantar fasciitis (PF) and heel spur (HS) 
Two conditions that are often confused and used interchangeably are PF and HS.  
Some clinicians believe they are the same condition, while others believe they are a continuation 
of one another with a cause-and-effect relationship (9, 13, 19-22).  PF is one of the most common 
causes of foot pain for which patients seek medical attention.  One study has found that 
approximately 10% of the United States population visit the health system for this pain (12). PF is 
considered a degenerative inflammation of the plantar fascia, resulting from repeated trauma or 
microtrauma on the calcaneal bone (22). Some authors consider PF to be multifactorial; however, 
its etiology remains widely disputed. Some suggest that long-distance running causes the 
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inflammatory process, leading to fibrosis or degeneration, while others suggest the pain may be 
secondary to periosteal inflammation of the calcaneum. (22). Another condition which also 
contributes to heel pain is the HS. The plantar calcaneal spur (PCS) is a boney growth formed at 
the calcaneal tuberosity. It is caused by prolonged stress on the plantar fascia ligament and muscles 
of the foot, which cause the heel spur to appear at the attachment of the heel bone. However, some 
researchers believe the HS may not be the source of heel pain (20, 23). The PCS is typically 
described as bony outgrowths arising just anterior to the medial process of the calcaneal tuberosity. 
A review conducted by Kirkpatrick et al. noted that some authors define as a projection larger than 
1 or 2 mm while others use microscopy or subjective assessments (23). According to ethnicity, the 
prevalence of the PCS varies with reported rates of 11% in India, 13% in Ireland, 15% in 
Zimbabwe, 17% in Thailand, 17% in Europe, and 21% in America. This rate increases with age, 
rising to 55% in those over 62 to 59-78% in those with current or previous heel pain and up to 81% 
in patients with osteoarthritis (23). According to the study by Ahmed et al. (20), the plantar heel 
spur is classified based on shape and size in patients with PF, with no significant correlation 
between the differences of the size or shape of the spur and patients’ symptoms.  
- Myofascial Pain Syndrome (MPS) 
The most common pain in the musculoskeletal system is MPS. The  conventional definition of 
MPS is a regional pain syndrome, originating from hyperirritable spots located within the taut 
bands of skeletal muscles, known as myofascial trigger points (MTrPs) (24). MTrPs are palpable 
nodules of taut bands within the muscle fibers. When these nodules are mechanically stimulated, 
local or referred pain is aggravated. This pain can be induced with a visible local twitch response 
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(LTR) (25, 26). Muscle trigger points can be either latent (LTrPs) or active trigger points (ATrPs), 
each having its own set of characteristics. LTrPs are well-known for their clinical characteristics: 
local tenderness with or without referred pain, restricted range of motion (ROM), muscle 
weakness, muscle fatigue, alternating muscle activation patterns, and ability to induce muscles 
cramps (27). ATrPs have the same clinical characteristics, furthermore, they provoke spontaneous 
referred pain. ATrPs can contribute to significant regional pain and neuromuscular dysfunction, 
and they are the main generator of peripheral pain, generalized musculoskeletal pain disorders 
such as fibromyalgia (FA)  and whiplash (26, 27). LTrPs turn into an active trigger point when 
irritated.   
The etiology of MTrPs is not well understood to date. Knowledge of the potential factors is 
essential to clinically understand the development of these MTrPs and limit recurrence.  Several 
precipitating and perpetuating factors exist which involve MTrPs. There is general agreement that 
muscle trauma, whether direct or indirect, micro or macro trauma, overuse, repetitive low-level 
muscle contractions, maximal or submaximal concentric muscle contraction, muscle ischemia, 
muscle wasting can lead to their development. Also, non-muscular factors play a role in their 
development, such as anxiety, visceral pain, radiculopathy compression of the motor nerve, and 
climate-related factors (24, 28). According to the available evidence, the first step of trigger point 
formation is the development of contracted muscle fibers or a taut band, which may or may not be 
tender (29). The electrodiagnostic characteristic of a MTrP is the spontaneous electrical activity 
(SEA) or endplate noise, which is presented as a fast low-amplitude electrical activity (30). The 
electromyography studies available enable the identification of two types of independent electrical 
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potentials at MTrP sites; one of which is a low potential with an amplitude of 10µV to 80 µV, 
whereas the other finding is high potentials with an amplitude of approximately 100 µV to 600 µV 
with both normal and abnormal wave shapes (31). Evidence of increased frequency of low-voltage 
(50-100 microvolts) electrical activity was found at the point of maximum tenderness in the taut 
band of a human subject, localized to the neuromuscular junction of the endplate zone of the taut 
band. Also, an abnormally increased frequency of miniature endplate potentials has been observed 
in in vivo models and humans (32). The pathophysiology of the MTrPs appears principally located 
at the center of the muscles in its motor endplate zone, the zone where the motor nerve enters the 
muscle and divides into several branches with each of these having a terminal claw-like motor 
endplate embedded in the surface of a muscle fiber (24). The spontaneous electrical activity (SEA) 
is one of the characteristics of MTrPs, SEA originates from the dysfunctional extrafusal motor 
endplate potential (EPP), rather than the gamma motor units within the muscle spindle. The EPP, 
which is a local depolarization of the muscle fibers, spreads a short distance along the muscle 
fibers, with a decrement of approximately 50-75 percent per millimeter. Supposing the EPP 
exceeds a certain critical level, in this case, endplates spikes are initiated, which explains the 
clinical phenomenon of SEA associated with MTrPs, which is registered only at a localized spot 
in the muscle with an intramuscular needle (EMG) (26), leading to the assumption that the SEA is 
a combination of endplate noise and endplate spikes in action potentials generated by sufficient 
amount of released ACh. The perpetuating factor due to the excessive ACh release from the motor 
endplate combined with inhibition of acetylcholine esterase (AChE), an upregulation of nicotinic 
ACh receptors, leads to the hypothesis that sustained sarcomere contracture results in increased 
local metabolic demands and compression of capillary circulation, with reduced blood flow and 
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minimized source of adenosine triphosphate ATP. Therefore, muscle fibers become locked in a 
contracture without sufficient energy to return the Ca2+ to the sarcoplasmic reticulum to restore a 
polarized membrane potential. It is suggested that the extra leakage of Ach at the nerve ending 
triggers a failure in the motor endplate function.  The excitation of the ACh receptors within the 
postsynaptic membrane produces a continuous local depolarization and prompts the sarcoplasmic 
reticulum to release a large amount of calcium. There is an increased concentration of serotonin, 
histamine, bradykinin, and substance P in the surroundings of contracted nodules, which is related 
to local ischemia and sensitization of the afferent nerves. This results in MTrP-related pain and 
local sympathetic symptoms; the pathological changes induce a feeling of local cold 
(vasoconstriction), anxiety, and mental stress (31, 33). The local hypoxia elicits the release of 
neuro-reactive and metabolic substances by sensitizing peripheral nociceptors (29, 33). 
1.4 MISCELLANEOUS  
Plantar heel pain can be associated with systemic diseases such as autoimmune, infectious, or 
neurological diseases. A detailed medical history, as well as clinical examination, can guide us to 
the proper diagnosis.  Some of the most common causes are listed below.  
1.4.1 ACHILLES TENDINOPATHY  
This is a prevalent cause of disability. The inflammatory process within the Achilles tendon's 
tendinous insertion can be categorized and referred to as tenosynovitis, peritendinitis, paratenonitis 
(acute disease), tendinosis (chronic), and achillodynia. The acute phase is secondary to acute 
overexertion, blunt trauma, chronic overuse, and muscle (34). Tendon vascularity, gastrocnemius-
soleus dysfunction, age, sex, body weight and height, pes cavus, and instability of the ankle are 
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common factors for the rise of tendinopathy (35). Tendinosis is a degenerative condition of the 
Achilles tendon, characterized by thickening of the tendon (34) due to damage at a cellular level, 
which is supposedly caused by microtears within the connective tissues in the tendon.  
1.4.2 HAGLUND'S DEFORMITY (HEEL BUMP)  
Haglund's deformity, first described by Patrick Haglund in 1927, is known as retrocalcaneal 
exostosis or Mullholland deformity. Despite being a common clinical condition, it is poorly 
understood. On clinical examination, there is localized pain at the superior posterior aspect of the 
calcaneus, which is hypothesized to be related to shoe wear. The soft tissues near the Achilles 
tendon become irritated when the boney enlargement rubs against the shoes, often leading to 
painful bursitis (34, 36, 37). 
1.4.3 HEEL NEURITIS  
Heel neuritis results from compression of a branch of the lateral plantar nerve, which causes 
tingling, numbness, and pain in the heel area. It usually appears after a micro or macro trauma, a 
sprain, or sometimes due to a varicose (swollen) vein near the heel (34) 
1.4.4 HEEL BURSITIS  
Bursitis is a swelling of the bursa. It is typically felt either deep inside the heel or behind the heel, 





1.5 MANAGEMENT AND TREATMENT 
There is a lack of consensus regarding the ideal management approach for PHP (15, 38, 39).  
Clinical practice guidelines support the use of conservative treatment, such as joint and soft tissue 
mobilization or self-stretching home programs (SSHP) (7, 12). In particular, SSHP are effective 
for addressing PHP (7, 14, 40), although recent randomized clinical trials (RCTs) have shown that 
there is an additional effect in reducing the severity of pain when SSHP is combined with ischemic 
compression (41). In the case of failure of conservative treatments, minimally invasive therapies 
are often employed, and it is here where we find the lack of consensus and controversy. Many 
treatment modalities are categorized as minimally invasive therapies and can be used in the 
treatment of PHP. These vary from corticosteroid injections (CSI's) (42-44), platelet-rich plasma 
(PRP) (45-52), botulinum toxin (BOTOX) (53, 54), prolotherapy (55, 56), acupuncture (57-60) or 









1.6 NON-INVASIVE TREATMENTS FOR PLANTAR HEEL PAIN  
1.6.1 CONSERVATIVE THERAPY 
Treatment usually follows a step-wise approach. Patients receive different types of medication, 
depending on the severity of the pain. Over-the-counter medications are initially used, although 
NSAIDs are the first line of treatment to decrease pain and inflammation. Medications are usually 
prescribed in conjunction with a rehabilitation plan, which is set depending on the clinician's 
preference. The rehabilitation program may involve using different modalities such as therapeutic 
ultrasound, electrotherapy, hot and cold packs, and exercises to strengthen the muscles or relieve 
tension (7). 
1.6.2 MANUAL THERAPY:  MOBILIZATION & MANIPULATION / ISCHEMIC 
COMPRESSION  
Worldwide, manual therapy is provided by many professions such as osteopaths, chiropractors, 
physical therapists, or physicians. The difference lies in the technique each specialist uses and the 
force and velocity of the manipulation or adjustment. A recent study has shown that this type of 
treatment produces an overall improvement in the reduction of pain and disability and an increase 
in ankle dorsiflexion (64). A RCT conducted in Brazil showed a significant improvement in 
individuals who received ischemic compression and manual therapy compared to patients who 
received stretching exercises and a self-stretching protocol (41). 
1.6.3 INSOLES & ORTHOTICS  
Individuals with PHP have significantly greater difficulty with footwear comfort, fit, and choice 
than unaffected individuals. Pain level, age, BMI, foot and ankle ROM, strength, calf endurance, 
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foot contact with the surface during postural standing or walking are all critical factors (65). In an 
attempt to overcome these difficulties, some people use insoles and orthotics. 
There are many varieties of insoles and orthotics. Some factors need to be considered when 
prescribing insoles and orthotics to patients with PHP. These include the material used and its 
stiffness, whether these are prefabricated or custom made, and the patient's weight and height.  No 
studies to date have demonstrated the effectiveness of insoles or orthotics in decreasing pain.  
Moreover, the use of custom-made foot orthoses was found to be more effective than sham 
orthoses in improving function, although not for reducing pain (7).   
1.6.4 NIGHT SPLINT  
The use of the night splint is based on enabling extended stretching of the calf muscles. According 
to the American Association of Physical Therapy's clinical guidelines, the night splint should be 
considered for patients with symptoms of pain lasting over six months. The desired period for 
wearing the night splint is 1-3 months; furthermore, the design of the night splint did not affect the 
outcome (7).  
One study recruited thirty-three patients who followed a program consisting of directed 
gastrocnemius stretching exercises, wearing a Strassburg Sock or night splint, and silicone heel 
insoles, as required. This study found a strong, statistically significant correlation between 





1.6.5 TAPING  
Many types of therapies exist involving taping, these include the use of Kinesiotape, low-dye tape 
and K-Tape. A recent study has demonstrated that calcaneal or low-dye taping can be used to 
provide short-term (7-10 days) pain relief. This study proved that taping could cause functional 
improvement. Calcaneal taping proved to be a more effective tool for PHP relief than a stretching 
protocol, sham taping, or a control group with no treatment (67). Clinicians are advised to use 
taping to improve foot function and avoid over-pronation leading to pain reduction. Also, they can 
use elastic tape on the gastrocnemius and plantar fascia for a short period of pain reduction lasting 
one week (7). Low-dye tape was an effective treatment despite minimal adverse events such as 
tape that was too tight or allergic reactions (68).  
1.6.6 THERAPEUTIC EXERCISE AND NEUROMUSCULAR RE-EDUCATION   
According to an expert opinion published in the clinical practice guidelines of the International 
Classification Functioning Disability and Health American Physical Therapy Association, 
therapeutic exercises are not recommended as a treatment for PHP. Nevertheless, clinicians may 
prescribe strengthening exercises and movement training for muscles that control pronation and 
which attenuate forces during weight-bearing activity (7) 
1.6.7 EXTRACORPOREAL SHOCKWAVE THERAPY  
Extracorporeal shockwave therapy (ESWT) was first introduced to treat urinary stones. It was a  
less invasive approach compared to the commonly used surgeries available at the time (69). 
Gradually, ESWT was employed in other areas of medicine, such as for musculoskeletal and 
orthopedic uses, the treatment of many painful disorders such as elbow epicondylitis, 
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calcifications, or plantar fasciitis, as well as the non-union of long bone fractures. A meta-analysis 
suggested that focused shockwave therapy (FSW) was associated with a higher success rate in pain 
reduction than sham therapy in chronic PF (70).  
1.6.8 LIGHT AMPLIFICATION BY STIMULATED EMISSION OF RADIATION 
(LASER) THERAPY 
LASER therapy has various uses in medicine, ranging from esthetic medicine targeting wrinkles 
and fine lines, for example, to tissue remodeling and bone repair and even in post-surgical stages 
or for radiotherapy management of breast cancer (71) (72). In addition to the various uses of 
LASER therapy in medicine, there are many types of LASER therapies, ranging from low-level 
LASER therapy (LLLT) to high-level laser therapy (HLLT) and photobiomodulation (PBM). 
Currently, there is a vast amount of data to support the use of laser therapy for different medical 
conditions. Many studies and research are supporting the use of laser therapy (73-75). In a 
comparative study between LLLT and ESWT, used together with conventional treatment 
involving exercises and orthotic management, the results showed a significant improvement in 
reduction of pain levels after the third month in all groups, favoring the use of LLLT, which 
demonstrated an improvement of 79% compared with the ESWT group (61%) three months post-
treatment (76).  
A systematic review with meta-analysis was conducted to determine the parameters and 
effectiveness of PBM. Out of 3865 studies, seven were RCTs selected after the final review, and 
four articles were selected for meta-analysis. There was a significant difference between PBM and 
control for visual analog scale (VAS) (Chi2=29.30; P <0.00001) with an I2 value of 90% in favor 
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of PBM versus the control group. The overall score was statistically significant (P < 0.02) in favor 
of PBM.  This meta-analysis provided evidence that PBM is an effective treatment modality to 
reduce pain and improve foot function  in patients with chronic PF, and the ideal treatment 
parameters for PF need to be further elucidated (77). 
1.7 MINIMALLY INVASIVE TREATMENTS FOR PLANTAR HEEL PAIN 
1.7.1 CORTICOSTEROID INJECTIONS  
Corticosteroids have been used worldwide for the treatment of different musculoskeletal ailments.  
They have been the most extensively studied, and their safety profile is widely known. Steroids 
have different compositions, which affect the duration of their effects, and the formulation used is 
mainly dependent on availability. Corticosteroids can be divided into short, intermediate, and long-
acting medication. However, consensual guidelines regarding the use of corticosteroids in MSK 
health are lacking  (78-83) 
Despite PF being identified as a degenerative condition with an inflammatory component, 
corticosteroids, which are a type of anti-inflammatory medication, are commonly prescribed 
treatments. The current evidence shows that corticosteroid injections (CSIs) are more effective 
than placebo injections but not more than other types of therapies such as PRP (43). CSIs can 
provide relief for heel pain in the short term, as proven by a study which showed a statistically 
significant reduction of pain at one month (p= 0.02) in favor of steroids (84). 
The recommendation of CSIs as an initial treatment option by the American College of Foot and 
Ankle Surgeons (ACFAS) was met with skepticism and raised specific controversial issues, 
28 
 
especially in recent years, with the rise of regenerative medicine. This made the treatment of PF 
more challenging for clinicians. There was a dispute about the superiority of the corticosteroid 
formulation and the anatomical approach used for CSIs (82).  
A meta-analysis by Gaujoux-Viala et al. found no difference in efficacy between the different 
types of corticosteroids used. This author also concluded that there was no long-term effect of 
using CSIs (82, 85-87). 
A comparative study of CSIs versus placebo and US-guided procedures versus non-guided 
procedures among 65 patients with inferior heel pain showed no difference in VAS scores 
following steroid injection between the US-guided and the non-guided groups at either time point. 
On the other hand, there was a significant decrease in plantar fascia thickness after injection in 
both active treatment groups (P=0.00) over six weeks, which was maintained at 12 weeks (88). 
Some studies have reported that CSIs yield better results than other treatment modalities. However, 
the effect of CSIs in these studies was short-lived, lasting 4-12 weeks in duration. Furthermore, 
complications were noted, such as PF rupture, in 2.4% to 6.7% of cases, and heel fat pad atrophy. 
Also, diabetic patients may experience elevated blood sugar levels for up to two weeks post 
procedure. There were also certain practical aspects of CSIs that should not be neglected in patients 
taking oral anticoagulants. Patients taking warfarin should have their International Ratio (INR) 
checked before the procedure, aiming for INR < 1.5. Cessation of newer anticoagulants or 
antiplatelets such as rivaroxaban, dabigatran, apixaban, clopidogrel should occur 48 hours before 
CSIs, and resumed post-procedure (82, 85-87). 
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 A systematic review showed that numerous varieties of corticosteroids can be categorized based 
on their duration of action, ranging from short-acting corticosteroids such as hydrocortisone, to 
intermediate-acting corticosteroids, such as methylprednisolone, prednisolone, and triamcinolone, 
and finally long-acting corticosteroids such as dexamethasone and betamethasone. However, there 
is no specific recommendation or guideline, or justification for the use of one type over the other.  
Furthermore, there are many different techniques that are used to inject the medications; some 
prefer the posterior approach over the medial approach  while others use the peppering techniques 
of injection (82). 
In recent times, many studies have been carried out or are underway to compare the effectiveness 
of cortisone therapy with other minimally invasive techniques such as PRP or Botox injections 
(guided or unguided), as well as with non-invasive techniques such as manual therapy, exercises, 
or shockwave therapy (89-96). 
1.7.2 BOTULINUM TOXIN 
Botulinum toxin, commonly known as BOTOX, is a neurotoxin produced by the bacterium 
Clostridium botulinum.  It was initially used by an ophthalmologist to treat strabismus and rapidly 
other uses were reported by many medical specialties (97). There are several types of botulinum 
neurotoxins; type A (BoNT/A) is well established, especially in treating conditions characterized 
by hyperactivity of cholinergic neuromuscular fibers such as focal dystonia.  It is also the most 
common type used for the treatment of pain related to musculoskeletal (MSK) origin and 
neurological conditions (98).  
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Many studies have evaluated the effect of BoNT/A on PHP and PF. A multicenter, double-blind, 
placebo-controlled study of 40 patients who were randomized to receive 200 units of BoNT-A  
injected directly into the calcaneal origin of the plantar fascia administered in a fan-shaped manner. 
The patients in the BoNT-A group achieved a response at week six (25% vs. 5% for placebo; 
p=0.18) There were no statistically significant differences between the groups on secondary 
outcome measures for pain.  Furthermore, no adverse events were noted. There is a need for larger, 
prospective, long term effect studies (99). 
Another double-blinded controlled study conducted in Taiwan using a US-guided procedure on a 
cohort of 50 patients with chronic unilateral plantar fasciitis. Participants were divided into an 
experimental group, who received 50 units of BoNT/A, and a control group, who received normal 
saline. Both groups received the respective treatment under ultrasound guidance. The outcome 
measure included a comparative VAS, changes in thickness of the PF and the fat pad, and gait 
assessment, including the maximal center of pressure velocity during the first step loading 
response. Visual analogue pain scale and plantar fascia thickness in the symptomatic foot 
decreased significantly, as noted at follow-up 3 weeks and 3 months after BoNT/A injections 
(p=0.001), whereas the fat pad remained unchanged. The center of pressure velocity during loading 
response increased three months post-injection (p=0.05), whereas the control group remained the 
same, concluding that BoNT/A was influential in treating foot pain without inducing fat pad 
atrophy (100). 
Recently, a molecular mechanism has been found to underlie the neuromuscular block caused by 
the seven BoNT serotypes. The different BoNT serotypes may be useful when a specific immune 
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resistance related to BoNT/A has been proven. Serotype F was injected into the human muscle, 
however, its effects are shorter compared to BoNT/A, whereas BoNT serotype V (BoNT/B) is 
effective in humans only if injected at a very high dose. BoNT serotype C (BoNT/C) has a general 
profile action similar to BoNT/A, although there is no comparison between these types of BoNT 
in humans (97). A recent study conducted in Iran aimed to determine the effectiveness of injecting 
BoNT/A (the most common type used in MSK clinical practice) in the medial head of the 
gastrocnemius muscle on improvements in functions and disability in people with chronic PF.  
Thirty-two patients were randomly allocated to treatment and placebo groups and were followed 
up for one year, evaluating function and pain using the AOFAS and VAS, respectively. The results, 
determined at a 12-month follow-up, demonstrated a decrease in the mean VAS from 7.8 to 4 in 
the placebo group and from 8 to 0.33 in the BoNT/A group. The mean of AOFAS scores increased 
from 48.4 to 65.3 in the placebo group and from 45.5 to 90.6 in the BoNT/A group. The patients 
treated with BoNT/A showed improvements after one-year follow-up (101).  
1.7.3 PLATELET-RICH PLASMA THERAPY  
Platelet-rich plasma is a biological therapeutic modality that consists of the preparation of a 
concentration of platelet and plasma proteins. This treatment aims to improve the reparability of 
endogenous cells. It is based on the intraarticular delivery of autologous platelet-rich plasma 
preparations containing a large pool of growth factors and proteins in the alpha-granules of the 
platelets. These growth factors and proteins promote the induced healing of the damaged tissue. 
Numerous growth factors found in PRP stimulate the matrix synthesis and counteract the effect of 
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catabolic cytokines such as interleukin-1 and tumor necrosis factor-alpha. Basic scientific evidence 
supports the therapeutic potential of PRP (102). 
In recent years, there has been a surge in the demand of PRP, together with numerous studies for 
use of PRP in many medical branches such as aesthetic medicine, dermatology, orthopedics, 
regenerative medicine, and many other specialties. The most common one was in orthopedic 
medicine, and specifically for cartilage diseases and regeneration. One study found that 
chondrocytes treated in vitro with releasate from thrombin-clotted leukocyte-PRP (L-PRP), 
resulted in a significantly increased cell proliferation synthesis rate and accumulation of 
glycosaminoglycans and collagen type II (COL2), compared with the control group (103).  
A Cochrane systematic review carried out in 2013 concluded that, overall, for individual clinical 
conditions, there is currently insufficient evidence to support the use of PRP for the treatment of 
soft tissue musculoskeletal injures. The researchers contemplating RCTs should consider the 
current ongoing trials when evaluating the need for future RCTs on each specific condition, 
bearing in mind that there is a need for standardization of PRP preparation methods. The available 
evidence is insufficient to indicate whether the effects of PRP will notably differ in individual 
clinical conditions (46).  
A comparative RCT evaluated the efficacy of autologous conditioned plasma (ACP) with 
extracorporeal shockwave ESWT, and conventional treatment of stretching exercises and orthotics 
for the treatment of plantar fasciitis. Fifty-four patients (age range 29-71 years) with unilateral 
chronic plantar fasciitis with more than four months of symptoms participated. The primary 
outcome measure was VAS, AOFAS, and the ultrasound exam of plantar fascia thickness assessed 
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at baseline, before treatment, and at one month, three months, and six months post-treatment. The 
VAS and AOFAS scales, as well as plantar fascia thickness, improved in all groups. Pain also 
significantly improved in the ACP group compared to conventional treatment in the first month, 
and for the ESWT group, compared with conventional treatment at one, three, and six months. 
Significant improvements in plantar fascia thickness were seen in the ACP group at one month 
and three months when compared with conventional treatment, and at three months and six months 
when compared with ESWT. The study concluded a significant reduction in the ACP group 
compared to the ESWT, with no adverse events reported in this study (89).  
A double-blind comparative study was also performed to analyze the effect of PRP versus 
corticosteroid and a control group who received a placebo (normal saline) for the treatment of 
chronic plantar fasciitis. The study was carried out with 75 randomly allocated patients who 
received one of the treatments and were assessed with VAS for pain and the AOFAS score prior 
to the injections and at a follow-up at three weeks and three months. The mean VAS score in both 
the PRP and Corticosteroid groups decreased from 7.44 and 7.72 pre-injection to 2.52 and 3.64 at 
final follow-up, respectively, whereas the mean AOFAS score in the PRP and Corticosteroid 
groups improved from 51.56 and 55.72 pre-injection to 88.24 and 81.32 at final follow-up, 
respectively. There was a significant improvement in both groups with no significant improvement 
in placebo. The study concluded that both PRP and corticosteroids were effective for the treatment 
of PHP (104).  
Increasingly, a major question is whether PRP injection is more effective than steroid injection for 
the treatment of PF in the long term. Although steroids have proven to be a pain management 
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medication they do not promote tissue healing. Sixty patients diagnosed with heel pain for over 
six weeks after failed conservative treatment and with plantar fascia thickness greater than 4mm 
were included in a prospective, double-blind study. Patients were randomly divided into two 
groups, receiving PRP or steroid injections. They were all assessed with VAS and AOFAS scores. 
Assessments were performed at baseline, at six weeks, three months, and six months follow-up 
post injections. Plantar fascia thickness was assessed at baseline and six months after treatment 
using sonography. The mean VAS score in the PRP group decreased from 7.14 at baseline to 1.41 
post injection, whereas in the corticosteroid group these values reduced from 7.21 at baseline to 
1.93 post injection. The mean AOFAS score improved in the PRP group from 54 to 90.03 and in 
the corticosteroid group from 55.63 to 74.67 at the six-month follow-up. The improvements 
observed in the VAS and AOFAS scores were statistically significant; at six months, the plantar 
fascia thickness had reduced in both groups (5.78 mm to 3.35mm in the PRP group and 6.5 to 3.75 
in the steroid group). The study concluded that PRP is an effective treatment compared with 
steroids, with a long-lasting beneficial effect (105).  
There is a need for further research to determine the long-lasting effect of PRP and the 
effectiveness of the same. In another study, patients with chronic plantar fasciitis were allocated 
to receive a steroid injection or PRP. The primary outcome measure was the Foot Function Index 
(FFI) and the quality of life as scored with a short version of the World Health Organization 





1.7.4 PERCUTANEOUS NEEDLE ELECTROLYSIS  
Percutaneous Needle Electrolysis (PNE) is a novel minimally invasive approach that involves 
applying a minimal galvanic current directly through an acupuncture needle. Several devices are 
available for the administration of the current, with different brand names, such as EPI, EPT, 
EPTE, Physio Invasiva, etc. This technique provides an organic reaction that produces localized 
inflammation and microtrauma to the affected soft tissue structures. The needle is directed into the 
soft tissue under direct ultrasound guidance, stimulating a local inflammatory response which leads 
to increased cellular activity and the rapid regeneration of injured tissue  (106, 107).  
The effect of PNE was first analyzed in a prospective study of 33 athlete-patients consecutively 
treated for tendinopathy and followed up for two years. Functional assessments were performed at 
the baseline and three months (P<0.001). 78.8% of patients returned to the same level of activity 
as prior to the injury by the end of treatment, which increased to 100%(P<0.001) at two years 
(107). 
Another study was conducted comparing the ultrasound-guided PNE technique vs. conventional 
electrophysical therapy to treat patellar tendinopathy. Sixty patients were randomized into two 
groups, and both groups received a program of eccentric exercises. All patients were assessed 
using the (VISA-P) Victorian Institute of Sport Assessment-Patella score. This study found that 
the best outcomes were obtained with a combination of ultrasound-guided PNE and eccentric 
exercise (108). 
Percutaneous needle electrolysis was also used in a study of 73 patients who were randomly 
allocated to receive ultrasound-guided PNE vs. placebo for the treatment of patients with chronic 
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PHP; the primary outcome was an 11-point numerical scale for the assessment of pain, the 
secondary outcome was function and disability, measured by the 21-item activities of the daily 
living subscale of foot and ankle ability measure (FAAM) questionnaire, and fascia thickness was 
measured under US. All the above mentioned outcomes were measured at 1,12,24 weeks. There 
was a significant improvement of (P<0.01), in the numerical pain rating scale, FAAM activity 
subscale (P<0.002) and ultrasonography measurements of the plantar heel (P<0.002), furthermore, 
the PNE improved both pain and function (109).   
A comparative study with a one-year follow-up for the treatment of plantar fasciosis using 
corticosteroid injection vs. PNE was carried out with 64 patients, including clinical and ultrasound 
assessments performed at baseline and at 3, 6, 12 months. Also, the VAS was used to measure 
pain and the Foot and Ankle Disability Index (FADI) was used to evaluate function. Both 
ultrasound-guided PNE and CI techniques were associated with significant clinical and 
sonographic improvements at 12 months post-treatment (P<.001) (110).  
A double-blind RCT was performed comparing PNE vs. DN vs. sham needling for the 
management of temporomandibular myofascial pain syndrome, involving 60 patients allocated to 
receive one treatment session per week for three consecutive weeks. A clinical assessment was 
performed at baseline and at 28, 42, and 70 days post-treatment. Statistically significant differences 
(P<0.01) were found for the PNE and DN group concerning pain reduction at rest, during chewing, 




A systematic review with meta-analysis found moderate evidence suggesting a large positive effect 
of PNE for the reduction of pain and for a large decrease in pain-related disability in MSK 
conditions in the short term, midterm and long term (111) 
1.7.5 DRY NEEDLING  
Dry needling is a technique that involves the insertion of a thin filiform needle into the trigger 
point for its release. The term DN is attributed to Dr. Janet Travell in her book "Myofascial pain 
and dysfunction: trigger point manual" (5). Karel Lewit first described this technique in 1979, 
which involved the insertion of the needle in the point of maximal tenderness at the trigger zone 
with immediate analgesia produced by the needle; he referred to this as "the needle effect" (112).  
A Cochrane review concluded that “DN appears to be a useful adjunct to other therapies for 
chronic low back pain" (29). Although DN research is increasingly available, the exact 
mechanisms of action of direct needling in the deactivation of trigger points are still unclear.  The 
most critical factors in deep DN are the depth of needle insertion, the amount and force of 
stimulation, and the elicitation of a "local twitch response" (LTR).  LTR is the involuntary spinal 
reflex resulting from contraction of affected muscle fibers after being manually stimulated with 
the needle, injection, or even stretching with manual therapy. LTR are frequently triggered with 
DN compared to other methods, which affect the taut band and the blood flow of the targeted tissue 
and muscles (113). 
The identification of MTrPs has been a challenge for many clinicians and researchers in the 
medical field. A novel preliminary study shows that US imaging techniques can be used to 
distinguish myofascial tissue containing MTrPs from normal myofascial tissue (lacking trigger 
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points), as it enables visualization of the LTR and some characterization of MTrPs and adjacent 
soft tissue (114). The identification of trigger points requires clinical skills and clinical applications 
to reach optimal results in the treatment of patients with plantar heel pain.  
In 2011, a comparative RCT was conducted in Australia to evaluate the effectiveness of DN for 
the treatment of PHP, compared to a control group receiving sham needling. The study consisted 
of two parallel groups. Eighty-four patients were enrolled with pain of one-month duration. The 
treatment consisted of one session per week for six weeks and a 12-week follow-up. The primary 
outcome measure was first step-pain measured with a VAS scale, and foot pain and function using 
the (FHSQ). The primary endpoint for predicting the effectiveness of DN pain was six weeks. At 
the primary endpoint, significant effects favored real DN over sham DN for pain (adjusted mean 
difference: VAS first step-pain 14.4 mm, 95% confidence interval [95% CI] 23.5 to 5.5 FHSQ foot 
pain 10.0 points, 95% CI 1.0 to 19.1). The difference between groups was lower than the minimal 
important difference. The DN intervention provided a statistically significant reduction in plantar 
heel pain, however the limitation of this study was the inability to blind the clinician (therapist) 
(61, 115) 
A comparative study for the treatment of plantar fasciitis using DN and corticosteroid injection 
was conducted in Iran to evaluate the superiority of each treatment; 60 patients were recruited to 
a single-blind clinical trial. Participants were allocated to receive 1 ml (40mg) of deop-Medrol 
(methylprednisolone acetate) or DN. They were followed up for 12 months. The mean VAS score 
at baseline was 6.96 ± 0.87 for the steroid group and 6.41 ± 0.83 for the DN group (P Values = 
0.54). Patients who underwent DN reported lower VAS scores at the end of the follow-up 
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compared with the steroid group. In conclusion, the steroid injection group is able to palliate the 
plantar heel pain rapidly, however, DN can provide more satisfactory results for patients with 



















CHAPTER 2 JUSTIFICATION  
Despite its prevalence, the etiology of PHP is not well understood (8, 12) and there is a lack of 
consensus regarding the ideal management approach for PHP (15, 38, 39). Although PHP may be 
provoked by a tendinous injury affecting the plantar fascia, it is well known that myofascial trigger 
points MTrPs within the plantar and lower leg musculature may play an essential role in people 
with PHP (5). Clinical practice guidelines support the use of conservative treatment, such as joint 
and soft tissue mobilization or SSHP (8, 12). In particular, SSHP have been shown to address PHP 
effectively (7, 8, 12, 41, 117). In contrast, recent RCTs have shown that there is an additional effect 
for the reduction of pain severity when SSHP is combined with ischemic compression (41) and 
DN (63).  
Physical therapy approaches continue to evolve, with minimal invasive techniques such as PNE, 
similar to DN but with the application of a galvanic electrolytic current through the needle to 
provoke a controlled local inflammatory process in the target tissue, which leads to phagocytosis 
and the subsequent regeneration of the affected tissue (107, 108).  
At present, DN techniques have shown to be effective for the treatment of PHP (115, 118), PNE 
has also demonstrated  its effectiveness for the treatment of tendinous pathologies (109, 119-122), 
however, to date there are no studies that have analyzed the effectiveness of PNE for the treatment 





CHAPTER 3 HYPOTHESIS AND OBJECTIVES  
From a biological point of view, it seems reasonable to hypothesize that subjects can display 
improvements thanks to the mechanical effects of the needle and patients may benefit more when 
the electrolysis effect is added to the mechanical stimulus provided by the needle. Therefore, the 
main objective of this research was to analyze and compare the effectiveness of DN versus PNE 
for reducing the level of pain in patients suffering from PHP. In addition, the following secondary 
objectives were established: 
1. To analyze the baseline characteristics of patients with PHP  
2. To analyze the main muscles that contribute to PHP 
3. To analyze the frequency of patient’s compliance to the home stretching program and their 
progress in PHP. 
4. To analyze the adverse effects associated to DN and PNE 
5. To analyze the effectiveness of DN and PNE to reduce maximum and mean pain 
6. To analyze the effectiveness of DN and PNE to improve foot function  
7. To analyze the effectiveness of DN and PNE to improve Quality of life  
8. To analyze the effectiveness of DN and PNE to improve general foot health  
9. To analyze the patient’s knowledge and limitations regarding proper shoe wear    
10. To analyze whether participants can achieve an important improvement in their pain and 






CHAPTER 4 METHODS 
A systematic review was conducted at the beginning of our research plan, from April 2016 to 
March 2017. The purpose of the review was to answer the following question: what is the 
effectiveness of minimally invasive non-surgical interventions, either applied on their own or 
combined, for the treatment of PF? The review was conducted in accordance with the Preferred 
Reporting System Items for Systematic Reviews and Meta-analyses (PRISMA) statement and was 
registered with PROSPERO (CRD42018083734) (83) (SEE ANNEX 1). 
The search strategy aimed to identify all available experimental studies evaluating the invasive 
non-surgical management of PF. Searches of MEDLINE, Web of Science, Cochrane, and PEDro 
databases were conducted. The last search was performed in March 2017. The search strategy used 
was: ((Efficacy OR management OR effectiveness) AND (plantar OR fasciitis OR fasciosis OR 
fascitis OR heel) AND (dry need* OR intratissue percutaneous electrolysis or acupuncture or 
electroacupuncture or injection or injectabl* or puncture and infiltrat*)). These keywords were 
identified after preliminary literature searches. There was no restriction by date. The inclusion 
criteria were: 1) Randomized controlled clinical trials with a sample size of at least 20 subjects per 
study (10 per group); 2) Age of subjects: 18 years and older; 3) Diagnosis of plantar fasciitis (or 
equivalent terms such as fasciosis or fasciitis or heel pain); 4) Studies investigating the 
effectiveness of any invasive non-surgical treatment for PF (e.g., DN and/or injections, 
acupuncture, infiltration). The exclusion criteria were: 1) Any study including a surgical procedure 
or oral pharmacological agents or topical ointment; 2) Studies with animals 3) Trials whose sample 
of participants included any of the following terms: diabetes, spasticity, neuropathy, tumor, 
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fracture, hemophilia, stroke, amputation, artificial limbs, and rheumatoid arthritis; 4) Articles in 
which the full text was not in English; 5) RCTs not reaching a score of 5 in the PEDro scale. The 
evaluation of the eligibility of each study was carried out by three independent reviewers (ZA, 
ML, MA) who performed an initial screen by title, a second screen by abstract, and subsequently 
compared the results. In case of disagreements, a fourth reviewer was consulted (EG). Thereafter, 
the full text of the selected articles was read to verify whether they met the inclusion and exclusion 
criteria. Subsequently, the studies were evaluated using the PEDro scale, and those obtaining less 
than 5 points were excluded. For the data extraction, a table was generated containing all the results 
classified by the outcome measurements, which helped group the results and enabled a comparison 
amongst the different studies. This systematic review enabled us to evaluate all the recent RCTs 
involving minimally invasive therapies for the treatment of PHP, considering all the available 
evidence.  
Based on the aforementioned systematic review, a protocol for a Randomized Clinical Trial was 
designed following the SPIRIT Guidelines. This protocol was published in the Journal of 
Orthopaedic Surgery and Research, (Volume (17) (SEE ANNEX 2). The study protocol was 
registered in clinical trials at Clinicaltrials.com, number NCT03236779 (Registered 2 August 
2017). This study was conducted in compliance with the Helsinki Declaration of Human Rights. 
Ethical approval was obtained by the Medical Ethics Committee of the State of Kuwait Ministry 
of Health (19th September 2017), with reference number 642/2017. After registering the protocol, 
we started the recruitment for the study, and the RCT was reported in accordance with the 
CONSORT statement for non-pharmacological trials. 
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Patient recruitment commenced in January 2018 and was completed by October 2018. This study 
was a prospective, parallel-group RCT with blinded outcome assessments. Participants were 
recruited from Kuwait City, the State of Kuwait, and both the assessment and intervention were 
conducted at the Physical Medicine and Rehabilitation Hospital in Kuwait by a physician. 
Participants who fulfilled the inclusion criteria received the standardized oral and written 
information, and, once they granted their consent to participate in the trial, they were randomized 
in a block system by blocks of 10 patients. Allocation to the groups was achieved using a computer 
program (Randomizer, https://www.randomizer.org/) with random patient file number sequences 
generated by a third person not involved in the study and based on their file number in Kuwait. 
This person was responsible for safekeeping the envelope with the information on the 
randomization. The envelopes were remained closed until the moment of the intervention to 
maintain the blinding. This professional also asked the patients for informed consent.  
To be eligible for the study, participants had to meet the following inclusion criteria: 
- A clinical diagnosis of PHP in accordance with the clinical guidelines linked to the 
International Classification of Function, Disability, and Health from the Orthopedic 
Section of the American Physical Therapy Association (8, 12, 62, 63) 
- Age 21 years or older at admission to the study, according to Kuwaiti law. 
- History of PHP for over one month, showing no improvements with previous conservative 
treatment. 
- Able to walk 50 meters without any support. 
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- The presence of MTrPs on plantar and calf muscles, based on initial physical examination 
carried out by a physiotherapist (MA) with experience and training in MTrPs. 
- Accepting treatment from a male physiotherapist. 
- The ability to understand the study and the informed consent, and signing the document. 
The exclusion criteria for the study consisted of:  
- Needle phobia.  
- Needle allergy or hypersensitivity to metals. 
- Presence of coagulopathy or use of anticoagulants according to medical criteria. 
- Presence of peripheral artery disease.  
- Pregnancy. 
- Dermatological disease affecting the DN area. 
- The presence of a chronic medical condition which might preclude participation in the 
study, such as malignancy, systematic inflammatory disorders (e.g., rheumatoid arthritis, 
psoriatic arthritis, ankylosing spondylitis, septic arthritis), neurological diseases, 
polyneuropathy, mononeuropathy, and sciatica. 
- Treatment of plantar heel pain with needling or acupuncture during the last four weeks. 
- History of injection therapy in the heel over the previous three months. 
- Previous history of foot surgery or fracture. 
Participants were controlled by using the appropriate medication dosage as prescribed by the 
physiatrist (analgesics and non-steroidal anti-inflammatory medications) and were required to 
report any changes to the assessor during the evaluations, including the consumption of any 
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additional medication or undergoing any other treatment during the intervention. They were 
willing not to receive or implement any form of treatment for the plantar heel pain (taping, night 
splints, massage therapy, or footwear modifications) while they participated in the trial. The 
participants had the right to withdraw from the study at any time without providing any 
explanation.  
In designing the study, the sample size was calculated, estimating that 94 participants with PHP 
were necessary. An initial prospective sample size calculation estimated that 39 participants per 
group would provide 80% power to detect a minimally significant difference of 13 points in the 
pain domain of the Foot Health Status Questionnaire (FHSQ) with a standard deviation of 20 points 
(123) and an alpha risk of 0.05, allowing 20% loss to follow-up (16 patients). Based on the initial 
data collection, the drop-out rate was recalculated to be 25% and the sample size was therefore 










4.1 STUDY VARIABLES 
4.1.1 BASELINE DATA 
The baseline data were gender, age, height, weight, BMI, details regarding the affected side (right, 
left, or bilateral), duration of symptoms, medication, and previous treatments. 
A blinded observer assessed all participants at baseline and at 4, 8, 12, 26, and 52 weeks post-
treatment [FIGURE 1]. 
 
Figure 1.  Schedule for enrolment and intervention. Extracted from Al-Boloushi et al 2019 (17) (SEE ANNEXE 
2)  
DN-G: DN group; PNE-G: Percutaneous needle electrolysis group. FHSQ: Foot Health Status Questionnaire; 




4.1.2 PRIMARY OUTCOME MEASURE 
Participants completed the FHSQ questionnaire at baseline and at 4, 8, 12, 26, and 52 weeks post-
treatment. The FHSQ consists of 13 questions reflecting four-foot health-related domains: pain (4 
questions), function (4 questions), footwear (3 questions), and general foot health (2 questions). 
Individual item scores were then re-coded, tabulated, and finally transformed to a scale ranging 
from 0 to 100 for each of the four domains (124). Greater scores reflect better foot health and 
quality of life (125). The FHSQ has been validated (126) and has been used in similar trials that 
have evaluated the effectiveness of different interventions for plantar heel pain (62, 127, 128). 
4.1.3 SECONDARY OUTCOME MEASURES 
Participants completed the VAS at baseline and at the 4, 8, 12, 26, and 52-week assessments and, 
additionally, before each treatment session. The level of pain that patients have experienced during 
the previous 48 hours before starting the treatment session was recorded. Participants were asked 
about the mean and the highest level of pain that they had experienced in the past 48 hours. The 
exact wording of the questions was: 1) what is the level of pain, on average, that you have felt 
during the last 48 hours? and 2) what is the maximum level of pain you have felt during the last 
48 hours? Additionally, after treatment, they were asked to score their current pain immediately 
upon standing up and walking a few steps. Participants were explained that a score of 0 indicates 
the absence of pain whereas a score of 10 represents the maximum tolerable pain. The VAS is 
widely used and is valid and reliable (129-131). Participants were also asked to indicate the areas 
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of perceived pain using an electronic body chart (Navigate pain, version 0.1.9.9, Aalborg, 
Denmark) (132). 
Quality of Life (QoL) was assessed with the EuroQoL-5 dimensions (EQ-5D), completed by the 
patients at baseline and the 4, 8, 12, 26, and 52-week assessments. The EQ-5D self-report 
questionnaire is a descriptive system with five questions, each representing one dimension of the 
Health-related Quality of Life (HRQoL), i.e., mobility, self-care, daily activities, pain/discomfort, 
and depression/anxiety. Each dimension can be rated on three levels: no problems, some problems, 
and major problems, together, the results serve to classify people into 1 of 243 possible health 
states (133). 
4.2 STATISTICAL ANALYSIS 
The statistical analysis was performed via an intention-to-treat analysis. The variables are 
presented as the percentage, mean (standard deviation) or median (interquartile range), according 
to their distribution. Quantitative variables were analyzed using the Shapiro Wilk test in order to 
confirm their distribution and to determine the correct statistical tests according to these results. 
The outcomes were analyzed using mixed linear and logistic regression models, considering 
participants as a random effect and treatment group as fixed factors. Baseline characteristics were 
introduced in the model as covariance factors. The numbers needed to treat the index were also 
calculated. The primary aim of the analysis was to calculate the difference obtained in the FHSQ 
score after the intervention (final measurement - initial measurement). Finally, the magnitude of 
the effect of the result was calculated and, therefore, its clinical importance, by using the following 
formula: r = √[𝑭(𝟏,𝒅𝒇𝑹)]/[𝑭(𝟏,𝒅𝒇𝑹)+𝒅𝒇𝑹]. The significance level for statistical tests was set at 
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p ≤0.05. The statistical analysis was performed using IBM SPSS Statistics (version 25, IBM, 
Chicago, IL) by intention to treat, with the last observation carried forward. The investigator who 
performed the analyses was masked to group allocation. The significance level for all statistical 
tests was set at P ≤ 0.05. Chi-squared tests were used to analyze whether there were differences in 
categorical variables between groups at baseline. In addition, independent Student t-tests and 
Mann-Whitney U tests were used for parametric and nonparametric quantitative variables, 
respectively. Chi-squared tests were used to evaluate the compliance of the self-stretching 
protocol.  
Following recommendations to estimate treatment effects in RCTs, mixed linear models adjusted 
for baseline values were used to test the mean effect of treatment interventions at the 4, 8, 12, 26 
and 52-week follow-up, for the Foot Health Status Questionnaire and EQ-5D-5L measures. Linear 
mixed models adjusted for baseline values were used to test the mean effect of treatment 
interventions in the second session, third session, fourth session, and at the 4, 8, 12, 26, and 52-
week follow-ups, for measures of VAS (average and maximum). Individual repeated measures 
(RM) ANOVAs were used to test time effects within each treatment group for primary and 
secondary outcomes. Cross-sectionally, at all linear mixed models and RM-ANOVAs, the 
Bonferroni correction was used to test between-group time point differences or within-group time 
changes, respectively. The Greenhouse-Geisser correction was applied for correcting against 
violations of sphericity, whereas eta-squared (η²) was used to estimate the magnitude of the 
difference between both groups (0.01 small effect, 0.06 medium effect, and 0.14 large effect). 
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(134) Independent t-tests were used to determine any difference between groups for measures of 
the level of pain immediately after each treatment session. 
 
4.3 INTERVENTIONS 
To determine which muscles were treated, muscles fulfilled the following two criteria: a) muscles 
that typically refer pain to the heel (5) and b) muscles that can be directly palpated or needled with 
precision and safety without ultrasound guidance. The clinician performed a physical examination 
to find MTrPs following Travell and Simons criteria: 1) the presence of a taut band and 2) 
identification of exquisite spot tenderness in a nodule (5). Flat palpation or a pincer palpation 
technique was used to palpate the MTrPs, depending on the muscle being assessed. The muscles 
that were treated were: soleus, gastrocnemius, quadratus plantae, flexor digitorum brevis, and 
abductor hallucis. If a muscle contained more than one MTrP, the most sensitive MTrP was treated 
according to the patient’s perceived pain upon palpation. If the patient had pain bilaterally, the 
clinician treated both sides. The patient’s position was always lying down on the treatment table; 
however, the exact position was dependent on each muscle (supine, prone or side-lying position) 
and will be the same for the assessment as well as for the intervention (135). 
During the first session, all participants were taught a self-stretching protocol (41), which had 
demonstrated to be effective for the management of PHP (7, 14, 41), and consisted of the following 
exercises: a) Self-stretching of the calf muscles: in standing, with the affected foot furthest away 
from the wall, the patient was instructed to lean forward, while keeping the heel on the floor. To 
focus the stretching on the soleus muscle, the affected knee was bent, whereas to focus on the 
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gastrocnemius muscle, the affected knee was kept in full extension. In this position, patients were 
taught to lean forward until they felt a stretch in the calf and Achilles region. All patients completed 
both versions of the stretch; b) Plantar fascia-specific self-stretching: in the sitting position, 
patients crossed the affected foot over the contralateral thigh. The patient placed his/her fingers 
over the base of the toes, grasped the base of the toes and pulled the toes back towards the shin 
until a stretch was felt in the plantar fascia (41). According to the evidence, we followed the same 
dosage for calf and plantar fascia-specific self-stretching exercises twice a day, using intermittent 
stretching lasting 20 seconds, followed by 20-second rest periods for a total of 3 minutes per stretch 
(41). The participants received four individual physiotherapy sessions once a week. The duration 
of the sessions was variable depending on the patient; however, these lasted approximately 30 
minutes. The participants were treated by a physical therapist registered at the Kuwait Ministry of 
Health and trained in the protocol. The clinician had a minimum of 5 years of practical experience 
in DN and appropriate training. 
4.3.1 INVASIVE INTERVENTIONAL GROUPS: DRY NEEDLING AND 
PERCUTANEOUS NEEDLE ELECTROLYSIS 
Specific needles for DN were used during invasive treatments (Agu-punt, Spain). Needle lengths 
were determined by the location of the MTrP, and they ranged from 30 to 50 mm in length (or 
longer if necessary, according to the patients’ characteristics). The needle diameter was 0.25 - 0.30 
mm. If the participant was sensitive to needle insertion, the level of manipulation was reduced. If 
this measure was insufficient for reducing the painful stimulus, needle manipulation was ceased 
altogether, and the needle was left in situ (112, 135). 
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To maintain appropriate hygienic conditions during the invasive treatments, the clinician wore 
latex gloves and thoroughly cleaned the skin of the area to be needled with an antiseptic solution 
(70% Propan-2-ol, Skin-des). Upon removal of the needle, the area was firmly compressed for 10 
seconds. The needle was discarded after every single use.  
In both groups, the intervention was terminated in the following circumstances: in the event of 
severe adverse effects, if the participant did not wish to continue, or if there was an unapproved 
use of medication. Any adverse effects were duly reported. 
4.3.2 DRY NEEDLING ARM 
In the case of the DN intervention, once the clinician located the MTrP, the needle was inserted 
repeatedly, and a rapid needle entry was performed. The chosen technique for manipulating the 
needle was the technique described by Hong (136), which consists of a rapid needle entry and exit 
(fast in/fast out) in order to obtain a local twitch response (LTR), lasting 5 seconds and employing 
a rhythmic movement at approximately 1Hz/sec (5 entries). The number of LTRs was counted and 
registered. 
4.3.3 PERCUTANEOUS NEEDLE ELECTROLYSIS ARM 
The electrotherapy equipment used (Physio Invasiva, PRIM Fisioterapia, Spain), which produces 
a continuous galvanic current through the cathode (needle) while the patient holds a hand-held 
anode (106) was used to apply treatment in the PNE group. Once the needle reached the relevant 
treatment area, the procedure was carried out exactly in the same manner as in the DN group, with 
the only difference being that the needle was transmitting an electrical current with an intensity of 




CHAPTER 5 RESULTS  
5.1 SYSTEMATIC REVIEW RESULTS 
Twenty-nine full-text articles of minimally invasive techniques were reviewed and included in this 
systematic review. These articles focused on corticosteroid injections, platelet rich plasma, 
botulinum toxin, dextrose injections, as well as comparative studies involving DN. The best results 




Figure 2. Flow diagram of studies through the different phases of the review. Extracted from Al-Boloushi et.al 
2019 (83)  (SEE ANNEXE 1)  
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Based on the findings of all the RCTs analysed, many authors consider that plantar fasciitis is a 
degenerative tissue condition rather than an inflammation at the site of origin of the plantar fascia 
at the medial calcaneal tuberosity. The histology of plantar fasciitis is the same as that of 
tendinopathies. This implies that degeneration can cause a micro tear within the fascia that does 
not heal, which can trigger inflammation. However, an interruption in the healing process due to 
poor circulation leads to degenerative changes in the connective tissues.The treatment of plantar 
fasciitis has dramatically improved in the past decade, with more minimally invasive techniques 
becoming increasingly available. The results demonstrate that the long term effects of minimally 
invasive (non-surgical) treatments such as shock wave therapy, botulinum toxin type-A injections, 
platelet-rich plasma injections, and intratissue percutaneous electrolysis DN show similar and 
sometimes better results when compared to corticosteroid injections. Most studies have used 
corticosteroids, which, as well as being associated with transient effects on pain and function, are 
associated with a number of complications, including infections, allergic contact dermatitis due to 
preservatives, skin atrophy, osteomyelitis of the calcaneus and rupture of the plantar fascia (137, 
138). Furthermore, higher doses of corticosteroids can be contraindicated in certain patients (138). 
Corticosteroids, the current mainstay of plantar fasciitis treatment, are classified based on their 
duration of action and, as of yet, consensuated guidelines regarding corticosteroid use are lacking. 





5.2 RANDOMIZED CONTROLLED TRIAL RESULTS 
One hundred and eighteen potential participants were screened for inclusion, and 102 participants 
were enrolled and randomly allocated to each of the treatment interventions. In total, 79 
participants (78%) completed the four treatment sessions and were assessed at four weeks, 78 
participants (77%) completed the eight-week follow-up, 76 (75%) participants completed the 12-
week follow-up, 75 (74%) participants completed the 26-week follow-up and 68 (67%) 




Figure 3. Participant flow chart. Abbreviations: DN, dry needling group; PNE, Percutaneous needle electrolysis 
group. Extracted from Al-Boloushi et.al 2020 (139)DN-G: Dry needling group; PNE-G: Percutaneous needle 
electrolysis group. (SEE ANNEX 3)  
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The mean time between each treatment session was 7.0 days (SD 1.1) for the DN group and 6.9 
days (SD 1.2) for the PNE group. 
The mean age of participants was 48.8 years (SD 8.8; range 24 to 60), and 71% were female. The 
mean duration of plantar heel pain was 7.9 months (SD 9.3; range 1 to 36). Both groups were 
similar for all baseline variables except for the consumption of medication for 
hypercholesterolemia (p=0.012) [TABLE 2].  
TABLE 2. Baseline characteristics of participants by intervention group 
  DN (n=51) PNE (n=51) 
Age, years 49.5 (8.9) 48.1 (8.8) 
Sex, n (%), male 15 (29.4) 15 (29.4) 
Height, cm  160.5 (8.2) 161.2 (7.9) 
Weight, kg  87.5 (16.5) 90.8 (15.2) 
BMI, kg/m2  33.9 (5.5) 35.1 (6.4) 
Duration of symptoms, months 6.0 (6.0) 9.9 (11.5) 
Affected Side, n (%)   
Right 14 (27.5) 16 (31.4) 
Left 13 (25.5) 20 (39.2) 
Bilateral  24 (47.1) 15 (29.4) 
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Non-medicated, n (%) 11 (21.6) 15 (29.4) 
Medications, n YES (%)   
Neuromodulators/antiepileptic 18 (35.3) 22 (43.1) 
Painkillers 16 (31.4) 16 (31.4) 
Anti-Inflammatory medication 16 (31.4) 17 (33.3) 
Myorelaxant medication 9 (17.6) 8 (15.7) 
Systemic medications, n YES (%)    
Hypercholesterolemia medication 12 (23.5) 3 (5.9) 
Hypertension medication 14 (27.5) 8 (15.7) 
Diabetes Mellitus medication 14 (27.5) 10 (19.6) 
Osteoarthrosis medication 3 (5.9) 4 (7.8) 
Lung disease medication 3 (5.9) 3 (5.9) 
Hormonal therapy 5 (9.8) 7 (13.7) 
Antidepressant medication 1 (2.0) 0 (0.0) 
Diet supplements 8 (15.7) 13 (25.5) 
Previous treatments, YES (%)    
Corticosteroid injections 4 (7.8) 10 (19.6) 
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ESWT 9 (17.6) 9 (17.6) 
Exercise  4 (7.8) 6 (11.8) 
Pain, FHSQ (100 - 0) 38.8 (18.8) 40.4 (21.9) 
Function, FHSQ (100 - 0) 57.2 (34.9) 55.5 (36.3) 
Shoe, FHSQ (100 - 0) 30.7 (35.3) 32.4 (35.9) 
GFH, FHSQ (100 - 0) 14.3 (18.2) 19.2 (23.7) 
VAS mean (0 -10) 6.0 (2.3) 5.9 (2.4) 
VAS maximum (0 -10) 7.6 (2.0) 7.5 (2.3) 
Abbreviations: DN, dry needling group; PNE, Percutaneous needle electrolysis group; BMI, Body 
Mass Index; ESWT, Extracorporeal Shock-Wave Therapy; FHSQ, Foot Health Status 
Questionnaire (0 corresponds to the worst foot health; 100, the best); GFH, General Foot Health; 
VAS, Visual Analog Scale (0 corresponds to absence of pain; 10, maximum tolerable pain). Values 
are expressed in mean (SD) unless stated. *P < 0.05, significant differences between groups.  
Baseline characteristics of participants by intervention group Extracted from Al-Boloushi et.al 2020 (139) (SEE 
ANNEX 3) 
There were two small hematomas in the PNE group and one in the DN group. No serious adverse 
events were reported. All withdrawals during the treatment period were due to an inability to 
withstand the pain related to needle insertion and stimulation of MTrPs. Nine withdrawals were 
registered during the follow-up, as these participants received other treatments during the study 
period (failure to comply to not receiving other treatments). 
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The frequencies of protocol compliance with self-stretching did not differ between groups (χ2(4) 
= 1.13, P=0.890) [TABLE 3]. 
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TABLE 3. Frequencies of compliance with self-stretching protocol achieved in the dry 
needling and percutaneous needle electrolysis groups 
 DN PNE 
Four full weeks complied 11 (22%) 10 (20%) 
Three full weeks complied 6 (12%) 4 (8%) 
Two full weeks complied 6 (12%) 9 (18%) 
One full week complied 9 (18%) 10 (20%) 
Any full week complied 19 (37%) 18 (35%) 
Abbreviations: DN, dry needling group; PNE, Percutaneous needle electrolysis group. 
Note: Values represent the number of participants (relative frequencies) for each compliance category of the four-
weeks self-stretching protocol. 
Frequencies of compliance with self-stretching protocol achieved in the dry needling and percutaneous needle 
electrolysis groups. Extracted from Al-Boloushi et.al 2020 (139) (SEE ANNEX 3) 
 
 
Regarding the primary outcome measure, there was no group x time interaction for Foot Pain, 
although individual RM-ANOVA showed a significant effect of time in both groups, with lower 
scores at baseline than at follow-up for all time points in the DN group (P<0.001; 29.7 [17.8 to 
41.5]) and the PNE group (P<0.001; 32.7 [18.3 to 47.0]) [TABLE 4]  
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TABLE 4. Mean scores, mean change within group and mean difference between groups for 
the Foot Health Status Questionnaire and EQ-5D-5L at baseline, week 4, week 8, week 12, 
week 26 and week 52. 
Variable 























Foot Pain, FHSQ 
(100 - 0) 















31.5 (18.7 to 
44.2) 











27.0 (13.9 to 
40.1) 











23.1 (10.6 to 
35.6) 











26.7 (12.0 to 
41.3) 












32.7 (18.3 to 
47.0) 








< 0.001   < 0.001       
Foot Function, 
FHSQ (100 - 0) 















16,2 (0,5 to 
31,8) 











20.3 (5.1 to 
35.5) 











15.6 (-0.7 to 
31.8) 











15.2 (-0.9 to 
31.3) 











22.5 (6.6 to 
38.4) 









< 0.001   < 0.001       
Footwear, FHSQ 
(100 - 0) 















-2.1 (-16.1 to 
11.9) 











-2.3 (-18.9 to 
14.3) 










3.4 (-13.0 to 
19.9) 











6.7 (-9.1 to 
22.5) 











23.5 (8.9 to 
38.1) 










GFH, FHSQ (100 - 
0) 















34.1 (19.4 to 
48.9) 











32.4 (16.5 to 
48.2) 











34.4 (20.1 to 
48.6) 











39.5 (23.3 to 
55.6) 











47.2 (30.1 to 
64.2) 








< 0.001   < 0.001       
















0.09 (0.01 to 
0.17) 











0.07 (0.01 to 
0.13) 











0.03 (-0.05 to 
0.11) 











0.06 (-0.03 to 
0.14) 











0.10 (0.02 to 
0.18) 








0.002   0.002       
Abbreviations: CI, confidence intervals; DN, dry needling group; PNE, Percutaneous needle electrolysis group; FHSQ, 
Foot Health Status Questionnaire (0 corresponds to the worst foot health; 100, the best); GFH, General Foot Health; 
EQ-5D-5L (0 corresponds to the worst quality of life; 1, the best). 
Positive between group differences represent greater change [improvement] in the PNE group compared to the DN 
group. 
*P < 0.05 after Bonferroni’s correction comparing follow-up against baseline scores within group. 
§P < 0.05, significant differences between groups. 
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†P-value after Bonferroni’s correction between group. 
‡Eta-squared (η²); between groups effect size. 
Mean scores, mean change within group and mean difference between groups for Foot Health Status 
Questionnaire and EQ-5D-5L at baseline, week 4, week 8, week 12, week 26 and week 52.Extracted from Al-
Boloushi et.al 2020 (139) (SEE ANNEX 3) 
Individual RM-ANOVAs also showed a significant effect of time in both groups for Foot Function 
DN: P<0.001; PNE: P<0.001), Footwear DN: P=0.031; PNE: P<0.001), General Foot Health DN: 
P<0.001; PNE: P<0.001), EQ-5D-5L  DN: P=0.002; PNE: P=0.002), VAS-mean DN: P<0.001; 
PNE: P<0.001) and VAS-maximum DN: P<0.001; PNE: P<0.001) [TABLE 4]. 
Regarding the different timelines for the secondary outcome measurements, Foot Function 
improved in the PNE group at eight weeks (P=0.002; 20.3 [5.1 to 35.5]) and 52 weeks (P=0.001; 
22.5 [6.6 to 38.4]), although without differences between groups. Footwear scores also improved 
significantly at 52 weeks in the PNE group (P<0.001; 23.5 [8.9 to 38.1]), without differences 
between groups. Regarding Quality of Life, there was a significant improvement at eight weeks 
(P=0.035; 0.07 [0.01 to 0.13]) and 52 weeks (P=0.003; 0.10 [0.02 to 0.18]) in the PNE group, with 
differences between groups in favor of the PNE group only at 52 weeks (P=0.032; 0.10 [0.01 to 
0.18]) [TABLE 4]. 
Regarding pain, the DN intervention provided a benefit over PNE for the mean VAS (P=0.009; -
1.36 [-2.37 to 0.35]) and VAS Maximum (P=0.043; -1.28 [-2.53 to -0.04]) at four weeks [TABLE 
5] 
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TABLE 5. Mean scores, mean change within group and mean difference between groups 
for Visual Analog Scale at baseline/1st session, 2nd session, 3rd session, 4th session, week 4, 










































-1.5 (-2.5 to -
0.5) 











-1.8 (-3.1 to -
0.5) 











-2.5 (-3.8 to -
1.1) 











-2.0 (-3.2 to -
0.8) 











-2.1 (-3.4 to -
0.8) 












-2.1 (-3.6 to -
0.7) 











-2.5 (-3.8 to -
1.1) 











-3.0 (-4.5 to -
1.6) 








  < 0.001       
















-2.0 (-3.0 to -
0.9) 











-2.2 (-3.6 to -
0.8) 











-3.0 (-4.4 to -
1.6) 











-2.6 (-4.1 to -
1.1) 












-2.5 (-3.8 to -
1.2) 











-2.4 (-3.9 to -
1.0) 











-2.9 (-4.5 to -
1.2) 











-3.4 (-5.1 to -
1.8) 








  < 0.001       
Abbreviations: CI, confidence intervals; DN, dry needling group; PNE, Percutaneous needle electrolysis group; 
VAS, Visual Analog Scale (0 corresponds to absence of pain; 10, maximum tolerable pain). 
Positive between group differences represent greater change [improvement] in the PNE group compared to the DN 
group. 
*P < 0.05 after Bonferroni’s correction comparing follow-up against baseline scores within group. 
§P < 0.05, significant differences between groups. 
†P-value after Bonferroni’s correction between group. 
‡Eta-squared (η²); between groups effect size. 
Mean scores, mean change within group and mean difference between groups for Visual Analog Scale at 
baseline/1st session, 2nd session, 3rd session, 4th session, week 4, week 8, week 12, week 26 and week 52. Extracted 




TABLE 6 shows the most frequently treated muscles.  
TABLE 6. Localization and frequency of myofascial trigger points needled in the dry 
needling and percutaneous needle electrolysis groups 
Muscles  DN PNE 
Gastrocnemius 178 168 
Soleus 176 162 
Quadratus plantae 122 105 
Flexor digitorum brevis 106 92 
Abductor hallucis 102 93 
Abbreviations: DN, dry needling group; PNE, Percutaneous needle electrolysis group. 
Note: Values represent the number of myofascial trigger points needled per muscle over the course of the study. 
Localization and frequency of myofascial trigger points needled in the dry needling and percutaneous needle 








The level of pain immediately after each treatment session, according to the VAS, did not differ 
between groups [TABLE 7]  








1st session 3.1 (2.9) 3.5 (2.6) 0.459 
2nd session 3.1 (2.8) 3.1 (2.6) 0.968 
3rd session 2.9 (2.6) 3.3 (3.2) 0.419 
4th session 2.2 (2.7) 2.4 (2.6) 0.792 
Abbreviations: DN, dry needling group; PNE, Percutaneous needle electrolysis group; VAS, Visual Analog Scale 
(0 corresponds to absence of pain; 10, maximum tolerable pain). 
†P-value after Independent T test. 
 
Mean scores for the visual analog scale immediately after each treatment session. Extracted from Al-Boloushi et.al 
2020 (139) (SEE ANNEX 3)
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CHAPTER 6 DISCUSSION 
Plantar heel pain is a common cause of foot pain and discomfort affecting the health and quality 
of life of patients, with a high tendency for relapse and chronicity (140). Previous studies have 
demonstrated the positive effect of conservative treatment in reducing painful conditions 
associated with PHP (41, 141), whereas other RCTs show that DN probably has a higher potential 
benefit over more traditional approaches (63). Nevertheless, according to our findings, new high-
quality RCTs are needed to provide evidence regarding the effectiveness of DN for symptomatic 
management in PHP (142). Even though the plantar fascia can be a source of pain in itself (143) 
and other studies performing invasive treatments have considered needling applications at the 
insertion of the plantar fascia (144), our hypothesis is restricted to evaluating the contribution of 
MTrPs towards PHP. 
If any future plans to update the protocol and guidelines for the treatment of PHP should consider 
the treatment protocols with an emphasis on first- and second-line treatments. Consideration 
should be placed on beginning with non-invasive techniques and lack of improvement following 
these techniques should cause the clinician to proceed towards minimally invasive techniques. 
As an innovative treatment modality, PNE is increasingly used in order to promote the regeneration 
of injured tendons (106-108, 145) and is being gradually recognized as a cornerstone for invasive 
approaches in physiotherapy. However, even though its use is increasing based on an additional 
effect to DN alone, there is no scientific evidence to support the use of this technique in clinical 
practice. Therefore, we aim to research whether PNE can offer an additional effect to DN for PHP 
management. To our knowledge, this is the first study to compare two invasive treatments for 
MTrPs associated with PHP. This study contributes not only to research regarding the possible 
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additional effects of PNE but also by analyzing differences in pain perception after therapy, which 
is a common patient complaint. Furthermore, cost-effectiveness was measured with the EQ-5D, 
thus providing a valuable economic variable to studies involving physiotherapy techniques. 
In this RCT important clinical improvements were observed in both groups (146) for the Foot Pain 
and General Foot Health domains of the Foot Health Status Questionnaire at all time points. 
However, Foot Function and Quality of Life did not follow the same pattern as the aforementioned 
domains. Thus, clinically significant improvements were observed at four weeks in both groups; 
however, at eight weeks and 52 weeks, improvements were only observed in the PNE group. 
Furthermore, at 52 weeks, differences between groups were only found for Quality of Life. These 
findings suggest a trend in the group receiving PNE, producing longer-lasting effects regarding 
Foot Function and Quality of Life compared to DN. Although there were statistically significant 
differences in Quality of Life, there is no consensus of what the minimum clinically important 
difference (MCID) is, which ranges from 0.03 to 0.54 (147) 
Patients allocated to both groups also had clinically important improvements in their mean and 
maximum level of pain since week one and during the 52 weeks of follow-up.(148) There were 
differences between groups after four weeks of treatment in favor of the DN group; however, this 
difference was not maintained over time. Both groups had similar results to those reported by 
Cotchett et al(115) at four weeks. However, at 12 weeks, although significant improvements were 
found in both groups, these findings differed from the aforementioned study, which we believe 
may be due to a higher number of drop-outs.  
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Both PNE and DN were effective for PHP management, with long-lasting effects (52 weeks) for 
Foot Pain and the General Foot Health scores, without differences between groups. Besides, both 
treatments were found to be effective for reducing mean and maximum pain since the first 
treatment session, with differences between groups in favor of the DN group at four weeks only.  
Although Foot Function and Quality of Life also improved at four weeks for both intervention 
groups, the PNE group showed improvements at eight weeks and 52-weeks, with significant 
differences between groups in the case of Quality of Life at 52 weeks.  
 
6.1 CLINICAL IMPLICATIONS  
Clinical implications may vary as it is possible that this study was underpowered and the sample 
size necessary to avoid this was a total of 78 patients at the end of the study. Therefore, once we 
realized that the drop-out rate was higher than initially estimated, we increased the recruited 
patients from 94 (considering a 20% of drop-outs) to 102 (considering a 25% of drop-outs). Despite 
this, in week 12 and the following weeks, the number of patients was lower than necessary to avoid 
underpowering, which could result in not detecting the treatment effect in week 12 or later. For 
this reason, we carried out a per-protocol analysis and compared the results with the intention to 
treat analysis, which was more conservative, revealing similar results for both analyses. In 
addition, we analyzed whether there were any results in week eight that were not maintained, 
which was observed in Foot Function and Quality of Life, revealing significant improvements at 
week eight and week 52 for the percutaneous electrolysis group. Although it is speculative, 
underpowering of the intention to treat analysis may explain the inconsistency of the results in the 
percutaneous electrolysis group, possibly leading to significant results in weeks 12 and 26.  
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From a clinical point of view, both groups reported similar levels of pain after the treatment; 
therefore, both treatment options should be considered to be equal in terms of pain tolerance or 
sensitization after treatment. Besides the minimal clinically important difference, it is also essential 
to consider the patient acceptable symptomatic state (PASS), which provides the basis for 
determining whether the treatment enabled patients to achieve a satisfactory state and a clinically 
relevant treatment target. In our study, we found that in both groups, the mean pain scores, 
measured using the VAS was five points lower since the first session, which fulfills the PASS 
values determined in populations with similar sociocultural characteristics,(149) even though this 
value was found to be unexpectedly high (50 mm) when compared to other populations. 
The 118 initially selected patients presented MTrPs on plantar and calf muscles, as this was part 
of our inclusion criteria, meaning that MTrPs could be directly or indirectly contributing to PHP. 
However, we were unable to find any previous study on the prevalence of MTrPs in patients with 









6.2 STRENGTHS AND LIMITATIONS 
This study presents several strengths and limitations. One of the strengths is that this is the first 
RCT that has analyzed the effectiveness of PNE and compared it with DN for PHP caused by 
MTrPs, with a large sample size and an extended follow-up. Several limitations should be noted. 
First, other sources of pain were not considered, as the study was designed to analyze the 
contribution of MTrPs in PHP. Furthermore, we did not measure the number of local twitch 
responses, which is a controversial factor, potentially affecting the treatment effectiveness of 
MTrPs.(150) Besides, 23 patients (22.5%) dropped out of the study during the intervention as they 
were unable to tolerate pain, which is a higher drop-out rate compared to other studies.(10, 115, 
151, 152) After the intervention period, drop-outs increased progressively throughout the follow-
up to 24 at 8-weeks (23.5%), 26 at 12-weeks (25.5%), 27 at 26-weeks (26.5%) and 34 at 52-weeks 
(33.3%), which is similar to the study published by Tasoglu et al(152), with 27.7% of drop-outs at 
12 weeks. However, these rates differ from other previously mentioned studies.(10, 115, 151) 
These differences may be due to the cultural behaviors towards pain in the region, which 
constitutes a limitation and a critical challenge that must be addressed by clinicians. It is important 
to note that both treatments were safe with minimal side effects, such as hematoma or bruising, 






CHAPTER 7 CONCLUSIONS 
7.1 SYSTEMATIC REVIEW CONCLUSIONS   
1- Many authors consider that plantar fasciitis is a degenerative tissue condition rather than an 
inflammation at the site of origin of the plantar fascia at the medial calcaneal tuberosity. 
2- Plantar fasciitis treatment has dramatically improved in the past decade, with minimally 
invasive techniques increasingly available.  
3- Corticosteroid injections have been associated with several complications, including infections, 
allergic contact dermatitis due to preservatives, skin atrophy, osteomyelitis of the calcaneus, and 
rupture of the plantar fascia. 
7.2 RANDOMIZED CLINICAL TRIAL CONCLUSIONS  
1. Both groups were similar in terms of all baseline variables, except for the consumption of 
medication for hypercholesterolemia (p=0.012) where female participants had a higher 
intake. 
2. The most frequent muscles containing MTrPs in the participants were medial and lateral 
gastrocnemius, soleus, quadratus plantae, flexor digitorum brevis and abductor hallucis. 
3. The frequencies of protocol compliance with self-stretching did not differ between groups. 
4. Both treatments were safe with no serious adverse effects during the clinical trial. A total 
of three minor adverse effects were recorded (2 patients from the PNE group and 1 patient 
from the DN group had a hematoma). 
5. PNE and DN are equally effective for reducing mean and maximum pain from the first 
treatment session and during 52 weeks follow-up, although DN was found to be more 
effective at four weeks.  
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6. PNE and DN are equally effective to improve Foot Function at 4 weeks, although PNE 
was more effective than DN at 8 weeks and 52 weeks. 
7. PNE and DN were equally effective for improving the Quality of life at four weeks, 
although PNE was more effective than DN in the case of QoL at 52 weeks. 
8. PNE and DN were equally effective for improving the General Foot Health at four weeks, 
although PNE was more effective than DN in the case of general foot health, producing 
long-lasting effects at 52 weeks.  
9. Footwear scores were significantly improved at 52 weeks in the PNE group, without 
differences between groups. 
10. Both groups had clinically significant changes in their pain and the level of improvement 
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a b s t r a c t
Background: Minimally invasive non-surgical techniques have been widely used worldwide to treat
musculoskeletal injuries. Of these techniques, injectable pharmaceutical agents are the most commonly
employed treatments, with corticosteroids being the most widely used drugs. The aim of this article is to
review current scientific evidence as well as the effectiveness of minimally invasive non-surgical tech-
niques, either alone or combined, for the treatment of plantar fasciitis.
Methods: This systematic review was conducted from April 2016 until March 2017, in accordance with
the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement and was
registered with PROSPERO. Randomized controlled trials (RCTs) of adult patients diagnosed with plantar
fasciitis were included as well as intervention studies, with a minimal sample size of 20 subjects per
study (10 per group). Assessment of study eligibility was developed by three reviewers independently in
an unblinded standardized manner. The physiotherapy evidence database (PEDro) scale was used to
analyse the methodological quality of studies.
Results: Twenty-nine full-text articles on minimally invasive techniques were reviewed. These articles
focused on corticosteroid injections, platelet-rich plasma, Botox, dextrose injections, as well as
comparative studies with dry needling vs sham needling.
Conclusion: The treatment of plantar fasciitis has dramatically improved in the past decade with mini-
mally invasive techniques becoming increasingly available. Research findings have shown that the long
term effects of minimally invasive (non-surgical) treatments such as shock wave therapy, botulinum
toxin type-A injections, platelet-rich plasma injections and intratissue percutaneous electrolysis dry
needling show similar and sometimes better results when compared to only corticosteroid injections.
The latter have been the mainstay of treatment for many years despite their associated side effects both
locally and systemically. To date, there is no definitive treatment guideline for plantar fasciitis, however
the findings of this literature review may help inform practitioners and clinicians who use invasive
methods for the treatment of plantar fasciitis regarding the levels of evidence for the different treatment
modalities available.
© 2018 Elsevier Ltd. All rights reserved.
1. Introduction
Plantar heel pain (PHP) is one of the main sources of complaint
in the general population, affecting approximately 2 million
Americans each year and as much as 10% of the population over the
course of a life-time (Martin et al., 2014;McPoil et al., 2008). Plantar
heel pain may include different sources of pain, and involves
different diagnoses such as myofascial pain syndrome, plantar
fasciitis or neuritis, amongst others. Although there are few high
quality epidemiological studies available, one study conducted in
the United States between 1995 and 2000 found that consultations
for PHP equalled approximately one million patient visits to phy-
sicians per year (Riddle and Schappert, 2004).
Plantar fasciitis (PF) is the most common cause of chronic pain
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beneath the heel in adults and may be treated using different
therapeutic strategies (Martin et al., 2014; McPoil et al., 2008).
Conservative treatments have always been the first approach for
treating PF, as recommended by the APTA (Martin et al., 2014;
McPoil et al., 2008). However, in some cases, minimally invasive
therapies such as corticosteroid injections (Grice et al., 2017; Karls
et al., 2016; Yucel et al., 2009), platelet-rich plasma (Ragab and
Othman, 2012; Sharma, 2013; van Egmond et al., 2015; Moraes
et al., 2013; Franceschi et al., 2014; Lee, 2013; Monto, 2013,
2014b), botulinum toxin (Venancio Rde and Zamperini, 2009; Diaz-
Llopis et al., 2013), acupuncture (Zhang et al., 2011; Tough et al.,
2009; Barbagli and Ceccherelli, 2003; Abbasoglu et al., 2015), dry
needling (Cotchett et al., 2014a, 2014b; Cotchett and Landorf, 2014;
Eftekharsadat et al., 2016) and prolotherapy (Kim and Lee, 2014;
Demir et al., 2015) have been used. Also, a recent meta-analysis was
published on the effect of dry needling on the treatment of PHP (He
and Ma, 2017).
The aim of this study was to review the current scientific evi-
dence regarding minimally invasive non-surgical techniques for PF.
2. Methods
This systematic review was conducted from April 2016 to March
2017. Its purpose was to answer the following question: what is the
effectiveness of minimally invasive non-surgical interventions,
either alone or combined for the treatment of plantar fasciitis? The
review was conducted in accordance with the Preferred Reporting
System Items for Systematic Reviews and Meta-analyses (PRISMA)
statement, and was registered with PROSPERO (CRD42018083734).
2.1. Design
A systematic review of scientific studies was conducted for the
treatment of plantar fasciitis using minimally invasive non-surgical
interventions.
2.2. Search strategy
Our literature search aimed to identify all available experi-
mental studies evaluating the invasive non-surgical management
of PF. Searches of MEDLINE, Web of Science, Cochrane, and PEDro
databases were conducted. The last search was performed inMarch
2017. The search strategy was: ((Efficacy OR management OR
effectiveness) AND (plantar OR fasciitis OR fasciosis OR fascitis OR
heel) AND (dry need* OR intratissue percutaneous electrolysis or
acupuncture or electroacupuncture or injection or injectabl* or
puncture and infiltrat*)). These keywords were identified after
preliminary literature searches. There was no restriction by date.
The inclusion criteria were: 1) Randomized controlled clinical trials
with a sample size of at least 20 subjects per study (10 per group);
2) Age of subjects: 18 years and older; 3) Diagnosis of plantar fas-
ciitis (or equivalent terms such as fasciosis or fascitis or heel pain);
4) Studies investigating the effectiveness of any invasive non-
surgical treatment for PF (e.g. dry needling and/or injections,
acupuncture, infiltration). The exclusion criteria were: 1) Any study
including a surgical procedure or pharmacological oral agents or
topical ointment; 2) Studies with animals 3) Trials whose sample or
participants included any of the following terms: diabetes, spas-
ticity, neuropathy, tumour, fracture, haemophilia, stroke, amputa-
tion, artificial limbs and rheumatoid arthritis; 4) Articles for which
the full text was not in English; 5) RCTs not reaching a score of 5 in
the PEDro scale (Fig. 1). The evaluation of the eligibility of the
studies was carried out by three independent reviewers (ZA, ML,
MA) who did an initial filter by title, a second filter by abstract and
subsequently compared the results. In case of disagreements, a
fourth reviewer was consulted (EG). Thereafter, the full text of
selected articles was read to verify whether they met the inclusion
and exclusion criteria. Subsequently, they were evaluated with the
PEDro scale and those obtaining less than 5 points were excluded.
For the data extraction, a table was generated containing all the
results classified by the outcome measurements, which helped to
group the results and enabled a comparison amongst the different
studies.
2.3. Evaluation of risk of bias
We evaluated articles using the Physiotherapy Evidence Data-
base (PEDro) Scale checklist (https://www.pedro.org.au/wp-
content/uploads/PEDro_scale.pdf) for RCTs (Fig. 2). In the PEDro
checklists, each article is scored as “high quality, low risk of bias,”
“acceptable quality, moderate risk of bias,” “low quality, high risk of
bias,” or “unacceptable quality” which resulted in rejection. We
defined each level based on scoring the checklists by assigning a
value of 0 or 1 for each “no” or “yes” response, respectively.
For RCTs, checklists had 10 items and quality scores were
assigned as follows: high quality, low risk of bias, 9e10; acceptable
quality, moderate risk of bias, 6e8; low quality, high risk of bias,
3e5; unacceptable (reject), 0e2 (Fig. 3).
At least three investigators evaluated each article. If there was
disagreement between reviewers, a fourth investigator reviewed
the paper and the majority rating was used after discussion among
reviewers. Studies of unacceptable quality were excluded from the
evidence tables.
2.4. Data extraction
Data were extracted from all included studies by at least three
investigators, with one serving as the primary extractor and the
second and third verifying the data. Disagreements were resolved
by discussion, including a fourth reviewer if necessary. The
extracted data were entered into a Microsoft Word table grouped
by the condition as outlined in the included studies (Table 1). Items
included on the data extraction form were as follows: study iden-
tification (first author); participants (dosage, gender, age, number of
treatment sessions over period); comparator (age, dosage, number
of treatment sessions over period); pain and functional outcome
measures used; results (in terms of pain and functional outcomes);
conclusions, (possible side effects).
A total of 1141 studies were identified from the databases.
Following inspection of the articles, 734 articles were excluded due
to the language or other exclusion criteria. Studies following the
inclusion criteria were filtered by title (n¼ 407) and then by ab-
stracts (n¼ 140). Further analysis of the remaining text yielded 29
articles which fulfilled the inclusion criteria (Fig. 3).
We scored the 29 articles using the PEDro scale and excluded
studies that obtained less than 6 points (n¼ 1). All the trials included
had a score of more than 5 in the PEDro scale (Tables 2 and 3).
3. Results
Twenty-nine full-text articles of minimally invasive techniques
were reviewed and included in this systemic review. These articles
focused on corticosteroid injections, platelet rich plasma, botuli-
num toxin, dextrose injections, as well as comparative studies with
dry needling. Each intervention claims that the patients improved,
and that the painwas decreased. There is no superior treatment but
rather a choice of interventions, as each treatment shows some
significant improvement.
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3.1. Corticosteroids
The most common treatment that has been employed over the
past decades is corticosteroid injections. Our literature search of
invasive methods retrieved 26 RCTs investigating the use of
different types of corticosteroids for the treatment of plantar fas-
ciitis. Some studies used long-acting corticosteroids such as dexa-
methasone (Ryan et al., 2014), and betamethasone (Li et al., 2014a),
while other studies employed intermediate-acting corticosteroids
such as methylprednisolone (Eslamian et al., 2016b; Celik et al.,
2016; Canyilmaz et al., 2015; Ball et al., 2012; Guner et al., 2013b;
Mahindra et al., 2016; Kiter et al., 2006a), prednisolone (Jain et al.,
2015a), dopomedrol (Jain et al., 2015a) and tenoxicam (Guner et al.,
2013b). There was no significant criteria or protocol used for
choosing the type of corticosteroid. A meta-analysis conducted by
Gaujoux-Viala et al. (Gaujoux-Viala et al., 2009) found no difference
between the various types of corticosteroid used. In addition, the
technique and application of the medication differed between the
studies; some studies used amedial approach to inject the patients,
while others used either a posterior approach or through the
plantar aspect of the heel pad. The approach used also depended on
whether the study was conducted using the palpation intervention
approach or under ultrasound guidance.
3.2. Botulinum toxin Type-A
Traditionally, botulinum toxin has been used in the treatment of
spasticity and nerve blocks. Only recently has it found its way into
musculoskeletal medicine. Three RCTs compared the effect of bot-
ulinum toxin type-A (BTA) on heel pain with steroids (Huang et al.,
2010a; Peterlein et al., 2012a; Díaz-Llopis et al., 2012). The studies
reported significant improvements with BTA. Furthermore, pa-
tients with plantar fasciitis who received BTA had significantly
longer lasting relief of dysfunction and pain than those who
received placebo. Further comparative studies are needed with
larger sample sizes (Ahmad et al., 2017).
3.3. Autologous platelet-rich plasma therapy
Platelet-rich plasma (PRP) therapy showed significant im-
provements in the 3-month follow-up. The use of PRP improves
blood flow at the site of injection, which aids in the regeneration at
the site of pain and inflammation, and the boost that occurs after
the injections help the regeneration of the site of pain and
inflammation. In chronic plantar fasciitis, local autologous whole
blood (AWB) injections were superior to conservative treatment
and comparable to corticosteroids, however the effects of AWB last
longer than those of corticosteroids and either can be used as a
second-line treatment, although the use of corticosteroids is asso-
ciated with a slightly higher risk of complications (Jain et al., 2015b;
Karimzadeh et al., 2017). This approach has been studied in nine
Fig. 1. Inclusion and exclusion criteria.
Fig. 2. Randomized controlled trial checklist (PEDro scale).
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RCTs for plantar heel pain showing that PRP injections are as
effective as corticosteroids and, in most cases, superior to the use of
corticosteroids. Some of the papers reviewed compared PRP with
corticosteroid injections, and some with other treatment
modalities.
3.4. Polydeoxyribonucleotide (PDRN) injections
Polydeoxyribonucleotide injections have clinical efficacy with
no notable complications and were associated with symptomatic
improvement in refractory plantar fasciitis. Two main pharmaco-
logical effects of PDRN are hypothesized: the stimulation of VEGF
and a decrease in inflammatory cytokines, such as TNF-a and IL-6,
and an increase in the anti-inflammatory cytokine IL-10, which
could result in the treatment effect on plantar fasciitis (Kim and
Chung, 2015).
3.5. Acupuncture
Acupuncture has been used in Chinese medicine for hundreds of
years however few RCTs were available in English. We retrieved
two articles that used acupuncture for the relief of heel pain with
high significant outcome, however these were based on small
samples and were lacking evidence supporting the use of the
acupuncture (Kumnerddee and Pattapong, 2012; Zhang et al.,
2011).
3.6. Dry needling
Dry needling is a more recent minimally invasive technique.
Considerable research has been conducted in the past few years to
prove the effectiveness of this technique, which shows promising
results with fewer side effects. The theory behind dry needling is
the release of the myofascial trigger point (MTrP), which is a hy-
perirritable spot in the skeletal muscle tissue. The reasons for
trigger point production are multifactorial and include micro-tears,
smoking, or a lack of oxygenated blood at the site of trigger point
which decreases the pH level and renders the site more acidic and
vulnerable to changes at the cytoskeletal level as well the cellular
level, and thus produces pain. To date, there are few studies sup-
porting the use of dry needling and its effects. Recently, two RCTs
have reported a good outcome for these patients with minimal side
effects. Over recent years, the use of dry needling is gaining
popularity within the medical field [23, 24].
4. Discussion
If any future plans to update the protocol and guidelines for the
treatment of plantar fasciitis are to be undertaken, treatment pro-
tocols should be put in place with emphasis on first- and second-
line treatments. The concept of referred pain to the heel, which
can originate from a myofascial trigger point, has been neglected. A
more in-depth assessment of patients must be considered before
prescribing any treatments. The needle effect was described by
Lewit in 1979, who emphasized that the trigger point can be the
Fig. 3. Flow diagram of studies through the different phases of the review.
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Table 1
Characteristics of the included studies.




(n¼ 40) Age 18e65 years. Chronic plantar
fasciitis.
Group 1: (n¼ 20) ESWTwith (41.45 ± 8.05)
years, 18 (90%) female.
2000 shockwaves/session of 0.2mJ/mm (2)
for 15min, 5 sessions in 3 days intervals.
Only Acetaminophen was recommended
during the trail.
Group 2: (n¼ 20) local
methylprednisolone injection with the age
of (42.85± 8.62) years, 15 (75%) females
Corticosteroid injection
40mg local methylprednisolone, 1%
lidocaine on palpation at the most tender
point, medial plantar or inferior calcaneal
area.
Outcome measures: pre-
treatment 4 weeks, and
post treatment 8 weeks.
Pain: (VAS)
Functional: (FFI)
[FFI decreased to 19.65± 21.26 points (67.4%
improvement) in ESWT vs 31.50± 20.53
points (47.7%) in injection group at week 8,
P¼ 0.072)]
The inter-group differences were not
significant, FFI was enhanced more with
ESWT and patients were more satisfied with
ESWT.
The shockwave therapy seems a safe





(n¼ 68) Acute plantar fasciitis >18 years.
Group 1: (n¼ 43) CSI
(44.68± 9.20) years, (28) female and (6)
Male 40mg of methyl prednisolone acetate
plus 1mL of lidocaine 2% was injected into
maximal tenderness point at the infra
medial calcaneal tuberosity.
Group 2: (n¼ 41) ESWT (43.91± 7.96), (29)
females and (5) males
ESWT 2000 impulses with energy of
0.15mJ/mm, total energy flux density of
900mJ/mm for consecutive 3 sessions at 1
week intervals
3 times weekly intervals, at the maximum
tender point marked with a skin marker
with an US gel applied as a medium. No
anaesthesia or narcotics applied.
Pain: VAS-3,6,12 weeks
follow-up.
The pain reduction in CSI group was
significantly in those in the ESWT group
(p< .0001).
In the ESWT and CSI groups, 19 (55.9%) and 5
(14.7%) patients experienced treatment
failure, respectively. Age, gender, body mass
index, and recurrence rate were similar
between the two groups (p> .05)
The patient were 4 times more irresponsive to
ESWT than CSI
ESWT and CSI can be used as a primary
treatment option for treating patients with
acute plantar fasciitis; however, the CSI





(n¼ 128) Chronic Fasciitis> 6 months of
evolution, have calcaneal spur and are over
40, no previous pharmacological treatment
is restricted.
Group 1: (n¼ 64) Receive radiation
therapy mean± SD, years
52.6 (40e74) years, 46 (76.7%) female
14 (23,3%) in male.
(A total dose of 6.0 Gy applied in 6 fractions
of 1.0 Gy three times a week).
Group 2: (n¼ 64) PG-Steroid injection
mean± SD, years
54.7 (40e74) years, 51 (79.7%) female
13 (20.3%)
Local corticosteroid injections; A 22-gauge
1.5-inch needle with 40mg of
methylprednisolone (1mL) mixed with
0.5mL of 1% lidocaine. The painful area and





scale, and a 5-level
function score.
Post treatment is: 3
months
Follow-up period of up to
6 months.
The patient underwent the
radiation therapy; the
median follow-up was 13
months
(PG) steroid injection arm,
it was 12.1 months;
The pre-treatment VAS score was higher in
radiation therapy:
VAS: 7.6 in radiation
6.9 in PG-Steroid
After three months, results in the radiation
therapy arm were
significantly superior to those in the PG
steroid injection arm (VAS P< .001; modified
von Pannewitz scale, P< .001; 5-level
function score, P< .001). Requirements for a
second treatment was not significant. The
time intervals for the second treatment was
significantly shorter in the PG-Steroid groups
(p¼ .045)
This study confirms the better analgesic
effect of radiation therapy compared to
mean Palpation
Guided steroid injection on plantar






Unilateral chronic PF whom did not




Group 1: (n¼ 20) 9 males, 11 females 59
years average of age range (24e74 years);
40mg DepoMedrol cortisone
Both group used 2% of chlorhexidine,
gluconate/70% isopropyl alcohol and then
local anaesthesia. Insertion of the injection
at the medial calcaneal tubercle. Patients
were placed into calm walker for 2 weeks,
allowed to return to activity as tolerated
with daily home eccentric exercises and
calf stretch
Group 2: (n¼ 20); 51 average age (21e67
years) 8 male and 12 females.
single guided US PRP
Both group used 2% of chlorhexidine,
gluconate/70% isopropyl alcohol and then
local anaesthesia. Insertion of the injection
at the medial calcaneal tubercle. Patients
were placed into calm walker for 2 weeks,
allowed to return to activity as tolerated
with daily home eccentric exercises and
calf stretch
PRP¼ 27 cc venous blood sample mixed
with 3 cc of anticoagulation citrate
dextrose solution formula to prevent
clotting of the sample, then centrifuged at










studies were obtained in
all cases to confirm the
diagnosis.
The cortisone group had AOFAS: score of 52
pre-treatments, which initially improved to
81 at three months post treatment but
decreased to 74 at six months, suddenly
dropped to near baseline levels of 58 at 12
months and proceeded to decline to a final
score of 56 at 24 months.
The PRP group began with an average pre-
treatment AOFAS score of 37, which
increased to 95 at three months, remained
elevated at 94 at 6 and 12 months, and had a
final score of 92 at 24 months.
PRP was more efficient and durable than
cortisone injection for
the treatment of chronic cases of plantar
fasciitis.
Kim, E (Kim and
Lee, 2014)
(n¼ 21) with unilateral foot pain for more
than 6 months with chronic PF confirmed
Group 1: (n¼ 10) PRP
36.2 (20e57 years), 6 females & 4 males
Functionally: FFI
Follow-up: Data
An improvement in the mean FFI total
scores from 132.5± 31.1 at baseline to
Both treatments seem to be effective for




















with an US (thickness >4mm) It is chronic
fasciitis that has failed conservative
treatment even with corticosteroid
injections before 6 months prior to the
study, no pharmacological Treatment.
Group 2: (n¼ 11) DP 37.8 (19e51 years),
DP 4 females & 7 males Dextrose
Prolotherapy, 1.5mL of 20% dextrose and
0.5mL of 0.5% lidocaine, resulting in a 15%
dextrose solution, within a 2.5-mL syringe.
Whole blood (20mL) was collected from
the antecubital fossa into a 25-mL syringe
that contained 2mL of anticoagulant
(Huons ACD-soln; sodium citrate 22mg,
citric acid 7.3mg, glucose monohydrate
24.5mg).
Injection was given in both group 2 times. 2
weeks and then after the next 2 weeks the
second injection
Patients were kept sitting position for 30min.
They were sent home with instructions
(allowing only indoor activities of daily
living) for approximately 72 h & to use
acetaminophen for pain. The use of
nonsteroidal anti-inflammatory drugs and
any type of foot orthoses was not allowed.
collected before the first
injection at 2 weeks and
at 2- and 6th month
123.7± 47.4 (3.8% improvement) at 10
weeks and to 97.7± 52.5 (15.1%
improvement) at 28 weeks' follow-up was
achieved in the DP group.
The main FFI improves were greater in PPR
group compared with DP (30.4% vs.15.1%)
Pain: 29.7% vs.17.1%
Disability: 26.6% vs.14.5%
Activity limitation: 28.0% vs 12.4%
Improvement achieved over time with no
adverse events accept of the pain after
injections.
PRP also may lead better initial




(n¼ 67) with unilateral Chronic plantar
fasciitis of 3 months' duration, exclude
those who previously had shock waves and
corticosteroid injections.
Group 1: (n¼ 22) Full length silicone insole
45.6± 9.3, 16 (80%) were female. A
prefabricated full-length silicone insole
daily lives for 1 month both indoors and
outdoors as possible, (acetaminophen) was
allowed if necessary, except last 24 h
before evaluations.
Group 2: (n¼ 22) 47.4± 7.9, 16 (80%) were
female Guided corticosteroid injections
To injection group, A 4-cm 21-gauge needle
was positioned in a caudo-cranial oblique
manner into the area of maximal
ultrasound abnormality, 1mL of
betamethasone dipropionate (6.43mg/mL)
and betamethasone sodium phosphate
(2.63mg/mL) combination. Plus 1mL
lidocaine HCL. (20mg/2mL)
Pain: first step heel pain




thickness of PF in both
groups.
Both groups showed significant change in
VAS at one month from baseline
Injection group:
6.45± 1.23 to 3.70± 1.45
Insole group:
6.95± 0.94 to 4.65± 1.34
VAS scores were significantly better in
injection group than in insole group
(p< 0.05)
Both ultrasound-guided corticosteroid
injection and wearing full-length silicone
insole were effective in the conservative
treatment of PF.
The study recommends the use of silicone
insole as the first line of treatment for
persons with plantar fasciitis.
No adverse events occurred
Chew, KTL (Chew
et al., 2013)
(n¼ 54) with unilateral
chronic plantar fasciitis with more than 4
months of symptoms. excluding those who
have injection with corticosteroids or
another injection 4 months before the
study, did not exclude those who had
physiotherapeutic treatment or splints, all
carry conventional treatment
3 Groups
Group 3: (n¼ 16) 47.5 (41e53 years) 8
Male/8 Females
to conventional treatment alone.
Conventional treatment included
stretching exercises and orthotics if
indicated.
Group 1: ACP (n¼ 19) age 46 years (38
e51), 10 males/9 females.
10mL of peripheral blood drawn and
centrifuged at 1500 rpm for 5min No
buffer or preservative was added, per
manufacturer's protocol. 23-gauge, 1.5-
inch needle at a single peri-fascial target at
the site of plantar fascia thickening and
tenderness at the medial calcaneal
tubercle.
Group 2: (n¼ 19) 45 (37e53 years) 11
Male/8 Female to ESWT: 2000 shockwaves
with energy levels progressing gradually
from 0.02 mJ/mm3 to 0.42 mJ/mm3. The
total treatment duration was 10min. No
local anaesthetic was administered.
Pain: VAS
Functionally: AOFAS
US thickness assessed at
baseline and 1,3,6
months
ACP Group: significant VAS pain score
improvements compared with the
conventional treatment at month 1
(p¼ .037)
The AOFAS ankle-hind foot scale improved in
ACP at third month and sixth month (p¼ 0.04
and p¼ .013)
PF thickness was seen in the ACP at 1st and
three months (p¼ .015 and p¼ .14)
ESWT: 1,3,6 months (p¼ 017, p¼ 0.22,
p¼ 0.42)
The AOFAS ankle-hind foot scale improved
in ESWT at the first month and third month
(p¼ 0.11 and p¼ .003)
PF thickness was seen in the ACP at 1st, and
three months (p¼ .019 and p¼ .027)
PF thickness improved in all groups.
There was no significant difference
between ACP & ESWT regarding VAS &
AOFAS ankle-hind foot scale
improvements, although the ACP group
showed a greater reduction in PF thickness.
ACP treatment resulted in greater
decreases in ultrasound plantar fascia
thickness than ESWT, The ACP treatment
group displayed better objective
improvements, when compared with the
conventional treatment group at the 6-
month follow-up. with an overall median
decrease of ultrasound plantar fascia
thickness by 1.3mmat the 6-month
follow-up. Changes in plantar fascia
thickness more than 0.6mm are
considered changes in thickness not due to
measurement error





(n¼ 30) Chronic Fasciitis of 6 months of
evolution that does not work conservative
treatment, excluding those who have
received injection of corticosteroids in less
than 6 month.
Group 2: (n¼ 15) (52.4± 10.5) years, (12)
females, 3 males. same conventional plus
10 sessions of electro-acupuncture twice
weekly.





VAS decreased significantly from
6.00± 1.69 to 1.89± 1.59 and from
6.27± 2.34 to 5.40± 2.26 in acupuncture
and control group (p< 0.05) acupuncture
group had higher success rate than the
Electro-
acupuncture coupled with
conventional treatment provide success
rate of 80% in chronic PF which was more
effective than conventional treatment




















Table 1 (continued )
Author Participants Comparator Outcome Results Conclusion
Group 1: (n¼ 15) (52.4± 10.5) years, 12
females conventional treatment stretching
exercise, shoe modification and rescue
analgesics
prilocaine cream (Emla) was applied
30min prior treatment 2e6 needles were
inserted at the most tender spot over
anteromedial aspect no manipulation or
twisting applied only a stimulated for
30min using the SDZ- II nerve and muscle
stimulator
by a minimum of a 50%
decrease (VAS) and (FFI).
control group (80% and 13.3% respectively)
FFI was in acupuncture group was better
than those control group (<0.001)
Six week follow up acupuncture group
showed a better FFI and success rate for
pain during the day than those in control
group (p< 0.05)





(n¼ 50) unilateral chronic plantar fasciitis,
double blind
Group 1: (n¼ 25) (54.4 SD 9.6), 6:19 male
to female.
50 units of botulinum toxin type A
Group 2: (N¼ 25) (51.5 5.5 years) Normal
saline under US. 1mL normal saline, by
injection into the plantar fascia under
ultrasonographic guidance us- ing a 25-
gauge, 1.5 inch needle. Subjects in the
control group were injected with 1mL
normal saline into the plantar fascia under
ultrasonographic guidance.
Pain: VAS





pressure during the first
loading step.
Follow up three weeks and three months after
Botox-A injection (p< 0.001).
The fat pad thickness remained unchanged,
the centre of pressure velocity during loading
response increased three months after
injection (p< 0.05) outcome measure of the
control group remained unchanged.
BTX- A is effective in the treatment of foot
pain associated with PF and increases the
centre of pressure velocity during loading
response without inducing fat pad atrophy.
Kalaci, A (Kalaci
et al., 2009)
(n¼ 100) with PF
using four differentmethods
of local injection, patients were blinded to
the treatment given. Exclusion were if
previous 6 months any surgery was done,
or an abnormal erythrocyte sedimentation
rate or C-reactive protein level, previous
injections for plantar fasciitis were not
included.
Group A: (n¼ 25) Age (52.88 ± 11.11), 6
males were treated with 2mL of
autologous blood alone
Group B: (n¼ 25) Age (49.92± 10.8), 7
males an anaesthetic (2mL of lidocaine)
combined with peppering
Group C: (n¼ 25) age (49.87 ± 9.36), 8
males a corticosteroid (2mL of
triamcinolone) alone
Group D: (n¼ 25) age 52.22± 8.49, 9
males, a corticosteroid (2mL of
triamcinolone) combined with peppering.
No additional medication was given, and no
restriction of activity was advised. Patients
were evaluated by re- viewers who were
blinded to the study method.
Pain: 10-cm VAS and
modified criteria of the
Roles and Maudsley
score.
Follow-up: in 3 weeks




Successful results in all the groups post-
treatment were higher than those in the pre-
treatment condition (P¼ .000).
In both C and D groups, in which local
corticosteroid injections used, excellent
results were obtained, with excellent effect in
the group in which peppering was used
(P< .05).
The treatment of PF, combined







(n¼ 132) unilateral with manifest of
6weeks PF.
Exclusion of Previous surgery, CSI, or ESWT
for heel pain.
, Clinical features suggestive of
seronegative spondyloarthropathy, Clinical
features suggestive of regional pain
syndrome.
Group C: (n¼ 19) age 38.1 (21e61) 6
males. non-randomized patients who
performed stretching program only
All patients standardized a stretching
program of the soleus, gastrocnemius, and
plantar fascia each stretch consists of 2min/4
times a day, ice massage and continuing the
ADL with tolerance to pain.
Group A: (n¼ 64) age 39.9 (21e80 years)
20 males single CSI.
One millilitre betamethasone (5.7mg) and
2mL of lignocaine 1% were injected into
the site of maximal tenderness. The medial
calcaneal tuberosity was infiltrated until
the patient declared that his/her
tenderness and symptoms had gone.
Patients were instructed not to take part in
any running or impact activities for at least
10 days following the injection.
Group B: (n¼ 61) age 38.6 (18e81 years)
22 males Low dose of ESWT 3 treatments
over 3 weeks.
Patients randomized to group B each
received 3 applications of 1000 pulses of an
energy flux density of 0.08/mm2. 1000
impulses were applied 3 times at weekly





VAS pain scores, values for the CSI (1.48; 0
e7) were significantly lower than both
ESWT (3.69; 0e8), and controls (3.58; 2e5)
at 3 months. At 12 months, VAS scores for
CSI (0.84; 0e7) and ESWT (0.84; 0e4) were
both significantly lower than controls
(2.42; 1e4). The tenderness values at 3
months were significantly higher for CSI
(9.42; 7e11) than both ESWT (6.72; 4e11)
and controls (7.63; 6e9). P< 0.05 was used
throughout
Corticosteroid injection is more efficient
and more cost-effective than ESWT in the
treatment of plantar fasciitis that has been
symptomatic for more than six weeks.
Of the 64 heels that received CSI, there were
no infections and no cases of rupture of the
plantar fascia. There were 8 cases of post-





Group 1: received Dextrose Prolotherapy




The analysis demonstrated statistically
significant improvements in all parameters
from baseline to 1 and three months
Prolotherapy, corticosteroid, and
phonophorosis therapies were well




























(p< 0.05). There was no significant difference
between groups regarding the efficacy of
treatment (p > 0.05).
The plantar fascial thickness between the
baseline and final measurements revealed a
mean decrease in thickness, statistically
significant difference (p < 0.05) in three
groups. Between groups before treatment, 1
and three months after treatment in terms of
plantar fascia thickness there was no
statistically significant difference (p > 0.05)
benefit of patients with PF. As a result,
Prolotherapy can be an effective way to
treat PF.
Aside from injection-associated pain, no
adverse reactions were reported.
Li S, Shen T (Li
et al., 2014a)
(n¼ 61) after 6 months of filed
conservative treatments. patients were
excluded if they had fracture or arthritis of
the ankle and knee, previous foot surgery
or trauma, nerve injury, a severe systemic
disease, contralateral heel pain, or a history
of MSN release treatment or local steroid
injection
age (54.74± 10.16), 10 males, 19 females)
Group 1:MSN (n¼ 31) age (54.74 ± 10.16),
10 males, 19 females)
2mL of 2% lidocaine. then, the
MSN(diameter 0.80mm, length 50mm),
inserted into the tender point vertically
with the direction of the MSN parallel to
the long axis of the foot. the release of
plantar fasciitis was performed by moving
the MSN up and down 3e5 times without
rotation, the MSN was withdrawn, and
pressure was applied to the wound for
2min to avoid bleeding the hole was
covered with a simple adhesive bandage
for 2 days.
Group 2: CSI (n¼ 30) age (56.93 ± 9.25, 7
males, 25 females) steroid injection
2mL of 2% lidocaine plus 2mL
triamcinolone acetonide (20mg) was
injected into the most painful tender point.
After treatment, the patients in both groups
were observed for 30min to record any
adverse reaction. All patients were asked to






In the MSN group, the VAS scores for morning
pain, and overall pain were significantly
improved at 1, 6, and 12 months after
intervention compared to the baseline scores
( < 0.01).
There were no statistical differences in the
VAS scores observed between 1, 6, and but no
significant improvement in pain was
experienced at 6 or 12 months after
intervention compared to the baseline levels
(> 0.05)
The study suggests that the MSN release
treatment is safe and has a significant
benefit for PF compared to steroid
injection.
No severe side effects were observed with
MSN treatment. The study suggests that MSN
release treatment is safe and has a significant





(n¼ 75) Patients had not responded to at
least 3 months of conservative therapy,
including physical therapy, NSAIDs,
bracing, and orthotics. Treatment with
NSAIDs was discontinued 1 week before
injection.
Group C (Normal saline): age
(35.48± 9.54) 11 males. assigned to receive
normal saline.
Group A (PRP): (n¼ 25) age (30.72± 7.42)
8 males was assigned to receive platelet-
rich plasma
27mL of blood was withdrawn placed in a
glass tube containing 3mL of citrate
dextrose solution. Citrate dextrose solution
was used to prevent clotting. The blood
was centrifuged at 3200 rpm for 12min,
and 2.5e3mL of platelet-rich plasma was
obtained by this method. No activating
agents were used.
Group B (CSI): age (33.92± 8.61) 12 males
was assigned to receive corticosteroid
2mL of 40mg of methylprednisolone was
used for injection
Injection was given at the point of
maximum tenderness in the heel with a
22-g needle using a peppering technique
Outcome measure: VAS
and AOFAS
Follow-up at 3 weeks
and 3 months by a
blinded observer.
Mean VAS and AOFAS scores improved
over time after injection in groups A and B.
In group A, VAS score decreased
significantly from the pre-injection level at
follow-up of three weeks (P¼ 0) and 3
months (P¼ 0).
Compared with the pre-injection level,
AOFAS score improved significantly at
follow-up of three weeks (P¼ 0) and 3
months (P¼ 0). Similarly, in group B, VAS
score decreased significantly from pre-
injection level at follow-up of three weeks
(P¼ 0) and 3 months (P¼ 0).
The AOFAS score improved significantly at
follow-up of three weeks (P¼ 0) and 3
months (P¼ 0) in group B.
In group C, no significant difference was
observed in VAS score pre, and post
injections score at three weeks (P¼ .11); at
three months (P¼ .41).
There were no significant difference
observed between pre-injection AOFAS
score and the score at three weeks
(P¼ .06); at three months (P¼ .39)
PRP is as effective or more than
corticosteroid injection in treating PF




















Table 1 (continued )





(n¼ 106) patients, above the age of 18 and
pain from 1 to 120 months. Median
duration 6 months (±20.6)
excluding patient who received
corticosteroid in less than 6 months.
69 female and 37 males mean age was 57
year (±12.9).
Group 1: (n¼ 27), Mean: (53.69), SD:
(14.28); 1ml of 25mg/ml of prednisolone
acetate with 1mL of
2% lignocaine;
Group 2: (n¼ 26), Mean (56.88) SD:
(13.02); 1mL of 25mg/mL of prednisolone
acetate with 1mL of 2% lignocaine given
after a tibial nerve block
Group 3: (n¼ 27) Mean (59.41), SD (11.84);
2mL of 1% lignocaine hydrochloride
Group 4: (n¼ 26) Mean (58.81)
SD: (12.48); 2mL of 1% lignocaine
hydrochloride given after a
After a tibial nerve block.
Pain: 10 cm VAS.
Follow-up: 1,3,6 months
There was a statistical difference between the
groups in favour of treatment with steroid at
one month (p¼ 0.02)
No statistically significant difference in
pain reduction could be detected between
the injected sub- stances for pain outcomes
taken at 3 and 6 months; the P values were
0.9 and 0.8, respectively.
No statistical difference existed in the
numbers of patients lost to follow-up
between the four groups (P¼ 0.7)
Mean VAS score at one month (p¼ 0.02)
There was no statistically significant
difference in pain reduction among the
groups for pain outcomes taken at three
months (p¼ 0.9) and six months (p¼ 0.8)
but thereafter no differences could be
detected. Patient comfort was not
significantly affected by anaesthesia of the
heel (P¼ 0.5)
A steroid injection can provide relief from
heel pain in the short term; there appears
to be no increase in patients comfort from
anesthetizing using tibial nerve block prior
heel infiltrations.
No adverse event mentioned
Kiter E (Kiter
et al., 2006b)
(n¼ 45) PHP in 3 groups, patients who
received CSI last year they were excluded,
average duration of heel pain was 19.3
months (range, 6e180 months).
Age and Gender: 31 Females and 14 Males.
The mean patient age was 50.7 years
(range, 26e70 years)
Group 1:(n¼ 15) patients underwent the
peppering technique
Group 2: (n¼ 15) underwent autologous
blood injection, a mixture of 2mL of
autologous blood drawn from the
ipsilateral or contralateral upper extremity
and 1mL of 2% prilocaine was infiltrated.
Group 3: (n¼ 15) underwent
corticosteroid injection. 40mg of
methylprednisolone acetate mixed with
1mL of 2% prilocaine was injected.
3 injections were given to all groups
Peppering group: In the peppering
technique group, after infiltration of 1mL
of 2% prilocaine
the needle was inserted, withdrawn,
slightly redirected, and reinserted 10 to 15
times with- out emerging from the skin.
During injection, a sensation similar to
crepitation due to dissection of the fascia or
degenerative tissue was felt
Pain: 10 cm VAS, Rear
foot score of AOFAS 0
e100 (100-best score)
Follow-up: 6 months.
At six-months assessment, statistically
significant improvement found in all groups
(VAS and rear foot scores) there was no
significant difference among the three
groups.
Rear foot score in 6-months:
Peppering group: (P .018)
Autologous blood injection: (P .025)
Corticosteroid injection: (P .30)
VAS score in 6-months:
Peppering group: (P< .001)
Autologous blood injection:(P< .001)
Corticosteroid injection: (P< .001)
Mean± SD visual analogue scale scores in
the peppering technique, autologous blood
injection, and corticosteroid injection
groups improved from 6.4± 1.1, 7.6± 1.3,
and 7.28± 1.2 to 2.0± 2.2 (P< .001),
2.4± 1.8 (P< .001), and 2.57± 2.9
(P< .001), respectively. Mean± SD rear
foot scores in the same groups improved
from 64.1± 15.1, 71.6± 1, and 65.7± 12.7
to 78.2± 12.4 (P¼ .018), 80.9± 13.9
(P¼ .025), and 80.07± 17.5 (P¼ .030),
respectively. There were no statistically
significant differences among the groups.
The curative mechanisms of both injection
modalities based on a hypothesis, they
seem to be great alternatives to
corticosteroid injection for the treatment of
plantar heel pain
No adverse events mentioned
Zhang SP (Zhang
et al., 2011)
(n¼ 89) onset of heel pain <3 months.
Excluding needle phobic, fractures,
pregnant and breast feeding.
Control group: (n¼ 25) age (50.0± 2.0, 6
males & 19 females)
The control group received needling at the
acupoint Hegu (LI 4), which has analgesic
properties
Treatment group: (n¼ 28): (47.0± 2.2,
Males 8 & 20 females) needling at the
acupoint PC 7, which is purported to have a
specific effect for heel pain
Pain: VAS, PPT
Follow-up: 1,3,6 months
There was a significant difference in
reduction in pain scores, favouring the
treatment group.
At one month for morning pain (22.6± 4.0
versus 12.0± 3.0, mean ± SEM).
Overall pain (20.3± 3.7 versus 9.5± 3.6)
PPT (145.5± 32.9 versus -15.5± 39.4)
The study provided that acupuncture can
cause a pain relief to the patient with PF,
The PC 7 point is a relatively specific
acupoint for heel pain.




(n¼ 60)< 6 month of pain with previously
field treatments, excluding previous CSI,
surgery. Patients were allowed to continue
Group A: (n¼ 33), age (44.7± 9.20, 5
males, 8 females) CSI
A 22- gauge, 1.5-inch needle was
Pain: 100-mm VAS and a
physician-assessed heel
The mean visual analogue scale score
changes were 4.0 for group A and 5.3 for
group B (P< .05 for both). Both groups
ESWT and corticosteroid injection






















Group B: (n¼ 27), age (42.9± 7.08
13 males and 14 females) ESWT
A fivefold nerve block (posterior tibial,
superficial and deep peroneal, sural, and
saphenous nerves) was applied to each
operative ankle with 20mL of prilocaine
hydrochloride, 2%. Patients received a
single application of 3000 shockwaves
using an electrohydraulic shockwave
generator. Com- mon ultrasound gel was
used as a contact medium
no additional treatment was permitted
during the study period, including night
splints, nonsteroidal anti-inflammatory
drugs, and physical therapy.
connected to a 2-mL syringe filled with
0.5mL of combined betamethasone
dipropionate (6.43mg/mL) and
betamethasone sodium phosphate
(2.63mg/mL) (Diprospan; and 0.5mL of
prilocaine hydrochloride, 2% (20mg/mL)
The injections were performed from the
medial side of the heel. The most painful
area over the medial calcaneal tuberosity
was determined by palpation, and the
injection was performed at this spot. Care
was taken to avoid the fat pad and injection
into the skin or subcutaneous tissues.
Patients were instructed to refrain from
running and impact activities for 10 days.
tenderness index.
Follow-up: 3-months.
showed significant improvement in visual
analogue scale scores, but there were no
significant differences in scores between
the groups 3 months after treatment
(P> .05).
Results of the visual analogue scale and
heel tender- ness index scores between
patients with and without a spur in groups
A and B were not significantly different
(P> .05). Eleven of the 13 patients (84.6%)
in group A and 10 of the 12 patients (83.3%)
in group B responded to therapy.
All of the patients in group A had pain
during injection. The pain lasted an average
of 5 days, 4 patients required analgesia. No
infections or other major complications
occurred in group A.
None of the patients experienced pain
during the ESWT protocol. Two patients
had a mild throbbing sensation that lasted
an average of 5 days, but did not require
analgesia. Two patients hadmild erythema.
Celik D (Celik
et al., 2016)
(n¼ 46) with unilateral PF
Group 1: (n¼ 22) age (45.4± 9.3), 6 male
and 14 females.
Joint Mobilization & Stretching.
Group 2: (n ¼ 21) age (45.6 ± 7.9), 5 males
& 14 females. Stretching &
mobilizations þ one CSI
1mL of corticosteroids (40mg
methylprednisolone acetate) or 4mL of 2%
(prilocaine HCL) using 22-guage at the heel





and at 3-week, 6-week,
12-week, and 1-year.
Significantly improvement in VAS & FAAM
pain and functional outcome in only 12
weeks and 1 year in group 1 (P¼ .002)
Both groups were statistically significant for
both FAAM (P¼ .001; F¼ 7.0) and VAS
(P¼ .001; F¼ 8.3) scores
At 3 weeks,-6 weeks and -12 weeks.
Between-group differences in VAS & FAAM
favoured the SI group at the 3-week
(P¼ .001, P¼ .001), 6-week (P¼ .002,
P¼ .001), and 12-week (P¼ .008, P¼ .001).
The Steroid Injection group exhibited
better outcomes at all 3-time points. The
noted improvements continued group 1 in
12-weeks to one year.
Jain K (Jain et al.,
2015a)
(n¼ 46) heels with intractable plantar
fasciitis who had failed conservative
treatments for 12 months (ESE, cushioned
insole, physical therapy) 14 patients were
treated bilateral heel, 19 left heel 31 right
heel.
Age & Gender: (mean 55.6 years) 31e79
years, 16 male
Group 2: (n¼ )Steroid injection.
Triamcinolone (Kenalog) 40mg and
Levobupivacaine hydrochloride
(Chirocaine) injection
Group 1: (n¼ )PRP injections 6 underwent
bilateral heel injection
27 (ml) of blood was withdrawn from the
patient and added to 3ml of sodium citrate
(anticoagulant). then centrifuge and spun
for 15min at 3200 rpm. The plasma portion
of the centrifuged mixture was discarded.
Since the anticoagulant introduced to the
whole blood used to produce the platelet
concentrate is acidic, the PRP portion
harvested is buffered with 8.4% sodium





treatment, at 3, 6 and 12
months.
Pre-injection, the two groups were well
matched with no statistically significant
difference. At three months, all three outcome
scores had significantly improved from their
pre-treatment level in both groups.
At 12 months, the RM, VAS and AOFAS scores
in the PRP arm (1.9, 3.3 and 88.5) were
significantly better than the Steroid arm (2.6,
5.3 and 75) with P values of .013, .028 and
.033, respectively.
PRP is significantly more efficient than
Steroid, making it better and more durable
than cortisone injection.
PRP is doesn't wear off with time.
At 12 months, PRP is significantly more
effective.
Kim JK (Kim and
Chung, 2015)
(n¼ 40) Patients with PF, excluding
patients underwent injections within 6
months.
Group 2: (n¼ 20) age 55 (42e71 years n 4
male & 16 females) Placebo injected with
normal saline.
Injections were performed weekly for
three weeks.
Group 1: (n¼ 20) age was 52 (34e68 years,
7 male & 13 female) injection (PDRN)
In the PDRN group, a half vial of PDRN
(1.5mL, was injected into the tender region
of the heel, medial to the insertion of the
plantar fascia. In the placebo group, the
same volume of nor- mal saline was




baseline and 4,12 weeks
after treatment began.
P value represent pairs t-
test with values of initial
status
The PDRN group show a significant
improvement in VAS and MOXFQ scores at
four weeks' post-treatment, and this
continued until 12 weeks' post-treatment.
The placebo group did not achieve a
significant improvement in the VAS or
MOXFQ scored at four or 12 weeks.
PDRN is an efficient and safe treatment
option and may be considered for PF
treatment.
We noticed no injection-related
complications, such as itching, urticaria,
redness or infection signs around the




(n¼ 84) patients with plantar heel pain of
at least one month's duration.
Age: mean± SD age of 56.1± 12.2 years
and 52% were male. The mean± SD
duration of plantar heel pain was
13.6± 12.2 months (range 1e95).
Group 1: (n¼ 42) Real Dry needling
The most frequently treated muscles were
soleus, gastrocnemius, quadratus plantae,
flexor digitorum brevis and abductor
halluces. Less frequently needled muscles
included abductor digiti minimi, and flexor




Significant results favoured real dry needling
over sham dry needling for pain (adjusted
mean difference: VAS first-step pain¼ -
14.4mm, 95% confidence interval [95% CI]¼ -
23.5 to -5.2; FHSQ foot pain¼ 10.0 points,
95% CI¼ 1.0 to 19.1)
Dry needling provided statistically
significant reduction in PHP.
However, the magnitude of this effect should
be studied against the frequency of minor
transitory adverse events.




















Table 1 (continued )
Author Participants Comparator Outcome Results Conclusion
Group 1: (n¼ 42) Real Dry needling
Group 2: (n¼ 42) Sham Dry needling
Patients received dry needling once per
week for six weeks
hallucis longus. Treatments averaged four




(n¼ 56) workers required to stand for
greater than 5 h/day with chronic plantar
fasciopathy took part.
Duration of heel pain at least 12 months no
mention of prior treatment
Group 1: Physiotherapy-lead exercises 7
different exercises.
Group 2: Dexamethasone Injection with
routine calf stretch.
The steroid injection procedure has been
described previously in the literature. A 22-
guage, 1.500 needle and 3 cm3 syringe filled
with 1ml of dexamethasone mixed with





100mm VAS for patients
Follow up: 6 and 12
weeks
The follow-up showed significant
improvement in FADI & VAS compared with
baseline scores (P< 0.001).
There were no significant between-group
differences.
No significant changes to PF thickness
reported at the 6- and 12-week follow-up
point.
Both improved significantly in the PHYSIO
(P¼ 0.003) and INJECTION (P< 0.001)
groups at 12-week follow-up.
The study showed that prolong standing
period workers experienced the same
short-term therapeutic effect. With a
physiotherapy-led exercise program





Gender: 47 (77%) women and 14 (23%)
men)
Mean age of 41.4 12.23 years (range, 18e60
years).
A total of 28 (45.9%) left, and 33 (54.1%)
right feet were studied.
Single injection for both groups
Group 1: (n¼ 31) Tenoxicam group treated
with local injection of 1mL of Tenoxicam
(20 mg/2mL) and one mL of 2% lidocaine.
Group 2: (n¼ 30) Steroid injection The
steroid group using a local 1-mL injection
containing 40mg of methylprednisolone
acetate and one mL of 2% lidocaine.
Pain: VAS
Follow-up: 12 months.
Mean VAS reduction from pre-treatment
to 12 month post-treatment was
statistically significant for both groups
Mean VAS scores of tenoxicam group:
8.26 (pre) / 2.94 (12 month) (p< 0.05)
Steroid group:
7.97 (pre) / 3.17 (12 month) (p< 0.05)
No significant difference was found
between the steroid and tenoxicam groups
in terms
of VAS
Tenoxicam is an effective treatment for PF.





(n¼ 40) the pain >4 months, had at least
two previous non-successful treatments of
non-operative therapy strategy.
Age: 51.54 (28e77) years old
Gender: 80% women's
Group 2: Normal saline injection
Weakness side: Concomitant treatment such
as the application of ice, iontophoresis, ESWT,
heel cups and orthosis, activity modification,
or stretching/strengthening programs, which
were prescribed before study start, was not
interrupted.
Medication changes were not recommended.
Group 1: BoNT-A injection
Botox (200 units) in 2mL 0.9% saline





The participants in the BoNT-A group
achieved a response at the 6th week (25% vs.
5% for placebo; P¼ 0.18).
Differences between treatments were for
BoNT-A on secondary measures of pain but
did not reach statistical significance.
Most of the participants in the BoNT-A group
achieved a response at week 6 (25% vs. 5% for
placebo; P¼ 0.18).
The difference was favouring the BoNT-A on
secondary measures of pain but did not reach
statistical significance. In the BoNT-A group,
52.7% (vs. 40% for placebo) assessed their
condition as slightly/significantly improved
at week 6
BoNT-A achieved a good response a large
prospective long-term should is
recommended.
(The author did not stop other intervention
which can be causing some effects of the
treatments, if not the control group the
placebo shall have some results which affect
the final findings).
No adverse events occur or was noticed.
Ball EM (Ball
et al., 2012)
(n¼ 65) PHP failed to response to 8 weeks
of conservative therapy, excluding
previous injection in heel pad.
Group 3: (n¼ 22) age [50.1 (10.6) 11males,
(52%)] ultrasound guided placebo; 1mL of
0.9% saline (placebo group) was injected
along the superficial border of the plantar
fascia enthesis under direct ultrasound
guidance.
All patients were asked to avoid weight
bearing on the heel pad for 48 h and could
continue with their usual analgesia.
Group 1: (n¼ 22) age [49.0 (12.9) male 10,
(45%)]
patient received ultrasound guided steroid
injections
A 21-gauge needle was inserted parallel to
the heel pad in line with the long axis of the
transducer, Either
0.5 mL (20 mg) of methylprednisolone
acetate þ0.5 mL of 0.9% saline (ultrasound
guided steroid group) or
Group 2: (n¼ 21) age [49.1 (10.7), males 8
(36%)]patients given steroid under
palpations
Pain: VAS (100) at 6, 12.




The difference significantly in VAS scores
between the groups at 6 and 12 weeks
(p¼ 0.018 and p¼ 0.004, respectively).
19.7 (95% CI 2.5 to 37.0) difference in mean
VAS scores at six weeks between the US-
guided steroid group, & the placebo group.
24.0 (95% CI 6.6 to 41.3) difference between
the unguided steroid group & the placebo
group at six weeks.
At the 12 weeks, the mean difference was
25.1 (95% CI 6.5 to 43.6) and 28.4 (95% CI 11.1
to 45.7) respectively between both steroid
injection groups and the placebo group.
Although both ultrasound-guided
corticosteroid injection and wearing a full-
length silicone insole were effective in the
conservative treatment of plantar fasciitis,
we recommend the use of silicone insoles
as the first line of treatment for persons
with plantar fasciitis.
There were no adverse events.
Any patient who failed to respond clinically
to injection at 12 weeks was then offered





















A 21-gauge needle was inserted parallel to
the heel pad in the direction of the medial
tubercle of the calcaneus. An amount of
0.5mL (20mg) of methylprednisolone
acetate and 0.5mL of 0.9% saline was
injected once the needle had been inserted
to the hilt.
No difference in VAS scores following steroid
injection within the US-guided & the
unguided groups at either time point.
PF thickness significantly reduced after
injection in both active treatment groups
(p¼ 0.00).
Patients in both
injection groups showed a statistically
significant reduction in VAS pain scores
compared with the placebo group
There were no significant differences






(n¼ 56) patient who undergo for 6 month
of conservative treatment's for PF. all
patients were initially treated with
stretching, with revision after several
weeks
patients with injections in the last 6
months were excluded.
Group 1: (n¼ 28) received Botox injection
[BTX, SD 51.50 (14.79), 9 males (32.14%)]
100 U of botulinum toxin type A were
diluted in 1mL of normal saline and 70 U
were injected: 40 U in the tender region of
the heel medial to the insertion of the
plantar fascia and 30U in the area between
one inch (2.5 cm) distal to the talar
insertion of the plantar fascia and the
midpoint of the plantar arch
Group 2: (n¼ 28) [CS, SD 56.36 (14.71), 10
males (35.7%)]
receive corticosteroid injection
corticosteroid (2mL of betamethasone
6mg/mL (as acetate and disodium
phosphate)) plus local anaesthetic (0.5mL
of 1% mepivacaine) in the same area of the
calcaneal tuberosity. In addition, a small
sub- cutaneous injection of placebo
(normal saline) was performed in the
middle of the medial side of the fascia to
make the injections
two different phases; patients with
therapeutic failure after the 1st
intervention crosses to the comparator
group (after one month) duration of heel
pain at least six months; prior conservative
treatment (NSAIDs, heel pads, insoles,




Injection of 40 units in tender region of
heel medial to insertion of plantar fascia
and
Unguided steroid injection group
2 mL (12 mg) betamethasone
acetate þ 0.5 mL 1% mepivacaine (LA) in
the same tender region of the heel and a
subcutaneous injection of placebo (normal
saline) in the middle of the medial side of
the fascia
Functionally and Pain:
(FHSQ 4 items) foot pain,
foot function, foot shoe,
and general foot health.
Follow-up: 1, 6 months
At 1 month, there was significant
improvement in all the item scores of both
groups compared to baseline, except in
item 3 (shoe) in the steroid injection group
Change at 1 month from baseline FSHQ1
BTX-A: 34.24 (21.10), p< 0.001 CS: 22.12
(27.42), p< 0.001
FSHQ2
BTX-A: 27.45 (20.58), p< 0.001 C S: 21.43
(24.85), p< 0.001
BoTX-A should be considered for the
treatment of chronic PF, the change found
by onemonth, in particularly at six months,
when this treatment clearly has better
results than corticosteroid injections.
There were no early or late adverse effects
related
to either of the two treatments administered
Lee TG (Lee and
Ahmad, 2007)
(n¼ 61) PF for 6 weeks, excluding previous
surgery.




A combination of 20mg (0.5mL of a 40mg/
Group 1: (n¼ 30) age (48.3± 10.5), range
(28e65) 4
males 28 females
received autologous blood group
For autologous blood injection, 1.5mL of
autologous blood obtained from the




Before treatment, both the autologous
blood group and corticosteroid group had
similarly high levels of pain (p¼ 0.306).
Over the 6-month follow-up, a significant
reduction in pain levels was noted in both
groups (p< 0.0001).
Significant difference was noticed in VAS in
Intralesional autologous blood injection is
efficacious in lowering pain and tenderness
in chronic plantar fasciitis, but
corticosteroid is more superior concerning
speed and probably extent of improvement
There was no fat pad atrophy, infection or




















Table 1 (continued )
Author Participants Comparator Outcome Results Conclusion
mL solution) of Triamcinolone Acetonide
with 2mL of Lignocaine HCL 1% was used.
All patients could walk but were advised to
avoid impact-loading activities, such as
running or jumping, for at least 10 days.
Nonsteroidal anti-inflammatory drugs
were prescribed for not more than 3 days,
and ice packs were allowed for post-
injection pain. Elevation of the foot was
advised for swelling
with 1mL of Lignocaine HCL 2%. Thus, for
both groups, there was an equal volume of
injection solution as well as an equal





rupture of the plantar fascia




(n¼ 20) patients with chronic plantar
fasciitis, Refuse needling and routine
physical therapy (e.g., cooling, stretch,
massage therapy and/or footwear
modifications),; diagnosis of coagulopathy
or taking anticoagulants except for
acetylsalicylic acid at dosages up to
325mg/day
Case Group 1: (n¼ 10) Age [Mean SD
(50.3 ± 8.9) 3 male & 7 females]
Control Group 2: (n¼ 10) [4 male & 6
females (50.9± 8.9)] Control group
50mg diclofenac sodium/12 h and
orthostatic plantar pad were prescribed for
all patients.
All patients were trained to do cold ice
massage and self-stretching for four weeks
DN: dry needling of MTPs one session per
week for four consecutive weeks. Diagnosis
of MTPs was based on detecting a tender
spot or nodule in a taut band of skeletal
muscle. Dry needling was based on calf
muscles trigger points, especially four
trigger points of gastrocnemius muscle
using a dry needle with the length of 30
e50mm and diameter of 0.6mm.
Treatment was conducted within a 30-min
timeframe.
Pain: VAS (0e10 cm), FFI
Functionally: Range of





DN effect was evaluated at three-time
points of baseline, 4 weeks after
intervention and 4 weeks after
withdrawing treatment.
Based on paired t-test, the mean VAS scores
were significantly decreased after four
weeks of intervention (p < 0.001) and four
weeks of cessation period (p< 0.001).
ROMDF of ankle joint was significantly
increased both after four weeks of
intervention (p < 0.001) and four weeks of
cessation period (p< 0.001).
ROMPE of ankle joint was not significant
after four weeks of intervention (p¼ 0.34),
the mean ROMPE of ankle joint was
significantly increased after four weeks of
cessation period (p< 0.04).
There was an insignificant effect on ROMDF
and ROMPE, trigger point dry needling.
dry needling and/or injection of
therapeutic medications (local
anaesthetics, steroids, botulinum toxin A)
have been studied for plantar fasciitis
treatment. Of these treatment options,
steroid injections are more commonly used
in treating acute and chronic plantar
fasciitis, especially when more
conservative managements are
unsuccessful.
Abbreviations; VAS: visual analogue scale SFMPQ: AOFAS: American Orthopedic Foot and Ankle Society, FFI: Foot Function Index,ESWT: Extracorporeal Shock Wave Therapy, ESE: Eccentric stretching exercises. Gy: is a derived
unit of ionizing radiation dose in the International System of Units, PG: Palpation Guide, PF: Plantar Fasciitis PHP: plantar heel pain. ISI: Intralesional Steroid Injection, AVBI: Autologous Venous Blood Injection, AOFAS: American
orthopedic foot ankle society, PRP: Platelet Rich Plasma Therapy, FAOS: Foot & Ankle outcome score, FHSQ: Foot Health status questioner, TT: Tenderness Threshold, HTI: Heel Tenderness Index, US: Ultrasonography, MSN:
Miniscalpel needle, PPT: Pain Pressure Threshold, ACP: Autologous condition plasma, FAAM: Foot Ankle Ability Measure, MOXFQ:Manchester Oxford Foot Questioner, PDRN: Polydeoxyribonucleotide, FADI: Foot Ankle Disability




















source of the pain.
Clinicians should consider starting treatment with non-invasive
techniques and lack of improvement following these techniques
should indicate the need to proceed towards minimally invasive
techniques (Fig. 4).
First line treatment should include exercise therapy and one
additional treatment modality, either shockwave therapy or
manual therapy, to treat the trigger points. As a second-line treat-
ment, dry needling techniques should be employed initially as
these are non-pharmacological and show promising results. How-
ever, this technique should be investigated further on a bigger
sample group with a longer follow-up period (Eslamian et al.,
2016a).
The use of intratissue percutaneous electrolysis has beenwidely
used in Europe, mainly in Spain, however, to date, there are no
published studies comparing its effectiveness for the treatment of
plantar fasciitis. Preliminary studies with prolotherapy are prom-
ising and this technique can be used if dry needling fails. Also,
prolotherapy has a better side effect profile compared to steroid
injections. Injectable corticosteroids have been the mainstay of
treatment for many years despite their associated side effects both
locally and systemically (Cole and Schumacher, 2005). Despite this,
there are no specific guidelines for the use of steroids indicating the
dosage, type or frequency of injections.
Radiation therapy is another treatment approach that has been
employed for pain relief of plantar fasciitis. Its mechanism of action
is unknown, however, it is thought to have anti-inflammatory
properties in low doses which may be attributed to the pain relief
seenwhen used in treatment of plantar fasciitis. Fractional doses of
0.5e1.0 Gy and total doses of 3e6 Gy are employed in the treatment
of plantar fasciitis. It is important to note that radiation therapy is
carcinogenic and patient selection is crucial as well as their
























1 Eslamian, F (Eslamian et al.,
2016b)
1 1 0 1 0 0 1 1 1 1 7/10
2 Mardani-Kivi, M (Mardani-
Kivi et al., 2015)
1 1 1 1 0 0 0 1 1 1 7/10
3 Canyilmaz, E (Canyilmaz et al.,
2015)
1 1 1 0 0 0 1 1 1 1 7/10
4 Monto, RR (Monto, 2014b) 1 1 1 0 0 0 1 1 1 1 7/10
5 Kim, E (Kim and Lee, 2014) 1 1 1 1 1 0 1 1 1 1 9/10
6 Yucel, U (Yucel et al., 2013) 1 1 1 0 0 1 1 1 1 1 7/10




1 1 1 1 0 0 0 1 0 1 6/10
9 Huang, YC (Huang et al.,
2010b)
1 1 1 1 0 1 1 1 1 1 9/10
10 Kalaci, A (Kalaci et al., 2009) 1 1 1 1 0 1 1 1 1 1 9/10
11 Porter, MD (Porter and
Shadbolt, 2005)
1 1 1 1 0 0 1 0 1 1 7/10
12 Demir G, (Demir et al., 2015) 1 1 1 1 0 1 1 1 1 1 9/10
13 Li S, Shen T (Li et al., 2014;
Monto, 2014a)
1 1 1 1 0 1 1 1 1 1 9/10
14 Mahindra P (Mahindra et al.,
2016)
1 1 1 0 0 0 1 1 1 1 7/10
15 Crawford F, Atkins D
(Crawford et al., 1999)
1 1 1 1 0 1 1 1 1 1 9/10
16 Kiter E (Kiter et al., 2006b) 1 1 0 1 0 1 1 1 1 1 8/10
17 Zhang SP (Zhang et al., 2011) 1 1 1 1 0 0 1 0 0 1 6/10
18 Yucel I, (Yucel et al., 2010) 1 1 1 1 0 0 0 1 1 1 7/10
19 Celik D (Celik et al., 2016) 1 1 1 1 0 0 0 1 1 1 7/10
20 Jain K (Jain et al., 2015a) 1 1 0 0 0 0 1 1 1 0 5/10
21 Kim JK (Kim and Chung, 2015) 1 1 1 1 0 1 1 1 1 1 9/10
22 Cotchett MP (Cotchett et al.,
2011)
1 1 0 1 0 0 0 1 1 1 6/10
23 Ryan M (Ryan et al., 2014) 1 1 1 1 1 1 1 1 0 0 8/10
24 Guner S (Guner et al., 2013a) 1 1 1 1 1 1 0 1 0 0 7/10
25 Peterlein CD (Peterlein et al.,
2012b)
1 1 1 1 0 1 1 1 1 1 9/10
26 Ball EM (Ball et al., 2012) 1 1 1 1 0 0 1 1 0 1 7/10
27 Díaz-Llopis IV (DíazLlopis
et al., 2012)
1 1 1 1 1 1 0 1 0 0 7/10
28 Lee TG (Lee and Ahmad, 2007) 1 1 1 1 0 1 1 1 1 1 9/10
29 Eftekharsadat (Eftekharsadat
et al., 2016)
1 1 1 0 0 1 1 1 1 1 8/10
Table 2
Summary of PEDro scale scores.
PEDro Scale Score Number of articles Found
5/10 (n¼ 1) article
6/10 (n¼ 4) articles
7/10 (n¼ 12) articles
8/10 (n¼ 3) articles
9/10 (n¼ 9) articles
10/10 (n¼ 0) articles
Z. Al-Boloushi et al. / Journal of Bodywork & Movement Therapies 23 (2019) 122e137 135
4.1. Conclusion
Based on the findings of all the RCTs analysed, many authors
consider that plantar fasciitis is a degenerative tissue condition
rather than an inflammation at the site of origin of the plantar
fascia at the medial calcaneal tuberosity. The histology of plantar
fasciitis is the same as that of tendinopathies. This implies that
degeneration can cause a micro tear within the fascia that does not
heal, which can trigger inflammation. However an interruption in
the healing process due to poor circulation leads to degenerative
changes in the connective tissues.
The treatment of plantar fasciitis has dramatically improved in
the past decade with more minimally invasive techniques
becoming increasingly available. The results demonstrate that the
long term effects of minimally invasive (non-surgical) treatments
such as shock wave therapy, botulinum toxin type-A injections,
platelet-rich plasma injections and intratissue percutaneous elec-
trolysis dry needling show similar and sometimes better results
when compared to corticosteroid injections. Most studies have
been using corticosteroids which, as well as being associated with
transient effects on pain and function, are associatedwith a number
of complications, including infections, contact allergic dermatitis
due to preservatives, skin atrophy, osteomyelitis of the calcaneus
and rupture of the plantar fascia (Canyilmaz et al., 2015;
Karimzadeh et al., 2017). Furthermore, higher doses of corticoste-
roids can be contraindicated in certain patients (Karimzadeh et al.,
2017). Corticosteroids, the current mainstay of plantar fasciitis
treatment, are divided based on their duration of action and, as of
yet, consensuated guidelines regarding corticosteroid use are
lacking. In conclusion, definitive treatment guidelines for plantar
fasciitis are still lacking. The best results were obtained by
combining several techniques with minimal invasive therapy such
as stretching or exercises in additional to the treatment that been
prescribed.
The findings of this literature review may help inform
practitioners and clinicians who use invasive methods for the
treatment of plantar fasciitis regarding the levels of evidence for
the different treatment modalities available.
4.2. Limitations and future study recommendations
We have identified 29 relevant RCTs, which covered a wide
variety of interventions and several procedural approaches that can
be employed to establish treatment protocols for plantar heel pain.
However, a wide range of dosages were used in some of the
treatments (number of treatments and interval of care), making it
difficult to draw exact conclusions about optimal dosage. Studies
should clearly describe treatment protocols, including frequency,
intensity and duration in order to reach optimal management.
Further research is needed to investigate the value of single and
combined modalities. Additionally, it is possible that some studies
were missed, despite the formal literature search.
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Abstract
Background: Both manual therapy techniques and dry needling have shown to be effective treatment options for
the treatment of plantar heel pain; however, in recent years, other techniques based on dry needling (DN), such as
percutaneous needle electrolysis (PNE), have also emerged. Currently, PNE is being used in clinical practice to
manage myofascial trigger points, despite the lack of studies comparing the effects of this technique over dry
needling. Therefore, the aim of this randomized controlled study is to compare the effectiveness of DN versus
PNE for improving the level of pain experienced by patients suffering from plantar heel pain provoked by myofascial
trigger points.
Methods: A randomized controlled trial will be conducted with blinded participants and outcome assessors. A sample
of 94 patients with a medical diagnosis of plantar heel pain will be recruited and divided into two treatment groups.
Eligible participants will be randomly allocated to either (a) treatment group with DN and a self-stretching
home program or (b) treatment group with PNE and a self-stretching home program. Each group will receive
one treatment session per week over a period of 4 weeks. The primary outcome measure will be the pain
subscale of the Foot Health Status Questionnaire. The secondary outcome measures will be a visual analogue
scale for pain (average and highest level of pain experienced during the previous 48 h; level of pain immediately after
the treatment session) and health-related quality of life (assessed using the EuroQoL-5 dimensions). Cost-effectiveness
data will be extracted based on the EuroQoL-5 dimensions. Follow-up measurements will take place at baseline and at
4, 8, 12, 26, and 52 weeks.
Discussion: The justification for this trial is the need to improve current understanding regarding the effectiveness of
treatments targeting the rehabilitation of plantar heel pain. This study will be the first randomized controlled trial to
directly compare the effectiveness of DN and PNE combined with a specific stretching program for the treatment of
plantar heel pain provoked by myofascial trigger points.
Trial registration: Clinical Trials NCT03236779. Registered at clinicaltrials.gov 2 August 2017.
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Background
Plantar heel pain (PHP) is one of the main sources of
pain in the foot, causing soreness or tenderness in the
sole of the foot, under the heel, and which sometimes
extends into the medial arch [1, 2]. This condition af-
fects both athletic and sedentary individuals and does
not seem to be influenced by gender [2]. The incidence
and prevalence of plantar heel pain is uncertain; how-
ever, it is estimated that over the course of a lifetime,
10% of the population may suffer this condition [3, 4].
Furthermore, results from a high-quality epidemiological
study in the USA from the 1990s found that approxi-
mately one million patient visits to physicians per year
were due to PHP [5], with an associated annual cost of
around $300 million [6].
Plantar heel pain may include different sources of pain,
involving various diagnoses, such as myofascial pain syn-
drome, plantar fasciitis, or heel spur, among others [7].
The diagnosis is usually made based on the patient’s his-
tory and physical examination, including pain during the
first steps in the morning or after prolonged rest, as well
as pain during prolonged standing or walking [3, 4, 6];
more in-depth examinations are used only to rule out
other disorders causing inferior heel pain, such as tu-
mors, infections, and neuropathic pain (including tarsal
tunnel syndrome) [8, 9]. The proper identification of
the main cause of pain can be difficult as, usually,
this may be multifactorial [10]. Current heel pain
guidelines identify risk factors that include limited
ankle dorsiflexion ROM, high body mass index (BMI)
in nonathletic individuals, running, and work-related
weight-bearing activities [3, 4].
There is a lack of consensus regarding the ideal manage-
ment approach for PHP [11–13]. Clinical practice guide-
lines support the use of conservative treatment, such as
joint and soft tissue mobilization or self-stretching home
programs (SSHP) [3, 4]. In particular, SSHP has shown to
be effective for addressing PHP [3, 10, 14], while recent
randomized clinical trials (RCTs) have shown that there is
an additional effect reducing the severity of pain when
SSHP is combined with ischemic compression [15] and
with dry needling (DN) [16].
Despite its prevalence, the etiology of PHP is not
well understood [3, 4]. Although PHP may be pro-
voked by a tendinous injury affecting the plantar
fascia, it is well known that the presence of myofas-
cial trigger points (MTrPs) within the plantar and
lower leg musculature may play an important role in
people with PHP [17], and recent studies have based
their hypothesis on this assumption [15, 16, 18, 19].
Some of these have demonstrated the effectiveness of
manual therapy techniques (i.e., ischemic compres-
sion) [15, 19] while others have also demonstrated
the effectiveness of DN [16, 18].
Physical therapy approaches continue to evolve and in-
clude the combination of DN and electrolysis, known as
percutaneous needle electrolysis (PNE), with promising
results for the treatment of tendon pathologies [20–22].
The PNE technique is a minimally invasive treatment
that consists of the application of a galvanic electrolytic
current that causes a controlled local inflammatory
process in the target tissue. This promotes phagocytosis
and the subsequent regeneration of the affected tissue
[20, 21]. Nowadays, PNE is being used in clinical prac-
tice to manage MTrPs; however, there are no studies
supporting any additional beneficial effects over DN.
Furthermore, there are cost variations between these
techniques, which affect the healthcare system. A
cost-effectiveness comparison will determine which
treatment intervention is the most efficient.
From a biological point of view, it seems reasonable to
hypothesize that subjects can display improvements
thanks to the mechanical effects of the needle and that
patients may benefit more when the electrolysis effect
is added to the mechanical stimulus provided by the
needle. Therefore, the aim of this randomized con-
trolled study is to compare the effectiveness of DN




The study subjects will be adults of both genders who
have been admitted to the Physical Medicine and Re-
habilitation Department in a Kuwait City hospital by a
medical registered doctor from the Ministry of Health.
To be eligible for the study, participants will have to
meet the following inclusion criteria:
– Clinical diagnosis of PHP in accordance with the
Clinical Guidelines linked to the International
Classification of Function, Disability and Health
from the Orthopedic Section of the American
Physical Therapy Association [3, 4, 16, 18]
– Age between 21 and 60 years at admission to the
study, according to the Kuwaiti law
– History of plantar heel pain for over 1 month,
showing no improvements with previous
conservative treatment
– Able to walk 50 m without any support
– The presence of MTrPs on plantar and calf muscles,
based on initial physical examination carried out by
a physiotherapist (MA) with experience and training
in MTrPs
– Accepting treatment from a male physiotherapist
– The ability to understand the study and the informed
consent, as well as having signed the document
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Exclusion criteria for the study will be based on:
– Needle phobia
– Needle allergy or hypersensitivity to metals
– Presence of coagulopathy or use of anticoagulants
according to medical criteria
– Presence of peripheral arterial vascular disease
– Pregnancy
– Dermatological disease affecting the dry needling
area
– The presence of a chronic medical condition which
might preclude participation in the study, such as
malignancy, systemic inflammatory disorders (e.g.,
rheumatoid arthritis, psoriatic arthritis, ankylosing
spondylitis, septic arthritis), neurological diseases,
polyneuropathy, mononeuropathy, and sciatica
– Treatment of plantar heel pain with needling or
acupuncture during the last 4 weeks
– A history of injection therapy in the heel over the
previous 3 months
– Previous history of foot surgery or fracture
Participants will be controlled by using the appropriate
medication dosage as prescribed by the physiatrist (analge-
sics and non-steroidal anti-inflammatory medications) and
will be required to report any changes to the assessor dur-
ing the evaluations if they take any additional medication
or undergo any treatment during the intervention. They
must be willing not to receive or implement any form of
treatment for the plantar heel pain (taping, night splints,
massage therapy, or footwear modifications) while they
participate in the trial. The participants will have the right
to withdraw from the study at any time without having to
provide any explanation.
Regarding sample size, 94 participants with PHP will
be recruited. An initial prospective sample size calcula-
tion estimated that 39 participants per group will pro-
vide 80% power to detect a minimally important
difference of 13 points in the pain domain of the Foot
Health Status Questionnaire (FHSQ) with a standard de-
viation of 20 points [23] and an alpha risk at 0.05, allow-
ing 20% loss to follow-up (16 patients).
Study design
Both the assessment and intervention will take place at
the Physical Medicine and Rehabilitation Hospital in
Kuwait.
This study is a prospective, two parallel groups (par-
ticipant) randomized controlled trial with blinded out-
come assessment at baseline and at 4, 8, 12, 26, and 52
weeks. The study flow chart shown in Fig. 1 conforms to
the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) guidelines for nonphar-
macological studies [24].
Participants who fulfill the inclusion criteria will re-
ceive the standardized oral and written information and,
once they consent to participate in the trial, will be ran-
domized in a block system by blocks of 10 patients. Al-
location to the groups will be achieved using a computer
program (Randomizer, https://www.randomizer.org/)
with random patient file number sequences generated by
a third person not involved in the study, and based on
their file number in Kuwait. This person will be respon-
sible for safekeeping the envelope with the information
of the randomization. The envelopes will remain
closed until the moment of the intervention in order
to maintain the blinding. This professional will also
ask the patients for informed consent. This research
study was approved by the Medical Ethics Committee
of the State of Kuwait Ministry of Health, with refer-
ence number 642/2017.
Interventions
To determine what muscles will be treated, muscles ful-
filling the following two criteria will be selected: (a) mus-
cles that typically refer pain to the heel [17] and (b)
muscles that can be directly palpated or that can be nee-
dled with precision and safety without ultrasound guid-
ance. The clinician will perform a physical examination
to find MTrPs following Travell and Simons’ criteria: (1)
the presence of a taut band and (2) identification of an
exquisite spot tenderness or a nodule [17]. A flat palpa-
tion or pincer palpation technique will be used to pal-
pate the MTrPs, depending on the muscle being
assessed. The muscles to be treated will be the soleus,
gastrocnemius, quadratus plantae, flexor digitorum bre-
vis, and abductor hallucis. If a muscle contains more
than one MTrP, the most sensitive MTrP will be
treated, according to the patient’s perceived pain upon
palpation. If the patient has pain bilaterally, the clin-
ician will treat both sides. The position of the patient
will always be lying; however, it depends on each
muscle (supine, prone, or lateral decubitus position),
and will be the same for the assessment as well as
for the intervention [25].
During the first session, all participants will be taught
a self-stretching protocol [15] which has demonstrated
to be effective for the management of PHP [10, 15, 26]
and will consist of the following exercises: (a) Self-
stretching of the calf muscles: in standing, with the af-
fected foot furthest away from the wall, the patient will
be instructed to lean forward, while keeping the heel on
the floor. To focus the stretching on the soleus muscle,
the affected knee will be bent, whereas to focus on the
gastrocnemius muscle, the affected knee will be kept in
full extension. In this position, patients will be taught to
lean forward until they feel a stretch in the calf and/or
Achilles region. All patients will complete both versions
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of the stretch. (b) Plantar fascia-specific self-stretching:
in the sitting position, patients will cross the affected
foot over the contralateral thigh. The patient will place
his/her fingers over the base of the toes, grasp the base
of the toes, and pull the toes back towards the shin, until
a stretch is felt in the plantar fascia [15]. According to
the evidence, we will follow the same dosage for calf and
plantar fascia-specific self-stretching exercises, twice a
day, using intermittent stretching lasting 20 s, followed
by 20-s rest periods for a total of 3 min per stretch [15].
Participants will receive four individual physiotherapy
sessions, once a week. The duration of the sessions may
change depending on the patient; however, these will last
approximately 30min. Participants will be treated by a
physical therapist registered at the Kuwait Ministry of
Health and trained in the protocol. The clinician will have
a minimum of 5 years practical experience in the field of
dry needling and appropriate training.
Invasive interventional groups: dry needling and
percutaneous needle electrolysis
Specific needles for dry needling will be used during in-
vasive treatments (Agu-punt, Spain). Needle length will
be determined by the location of the MTrP and will
Fig. 1 Flow diagram. Randomized controlled trial design
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range from 30 to 50mm in length (or longer if necessary
according to patients’ characteristics). The diameter of
the needle will be 0.25–0.30 mm. If the participant is
sensitive to the needle insertion, the level of manipula-
tion will be reduced. If this measure proves insufficient
for reducing the painful stimulus, manipulation of the
needle will cease altogether and the needle will be left in
situ [25, 27].
To maintain appropriate hygienic conditions during
the invasive treatments, the clinician will wear latex
gloves and thoroughly clean the skin of the area to be
needled with an antiseptic solution (70% Propan-2-ol,
Skin-des). Upon removal of the needle, the area will be
firmly compressed for 10 s. The needle will be discarded
after each single use.
In both groups, the intervention will be terminated
in the case of severe adverse effects, if the participant
does not wish to continue, and if there is an un-
approved use of medication. Any adverse effects will
be duly reported.
Dry needling arm
Once the clinician locates the MTrP, the needle will be
inserted over the same and a rapid needle entry will be
performed. The chosen technique for manipulating the
needle will be the technique described by Hong [28],
which consists of a rapid needle entry and exit (fast in/
fast out), in order to obtain a local twitch response
(LTR), lasting 5 s employing a rhythmic movement at
approximately 1 Hz/sec (five entries). The number of
LTRs will be counted and registered.
Percutaneous needle electrolysis arm
The electrotherapy equipment used (Physio Invasiva,
PRIM Fisioterapia, Spain) produces a continuous gal-
vanic current through the cathode while the patient
holds a hand-held anode [22]. Once the needle reaches
the relevant treatment area, this will be needled in
exactly the same manner as in the DN group, with the
only difference being that the needle will be transmitting
an electrical current with an intensity of 1.5 mA (inten-
sity may be adapted to patient’s characteristics according
to their pain’s tolerance).
Study variables
Baseline data
Baseline data will include gender, age, height, weight,
BMI, details regarding the affected side (right, left, or bi-
lateral), duration of symptoms, medication, and previous
treatments.
A blinded observer will assess all participants at base-
line and at 4, 8, 12, 26, and 52 weeks post-treatment
(Fig. 2).
Primary outcome measure
Participants will complete the FHSQ at baseline and at 4,
8, 12, 26, and 52 weeks post-treatment. The FHSQ con-
sists of 13 questions reflecting four foot health-related do-
mains: pain (4 questions), function (4 questions), footwear
(3 questions), and general foot health (2 questions). Indi-
vidual item scores will then be re-coded, tabulated, and fi-
nally transformed to a scale ranging from 0 to 100 for
each of the four domains [29]. Greater scores reflect better
foot health and quality of life [30]. The FHSQ has been
validated [31] and has been used in similar trials that have
evaluated the effectiveness of different interventions for
plantar heel pain [18, 32, 33].
Secondary outcome measures
Participants will complete the visual analogue scale (VAS) at
baseline and at the 4-, 8-, 12-, 26-, and 52-week assessments
and additionally before each treatment session. The level of
pain that patients have experienced during the previous 48 h
prior to starting the treatment session will be recorded. Par-
ticipants will be asked about the mean and the highest level
of pain they have experienced. The exact wording of the
questions will be: (1) what is the level of pain, on average,
that you have felt during the last 48 h? and (2) what is the
maximum level of pain you have felt during the last 48 h?
Additionally, after treatment, they will be asked to score
their current pain immediately upon standing up and walk-
ing a few steps. Participants will be explained that a score of
0 indicates the absence of pain, whereas a score of 10 repre-
sents the maximum tolerable pain. The VAS is widely used
and is valid and reliable [34–36]. They will also indicate the
areas of perceived pain on an electronic body chart (Navi-
gate pain, version 0.1.9.9, Aalborg, Denmark) [37].
Quality of life (QoL) will be assessed with the
EuroQoL-5 dimensions (EQ-5D), which will be filled out
by the patients at baseline and at the 4-, 8-, 12-, 26-, and
52-week assessments. The EQ-5D self-report question-
naire is a descriptive system with five questions, each
representing one dimension of health-related quality of
life (HRQoL), i.e., mobility, self-care, daily activities, pain/
discomfort, and depression/anxiety. Each dimension can
be rated on three levels: no problems, some problems, and
major problems, and together, the results serve to classify
people into 1 of 243 possible health states [38].
Cost analysis
Costs will be collected from the healthcare viewpoint. Dir-
ect healthcare costs are the costs of manual therapy,
physiotherapy or general practitioner care, additional visits
to other healthcare providers, drugs, and hospitalization.
Cost-effectiveness and cost-utility analyses will be carried
out with quality-adjusted life-year, estimated from EQ-5D
scores.
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Statistical analysis
The statistical analysis will be performed via an
intention-to-treat analysis. Variables will be described in
number (percentage) and average (standard deviation) or
median (interquartile range), according to their distribu-
tion. Quantitative variables will be analyzed with the
Shapiro Wilk test in order to confirm their distribution
and to determine the correct statistical tests according
to these results.
The outcomes will be analyzed using mixed linear and
logistic regression models considering participants as a
random effect and treatment group as fixed factors.
Baseline characteristics will be introduced in the model
as covariance factors. The numbers needed to treat index
will also be calculated. The primary aim of the analysis
will be to calculate the difference obtained in the FHSQ
score after the intervention (final measurement − initial
measurement). Finally, the magnitude of the effect of the
result will be calculated and, therefore, its clinical import-
ance, by using the following formula: r = √[F(1,dfR)]/
[F(1,dfR)+dfR].
The significance level for statistical tests will be set at
p ≤ 0.05.
Ethics and dissemination
The study design, procedures, and informed consent
procedure were approved by the Ministry of Health in
the state of Kuwait on 19 September 2017, and the study
will be conducted in compliance with the Helsinki
Declaration of Human Rights. The registration number
provided by ClinicalTrials.gov is NCT03236779 (regis-
tered 2 August 2017). Participants will be requested to
provide informed written consent before randomization.
The software used to assemble the papers included in
this review will be EndNote X7 v17.0.1. The participant
data obtained in this ongoing research will not to be
used for other purposes. All the personal information
collected such as the informed consent form and the
physical examination findings will be stored by category
in a specific filing cabinet before, during, and after the
trial, in order to protect confidentiality. After completing
the data analysis, and regardless of the findings, we plan
to disseminate all the trial results via conferences and
publications.
Discussion
Plantar heel pain is a common cause of foot pain and
discomfort affecting the health and quality of life of pa-
tients, with a high tendency for relapse and chronicity
[8]. Previous studies have demonstrated the positive ef-
fect of conservative treatment in reducing painful condi-
tions associated to PHP [15, 19], while other RCTs show
that DN probably has a higher potential benefit over
more conservative approaches [16]. Nevertheless, ac-
cording to systematic reviews, new high-quality RCTs
are needed on which to base the evidence regarding the
effectiveness of DN for symptoms management in PHP
[39]. Despite the fact that the plantar fascia can be a
Fig. 2 Schedule for enrolment and intervention
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source of pain in itself [40] and that other studies per-
forming invasive treatments have considered needling
upon the insertion of the plantar fascia [41], our hypoth-
esis is restricted to evaluating the contribution of MTrPs
towards PHP.
As an innovative treatment modality, PNE is being in-
creasingly used in order to promote the regeneration of
injured tendons [20–22, 42] and is being gradually recog-
nized as a cornerstone for invasive approaches in physio-
therapy. However, despite the fact that its use is increasing
based on an apparently additional effect to only DN, there
is no scientific evidence to support the use of this tech-
nique in clinical practice. Due to this fact, our aim is to re-
search whether PNE can offer an additional effect to DN
for PHP management. To our knowledge, this will be the
first study to compare two invasive treatments for MTrPs
associated with PHP. Not only this study will contribute
to research regarding the possible additional effects of
PNE, but also by analyzing differences in pain perception
after therapy, it will address a common patient complaint.
Furthermore, cost-effectiveness data will be extracted
based on the EQ-5D, thus providing a valuable economic
variable to studies involving physiotherapy techniques.
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ABSTRACT
Objectives To compare the effectiveness of dry needling 
(DN) versus percutaneous needle electrolysis (PNE) for 
improving the level of pain, function and quality of life 
(QoL) of patients suffering from plantar heel pain (PHP) 
provoked by myofascial trigger points.
Design A prospective, parallel- group, randomised 
controlled trial with blinded outcome assessment.
Setting A single treatment facility in the State of Kuwait.
Participants 118 participants were screened for 
eligibility. Of these, 102 participants were enrolled (30 men 
(49.5±8.9 years) and 72 women (48.1±8.8 years)) and 68 
of them completed the trial.
Interventions Two parallel groups, one study arm 
received DN and a stretching protocol whereas the other 
arm received percutaneous needling electrolysis with a 
stretching protocol.
Primary and secondary outcome measures The 
primary outcome measure was the Foot Pain domain of 
the Foot Health Status Questionnaire, with 13 questions 
related to foot health- related domains. Secondary 
outcome measures included the 0–10 numerical rating 
scale pain visual analogue scale (VAS) scores, performed 
before and after each treatment session. In addition, 
QoL was measured using the EuroQoL-5 dimensions. All 
measurements were taken at baseline, at 4, 8, 12, 26 and 
52 weeks.
Results Foot Pain domain improved at all time points for 
DN group (p<0.001; 29.7 (17.8 to 41.5)) and percutaneous 
needling electrolysis group (p<0.001; 32.7 (18.3 to 
47.0)), without significant differences between groups. 
Pain VAS scores decreased at all time points for both DN 
(p<0.001; −2.6 (−4.0 to −1.2)) and percutaneous needling 
electrolysis group (p<0.001; −3.0 (−4.5 to −1.6)). QoL 
improved at 4 weeks for both DN (p<0.01; 0.15 (0.5 
to 0.25)) and percutaneous needling electrolysis group 
(p<0.01; 0.09 (0.01 to 0.17)) and at 8 and 52 weeks 
for the PNE group (p<0.01; 0.10 (0.02 to 0.18)), with 
significant differences between groups for the QoL at 52 
weeks (p<0.05; 0.10 (0.01 to 0.18)). There were two small 
haematomas in the PNE group and one in the DN group. 
No serious adverse events were reported.
Conclusions Both PNE and DN were effective for PHP 
management, reducing mean and maximum pain since the 
first treatment session, with long lasting effects (52 weeks) 
and significant differences between groups in the case of 
QoL at 52 weeks in favour of the PNE group.
Trial registration number NCT03236779.
INTRODUCTION
Plantar heel pain (PHP) is a common problem 
affecting the foot, causing soreness or tender-
ness in the sole of the foot, and under the 
heel, sometimes extending into the medial 
arch.1 The frequency and incidence of PHP 
is uncertain; however, it is estimated that over 
the course of a lifetime 10% of the popula-
tion may suffer from this condition.2 3 Several 
pathologies may cause PHP, such as myofas-
cial pain syndrome, plantar fasciitis or heel 
spur, among others.4 The clinical diagnosis 
is usually established based on the patient’s 
history and physical examination, including 
pain during the first steps in the morning or 
after prolonged rest, as well as pain during 
prolonged standing or walking.2 3 5 The iden-
tification of the main cause of pain can be 
challenging as this is often multifactorial,6 
and despite its prevalence, the aetiology of 
PHP is not well understood.2 3 The presence 
of myofascial trigger points (MTrPs) within 
the muscles of the foot and lower leg may 
play an important role in people in PHP,7 an 
Strengths and limitations of this study
 ► This is the first randomised controlled trial compar-
ing the effectiveness of percutaneous needle elec-
trolysis with dry needling for plantar heel pain (PHP) 
provoked by myofascial trigger points (MTrPs), in-
volving a large sample and a long follow- up period.
 ► The assessor was blinded to group allocation for 
all assessments; however, neither the therapist nor 
the participants were blinded due to the difficulty of 
blinding investigators and participants when apply-
ing invasive treatment techniques.
 ► Due to the different potential causes of PHP, the re-
sults of this study are only valid if this is provoked 
by MTrPs.
 ► This is a single centre trial and results may not be 
generalisable.
 ► Due to the large number of drop- outs, our study had 
the limitation of being underpowered to report a dif-
ference between the two groups.
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implicit assumption underlying many recent studies.8–11 
In addition, there is a lack of consensus regarding the 
ideal management approach for PHP.12–14
Clinical practice guidelines support the use of conser-
vative treatment, such as joint and soft tissue mobilisation 
or self- stretching home programmes.2 3 In particular, 
self- stretching home programmes have shown to be 
effective for addressing PHP.2 6 15 Furthermore, recent 
randomised clinical trials (RCTs) have shown that there 
is an additional effect of reduction of pain severity when 
self- stretching home programmes are combined with isch-
aemic compression11 and with dry needling (DN).9 Phys-
ical therapy approaches continue to evolve and include 
the combination of DN and electrolysis, known as percu-
taneous needle electrolysis (PNE), with promising results 
for the treatment of tendon pathologies.16–18 The PNE 
technique is a minimally invasive treatment that consists 
of the application of a galvanic electrolytic current that 
causes a controlled local inflammatory process in the 
target tissue. This promotes phagocytosis and the subse-
quent regeneration of the affected tissue.16 17 Currently, 
PNE is being used in clinical practice to manage MTrPs; 
however, there are no studies supporting any additional 
beneficial effects of the same over DN.
From a biological point of view, it seems reasonable 
to hypothesise that subjects may display improvements 
thanks to the mechanical effects of the needle, and that 
patients may experience superior benefits when the 
electrolysis effect is added to the mechanical stimulus 
provided by the needle. Therefore, the aim of this RCT 
was to compare the effectiveness of DN versus PNE for 
improving the level of pain, function and quality of life 
(QoL) of patients suffering from PHP caused by MTrPs.
METHODS
Design
This study was a prospective, parallel- group RCT with 
blinded outcome assessment. Participants were recruited 
from Kuwait City, Kuwait, and both the assessment and 
intervention were conducted at the Physical Medicine and 
Rehabilitation Hospital in Kuwait. The study protocol has 
been previously published19 and the trial is registered at 
Clinicaltrials. com. This RCT was reported in accordance 
with the Consolidated Standards of Reporting Trials state-
ment for non- pharmacological trials.
Participants
The study subjects were men and women, enrolled at the 
Physical Therapy Department of the Physical Medicine 
and Rehabilitation Hospital in Kuwait City. Participants 
were included if they fulfilled the following criteria: (1) 
diagnosed of PHP in accordance with the Clinical Guide-
lines linked to the International Classification of Func-
tion, Disability and Health from the Orthopedic Section 
of the American Physical Therapy Association2 3 8 9; (2) 
aged 21–60 years at admission to the study, according to 
the Kuwaiti Ethical Committee; (3) a history of PHP for 
over 1 month, showing no improvements with previous 
conservative treatment; (4) the ability to walk 50 m 
without any support; (5) the presence of MTrPs on plantar 
and calf muscles based on an initial physical examination 
carried out by a physiotherapist (MA) with experience 
and training in MTrPs; (6) accepting treatment from a 
male physiotherapist; (7) the ability to understand the 
study and the informed consent, as well as having signed 
the consent form.
The exclusion criteria were: (1) needle phobia; (2) 
needle allergy or hypersensitivity to metals; (3) the pres-
ence of coagulopathy or use of anticoagulants according 
to medical criteria; (4) the presence of peripheral arte-
rial vascular disease; (5) pregnancy; (6) dermatological 
disease affecting the DN area; (7) the presence of any 
chronic medical condition which might preclude partici-
pation in the study, such as: malignancy, systemic inflam-
matory disorders (eg, rheumatoid arthritis, psoriatic 
arthritis, ankylosing spondylitis, septic arthritis), neuro-
logical diseases, polyneuropathy, mononeuropathy and 
sciatica; (8) treatment of PHP with needling or acupunc-
ture during the last 4 weeks; (9) history of injection 
therapy in the heel over the previous 3 months; and (10) 
history of foot surgery or fracture. Receiving or imple-
menting any form of treatment for the PHP (taping, 
night splints, massage therapy or footwear modifications) 
during the trial was considered withdrawal criteria.
The sample- size calculation initially estimated that 
39 participants per group would provide 80% power to 
detect a minimally important difference of 13 points in 
the pain domain of the Foot Health Status Questionnaire 
(FHSQ) with a SD of 20 points20 and an alpha risk at 0.05. 
Allowing for a 20% loss to follow- up, a minimum of 47 
participants was required in each group, equalling 94 
participants in total. Based on initial data collection, the 
drop- out rate was recalculated to be 25% and the sample 
size was therefore increased to a total of 102 patients.
Patient and public involvement
No patients were involved in the design, recruitment or 
conduction of this study and the burden of the interven-
tion was not assessed by patients themselves neither.
Randomisation
Participants who fulfilled the inclusion criteria received 
standardised oral and written information, and, 
after consenting to participate in the trial, they were 
randomised using block randomisation by blocks of 
10 patients. Allocation was randomly assigned using a 
computer program (Randomizer, https://www. random-
izer. org/) with random patient file number sequences 
generated by a third person not involved in the study.
Procedure and interventions
Two study groups were randomly formed. The first was 
treated with DN whereas the second group was treated 
with PNE. In both groups, during the first session, all 
participants were taught a self- stretching protocol11 which 
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has been demonstrated to be effective for the manage-
ment of PHP,2 6 11 consisting of self- stretching of the calf 
muscles and specific self- stretching for the plantar fascia.19 
The frequency of calf and plantar fascia- specific self- 
stretching exercises was two times a day, using intermit-
tent stretching lasting 20 s, followed by 20 s rest periods, 
for a total of 3 min per stretch.11 Compliance with the self- 
stretching protocol was registered before each treatment 
session and at the 4- week follow- up.
The muscles considered for invasive physical therapy 
treatment were the soleus, gastrocnemius, quadratus 
plantae, flexor digitorum brevis and abductor hallucis. 
These muscles typically refer pain to the heel and are 
muscles than can be directly palpated or that can be 
needled precisely and safely without ultrasound guid-
ance. The clinician performed a physical exam to find 
MTrPs following the criteria by Travell and Simons: (1) 
the presence of a taut band and (2) identification of an 
exquisite spot tenderness or a nodule.7 A flat palpation 
or pincer palpation technique was used to palpate the 
MTrPs, depending on the muscle being assessed. If a 
muscle contained more than one MTrP, the most sensitive 
MTrP was treated, according to the patient’s perceived 
pain on palpation. If the patient presented bilateral pain, 
the clinician treated both sides. The patient’s position 
(supine, prone or lateral decubitus position) depended 
on each muscle examined and was the same for the assess-
ment as well as for the intervention.
Each participant received four individual physical 
therapy sessions, once a week. Participants was treated by 
one physical therapist registered at the Kuwait Ministry 
of Health (ZA) with 5 years of practical experience in the 
field of DN and appropriate training in the protocol. The 
duration of each session was approximately 30 min.
Participants were instructed to use the appropriate 
dose of medication as prescribed by their Physical Medi-
cine and Rehabilitation physician (analgesics and non- 
steroidal anti- inflammatory medications) and were 
required to report any changes to the assessor during 
the evaluations if they took any additional medication or 
underwent any treatment during the intervention.
Invasive intervention groups: DN and PNE
Specific needles for DN were used during invasive treat-
ments (Agu- punt, Spain). Needle length was deter-
mined by the location of the MTrP and ranged from 30 
to 75 mm in length (or longer if necessary, according to 
the patients’ characteristics). The diameter of the needle 
was 0.25–0.30 mm. If the participant was sensitive to the 
needle insertion, the level of manipulation was reduced. 
If this measure proved insufficient for reducing the 
painful stimulus, needle manipulation ceased altogether 
and the needle was left in situ.21 22
To maintain appropriate hygienic conditions during 
the invasive treatments, the clinician wore latex gloves 
and thoroughly cleaned the skin of the area to be needled 
with an antiseptic solution (70% Propan-2- ol, Skin- des). 
On removal of the needle, the area was firmly compressed 
for 10 s. The needle was discarded after each single use. 
In both groups, the intervention was terminated in the 
case of severe adverse effects and if the participant did 
not wish to continue.
DN arm
Once the clinician located the MTrP, the needle was 
inserted over the same and a rapid needle entry was 
performed. The chosen technique for manipulating 
the needle was the technique described by Hong, which 
consists of a rapid needle entry and exit (fast in/fast 
out), in order to obtain a local twitch response, lasting 5 s 
employing a rhythmic movement at approximately 1 Hz/s 
(five entries).
PNE arm
The electrotherapy equipment used (Physio Invasiva, 
PRIM Fisioterapia, Spain) produced a continuous 
galvanic current through the cathode while the patient 
held a hand- held anode.18 Once the needle reached the 
relevant treatment area, this was needled in exactly the 
same manner as in the DN group, with the only differ-
ence being that the needle was transmitting an elec-
trical current with an intensity of 1.5 mA (intensity was 
adapted to patient’s characteristics according to their 
pain tolerance).
Study variables
An independent assessor (MA) blinded to treatment 
group allocation conducted all assessments at baseline, 
and at the 4, 8, 12, 26 and 52- week follow- up. Demo-
graphic and disease data were collected at baseline.
The primary outcome was the Foot Pain domain of 
the FHSQ, a validated measure of foot- health status23 
that has been used in similar trials, which evaluated the 
effectiveness of different interventions for PHP.8 24 25 Indi-
vidual item scores were inserted into a computer program 
(FHSQ V.1.03) which, after data transformation, provides 
a score ranging from 0 to 100 for each domain,26 with 
greater scores reflecting a better condition.27
Secondary outcomes were the Foot Function, Footwear 
and General Foot Health (GFH) domains of the FHSQ, 
as well as the average and maximum level of pain over 
the past 48 hours using the visual analogue scale (VAS). 
Participants were explained that a score of 0 indicated the 
absence of pain whereas a score of 10 represented the 
maximum tolerable pain. Additionally, before each treat-
ment session, they were asked to complete the VAS and 
after each treatment session, participants were asked to 
score their current pain immediately on standing up and 
walking a few steps. The VAS is widely used and is both 
valid and reliable.28–30
Quality of life (QoL) was assessed with the EQ- 5D- 5L, 
which was completed by the participants at baseline and 
at the 4, 8, 12, 26 and 52- week assessments. The EQ- 5D- 5L 
self- report questionnaire is a descriptive system with five 
questions, each representing one dimension of health- 
related QoL, that is, mobility, self- care, daily activities, 
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pain/discomfort and depression/anxiety. Each dimen-
sion can be rated on five levels: no problems, slight prob-
lems, moderate problems, severe problems and extreme 
problems. Together, the results serve to classify people 
into 1 of 3125 possible health states.31 These health states 
are subsequently transformed to QoL values with the 
EQ- 5D- 5L crosswalk value sets.32
Statistical analysis
The statistical analysis was performed using IBM SPSS 
Statistics (V.25, IBM) by intention to treat, with the 
last observation carried forward. The investigator who 
performed the analyses was masked to group allocation. 
The significance level for all statistical tests was set at 
p≤0.05.
χ2 tests were used to analyse if there were differences in 
categorical variables between groups at baseline. In addi-
tion, independent Student’s t- tests and Mann- Whitney U 
tests were used for parametric and non- parametric quan-
titative variables, respectively. χ2 tests were used to eval-
uate the compliance of the self- stretching protocol.
Following recommendations to estimate treatment 
effects in RCTs, linear mixed models adjusted for base-
line values were used to test the mean effect of treatment 
interventions at the follow- up at the 4, 8, 12, 26 and 
52 weeks, for the FHSQ and EQ- 5D- 5L measures. Linear 
mixed models adjusted for baseline values were used to 
test the mean effect of treatment interventions at the 
second session, third session, fourth session, and at the 
4, 8, 12, 26 and 52- week follow- ups, for measures of VAS 
(average and maximum). Individual repeated measures 
(RM) ANOVAs were used to test time effects within each 
treatment group for primary and secondary outcomes. 
Cross- sectionally, at all linear mixed models and RM- A-
NOVAs, the Bonferroni correction was used to test 
between- group time point differences or within- group 
time changes, respectively. The Greenhouse- Geisser 
correction was applied for correcting against violations of 
sphericity, whereas eta- squared (η²) was used to estimate 
the magnitude of the difference between both groups 
(0.01 small effect, 0.06 medium effect and 0.14 large 
effect).33 Independent t- tests were used to determine any 
difference between groups for measures of level of pain 
immediately after each treatment session.
RESULTS
Recruitment commenced in January 2018 and was 
completed by October 2018. One hundred and eighteen 
potential participants were screened for inclusion and 102 
participants were enrolled and randomly allocated to each 
of the treatment interventions. In total, 79 participants 
(78%) completed the four treatment sessions and were 
assessed at 4 weeks, 78 participants (77%) completed the 
8- week follow- up, 76 (75%) participants completed the 
12- week follow- up, 75 (74%) participants completed the 
26- week follow- up and 68 (67%) participants completed 
the 52- week follow- up (figure 1). The mean time between 
each treatment session was 7.0 days (SD 1.1) for the DN 
group and 6.9 days (SD 1.2) for the PNE group.
The mean age of participants was 48.8 years (SD 8.8; 
range 24–60) and 71% were women. The mean duration 
of PHP was 7.9 months (SD 9.3; range 1–36). Both groups 
were similar for all baseline variables except for the 
consumption of medication for hypercholesterolaemia 
(p=0.012) (table 1).
There were two small haematomas in the PNE group 
and one in the DN group. No serious adverse events were 
reported. All withdrawals during the treatment period 
were due to an inability to withstand the pain related to 
needle insertion and stimulation of MTrPs. Nine with-
drawals were registered during the follow- up, as these 
participants received other treatments during the study 
period (non- compliance of receiving other treatment).
The frequencies of protocol compliance with self- 
stretching did not differ between groups (χ2(4)=1.13, 
p=0.890) (table 2).
Regarding the primary outcome measure, there was no 
group×time interaction for Foot Pain, although individual 
RM- ANOVA showed a significant effect of time in both 
groups, with lower scores at baseline than at follow- up for 
all time points in the DN group (p<0.001; 29.7 (17.8 to 
41.5)) and the PNE group (p<0.001; 32.7 (18.3 to 47.0)) 
(table 3).
Figure 1 Participant flow chart. DN, dry needling; PNE, 
percutaneous needle electrolysis.
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Individual RM- ANOVAs also showed a significant effect 
of time in both groups for Foot Function (DN: p<0.001; 
PNE: p<0.001), Footwear (DN: p=0.031; PNE: p<0.001), 
GFH (DN: p<0.001; PNE: p<0.001), EQ- 5D- 5L (DN: 
p=0.002; PNE: p=0.002), VAS- average (DN: p<0.001; 
PNE: p<0.001) and VAS- maximum (DN: p<0.001; PNE: 
p<0.001) (table 3).
Regarding the different timelines for the secondary 
outcome measurements, Foot Function improved in 
the PNE group at 8 weeks (p=0.002; 20.3 (5.1 to 35.5)) 
and at 52 weeks (p=0.001; 22.5 (6.6 to 38.4)), although 
without differences between groups. Footwear scores also 
had a significant improvement at 52 weeks in the PNE 
group (p<0.001; 23.5 (8.9 to 38.1)), without differences 
between groups. Regarding the QoL, there was a signif-
icant improvement at 8 weeks (p=0.035; 0.07 (0.01 to 
0.13)) and 52 weeks (p=0.003; 0.10 (0.02 to 0.18)) in the 
PNE group, with differences between groups in favour of 
the PNE group only at 52 weeks (p=0.032; 0.10 (0.01 to 
0.18)) (table 3).
Regarding pain, the DN intervention provided a 
benefit over PNE for VAS average (p=0.009; −1.36 (−2.37 
to 0.35)) and VAS maximum (p=0.043; −1.28 (−2.53 to 
−0.04)) at 4 weeks (table 4).
Table 5 shows the most frequently treated muscles. The 
level of pain just after each treatment session according 
to the VAS did not differ between groups (table 6).
DISCUSSION
Important clinical improvements were observed in both 
groups20 for the Foot Pain and GFH domains of the 
FHSQ at all time points. However, Foot Function and QoL 
did not follow the same pattern as the aforementioned 
domains. Thus, clinically significant improvements were 
observed at 4 weeks in both groups; however, at 8 weeks 
and 52 weeks, improvements were only observed in 
the PNE group. Furthermore, at 52 weeks, differences 
between groups were only found for QoL. These findings 
suggest a trend in the group receiving PNE, producing 
longer lasting effects regarding Foot Function and QoL 
compared with DN. Although there were statistically 
significant differences in QoL, there is no consensus of 
what the minimum clinically important difference is, 
which ranges from 0.03 to 0.5434
Table 1 Baseline characteristics of participants by 
intervention group
DN (n=51) PNE (n=51)
Age, years 49.5 (8.9) 48.1 (8.8)
Sex, n (%), male 15 (29.4) 15 (29.4)
Height, cm 160.5 (8.2) 161.2 (7.9)
Weight, kg 87.5 (16.5) 90.8 (15.2)
BMI, kg/m2 33.9 (5.5) 35.1 (6.4)
Duration of symptoms, months 6.0 (6.0) 9.9 (11.5)
Affected side, n (%)
  Right 14 (27.5) 16 (31.4)
  Left 13 (25.5) 20 (39.2)
  Bilateral 24 (47.1) 15 (29.4)
  Non- medicated, n (%) 11 (21.6) 15 (29.4)
Medications, n yes (%)
  Neuromodulators/antiepileptic 18 (35.3) 22 (43.1)
  Painkillers 16 (31.4) 16 (31.4)
  Anti- inflammatory medication 16 (31.4) 17 (33.3)
  Myorelaxant medication 9 (17.6) 8 (15.7)
Systemic medications, n yes (%)
  Hypercholesterolaemia 
medication
12 (23.5) 3 (5.9)
  Hypertension medication 14 (27.5) 8 (15.7)
  Diabetes mellitus medication 14 (27.5) 10 (19.6)
  Osteoarthrosis medication 3 (5.9) 4 (7.8)
  Lung disease medication 3 (5.9) 3 (5.9)
  Hormonal therapy 5 (9.8) 7 (13.7)
  Antidepressant medication 1 (2.0) 0 (0.0)
  Diet supplements 8 (15.7) 13 (25.5)
Previous treatments, yes (%)
  Corticosteroid injections 4 (7.8) 10 (19.6)
  ESWT 9 (17.6) 9 (17.6)
  Exercise 4 (7.8) 6 (11.8)
  Pain, FHSQ (100–0) 38.8 (18.8) 40.4 (21.9)
  Function, FHSQ (100–0) 57.2 (34.9) 55.5 (36.3)
  Shoe, FHSQ (100–0) 30.7 (35.3) 32.4 (35.9)
  GFH, FHSQ (100–0) 14.3 (18.2) 19.2 (23.7)
  VAS mean (0–10) 6.0 (2.3) 5.9 (2.4)
  VAS maximum (0–10) 7.6 (2.0) 7.5 (2.3)
Values are expressed in mean (SD) unless stated.
*P<0.05, significant differences between groups.
BMI, body mass index; DN, dry needling; ESWT, extracorporeal 
shock- wave therapy; FHSQ, Foot Health Status Questionnaire 
(0 corresponds to the worst foot health; 100, the best); GFH, 
General Foot Health; PNE, percutaneous needle electrolysis; 
VAS, visual analogue scale (0 corresponds to absence of pain; 
10, maximum tolerable pain).
Table 2 Frequencies of compliance with self- stretching 
protocol achieved in the DN and PNE groups
DN PNE
Four full weeks complied 11 (22%) 10 (20%)
Three full weeks complied 6 (12%) 4 (8%)
Two full weeks complied 6 (12%) 9 (18%)
One full week complied 9 (18%) 10 (20%)
Any full week complied 19 (37%) 18 (35%)
Values represent the number of participants (relative frequencies) 
for each compliance category of the 4 weeks self- stretching 
protocol.
DN, dry needling; PNE, percutaneous needle electrolysis.
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Table 3 Mean scores, mean change within group and mean difference between groups for FHSQ and EQ- 5D- 5L at baseline, 
week 4, week 8, week 12, week 26 and week 52
Variable DN mean (SD)














Foot Pain, FHSQ (100–0)
  Baseline 38.8 (18.8) 40.4 (21.9)
  Week 4 73.4 (27.7)‡ 34.6 (21.7 to 47.5) 71.9 (25.7)‡ 31.5 (18.7 to 44.2) −2.0 (−12.2 to 8.3) 0.707 (0.001)
  Week 8 70.1 (28.4)‡ 31.4 (17.5 to 45.3) 67.4 (26.8)‡ 27.0 (13.9 to 40.1) −3.1 (−13.8 to 7.6) 0.567 (0.003)
  Week 12 66.8 (24.8)‡ 28.1 (16.2 to 39.9) 63.6 (26.1)‡ 23.1 (10.6 to 35.6) −3.8 (−13.6 to 5.9) 0.437 (0.006)
  Week 26 68.8 (25.3)‡ 30.0 (18.1 to 42.0) 67.1 (27.1)‡ 26.7 (12.0 to 41.3) −2.0 (−12.3 to 8.3) 0.700 (0.002)
  Week 52 68.4 (25.1)‡ 29.7 (17.8 to 41.5) 73.1 (29.0)‡ 32.7 (18.3 to 47.0) 4.3 (−6.3 to 14.8) 0.424 (0.006)
  Main effect of 
time; p value
<0.001 <0.001   
Foot Function, FHSQ (100–0)
  Baseline 57.2 (34.9) 55.5 (36.3)
  Week 4 79.4 (31.2)‡ 22.2 (6.5 to 37.9) 71.7 (32.4)‡ 16,2 (0,5 to 31,8) −7.1 (−18.4 to 4.3) 0.220 (0.015)
  Week 8 72.7 (30.1) 15.4 (−1.3 to 32.2) 75.9 (29.7)‡ 20.3 (5.1 to 35.5) 3.7 (−7.5 to 14.7) 0.502 (0.005)
  Week 12 65.7 (31.7) 8.5 (−8.6 to 25.5) 71.1 (29.8) 15.6 (−0.7 to 31.8) 5.9 (−5.6 to 17.3) 0.311 (0.010)
  Week 26 70.2 (29.6) 13.0 (−4.5 to 30.4) 70.7 (28.8) 15.2 (−0.9 to 31.3) 0.9 (−10.1 to 11.9) 0.871 (0.001)
  Week 52 69.8 (29.6) 12.6 (−4.9 to 30.1) 78.0 (30.2)‡ 22.5 (6.6 to 38.4) 8.6 (−2.6 to 19.9) 0.132 (0.023)
  Main effect of 
time; p value
<0.001 <0.001   
Footwear, FHSQ (100–0)
  Baseline 30.7 (35.3) 32.4 (35.9)
  Week 4 35.0 (35.9) 4.2 (−10.5 to 19.0) 30.2 (33.9) −2.1 (−16.1 to 11.9) −5.6 (−17.1 to 5.9) 0.333 (0.009)
  Week 8 37.6 (34.2) 6.9 (−7.3 to 21.0) 30.1 (35.4) −2.3 (−18.9 to 14.3) −8.3 (−20.3 to 3.7) 0.174 (0.019)
  Week 12 41.0 (32.1) 10.3 (−3.7 to 24.3) 35.8 (35.9) 3.4 (−13.0 to 19.9) −6.0 (−17.8 to 5.8) 0.316 (0.010)
  Week 26 43.3 (32.7) 12.6 (−1.9 to 27.0) 39.0 (35.8) 6.7 (−9.1 to 22.5) −5.0 (−16.8 to 6.7) 0.397 (0.007)
  Week 52 44.2 (31.3) 13.4 (−1.6 to 28.5) 55.9 (35.7)‡ 23.5 (8.9 to 38.1) 10.9 (−0.5 to 22.3) 0.061 (0.035)
  Main effect of 
time; p value
0.015 <0.001   
GFH, FHSQ (100–0)
  Baseline 14.3 (18.2) 19.2 (23.7)
  Week 4 59.9 (34.4)‡ 45.5 (30.4 to 60.7) 53.3 (37.0)‡ 34.1 (19.4 to 48.9) −9.4 (−22.7 to 3.9) 0.165 (0.019)
  Week 8 54.6 (34.4)‡ 40.2 (25.4 to 55.1) 51.6 (35.2)‡ 32.4 (16.5 to 48.2) −5.2 (−18.5 to 8.2) 0.445 (0.006)
  Week 12 49.5 (33.5)‡ 35.1 (21.3 to 49.0) 53.6 (34.4)‡ 34.4 (20.1 to 48.6) 1.1 (−11.4 to 13.6) 0.860 (0.001)
  Week 26 54.7 (34.3)‡ 40.4 (26.0 to 54.8) 58.7 (34.9)‡ 39.5 (23.3 to 55.6) 1.8 (−11.4 to 15.1) 0.785 (0.001)
  Week 52 54.7 (34.3)‡ 40.4 (26.0 to 54.8) 66.4 (38.6)‡ 47.2 (30.1 to 64.2) 9.2 (−4.7 to 23.2) 0.190 (0.017)
  Main effect of 
time; p value
<0.001 <0.001   
EQ- 5D- 5L (1–0)
  Baseline 0.63 (0.23) 0.67 (0.22)
  Week 4 0.78 (0.22)‡ 0.15 (0.05 to 0.25) 0.76 (0.24)‡ 0.09 (0.01 to 0.17) −0.04 (−0.12 to 0.03) 0.265 (0.013)
  Week 8 0.72 (0.23) 0.09 (−0.03 to 0.21) 0.74 (0.23)‡ 0.07 (0.01 to 0.13) −0.01 (−0.08 to 0.07) 0.889 (0.001)
  Week 12 0.64 (0.30) 0.02 (−0.11 to 0.15) 0.70 (0.26) 0.03 (−0.05 to 0.11) 0.03 (−0.07 to 0.12) 0.587 (0.003)
  Week 26 0.65 (0.29) 0.02 (−0.10 to 0.14) 0.73 (0.27) 0.06 (−0.03 to 0.14) 0.05 (−0.04 to 0.14) 0.276 (0.012)
  Week 52 0.66 (0.27) 0.02 (−0.10 to 0.14) 0.77 (0.25)‡ 0.10 (0.02 to 0.18) 0.10 (0.01 to 0.18) 0.032 (0.045)§
  Main effect of 
time; p value
0.002 0.002   
Continued
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Variable DN mean (SD)














Positive between group differences represent greater change (improvement) in the PNE group compared with the DN group.
*P value after Bonferroni’s correction between group.
†Eta- squared (η²); between groups effect size.
‡P<0.05 after Bonferroni’s correction comparing follow- up against baseline scores within group.
§P<0.05, significant differences between groups.
DN, dry needling; EQ- 5D- 5L, 0 corresponds to the worst quality of life; 1, the best; FHSQ, Foot Health Status Questionnaire (0 corresponds to the 
worst foot health; 100, the best); GFH, General Foot Health; PNE, percutaneous needle electrolysis.
Table 3 Continued
Table 4 Mean scores, mean change within group and mean difference between groups for VAS at baseline/1st session, 2nd 



















  Baseline/1st 
session
6.0 (2.3) 5.9 (2.4)
  2nd session 4.6 (2.2)‡ −1.4 (−2.5 to −0.3) 4.4 (2.7)‡ −1.5 (−2.5 to −0.5) 0.14 (−0.64 to 0.92) 0.725 (0.001)
  3rd session 4.0 (2.4)‡ −2.0 (−3.3 to −0.7) 4.1 (2.8)‡ −1.8 (−3.1 to −0.5) 0.16 (−1.11 to 0.79) 0.743 (0.001)
  4th session 3.5 (2.5)‡ −2.6 (−3.9 to −1.2) 3.4 (2.7)‡ −2.5 (−3.8 to −1.1) 0.01 (−0.95 to 0.97) 0.984 (0.001)
  Week 4 2.6 (2.5)‡ −3.5 (−4.9 to −2.0) 3.8 (3.0)‡ −2.0 (−3.2 to −0.8) −1.36 (−2.37 to 0.35) 0.009 (0.067)§
  Week 8 3.3 (2.8)‡ −2.7 (−4.2 to −1.2) 3.8 (2.7)‡ −2.1 (−3.4 to −0.8) −0.54 (−1.57 to 0.49) 0.298 (0.011)
  Week 12 3.3 (2.7)‡ −2.7 (−4.2 to −1.2) 3.7 (2.8)‡ −2.1 (−3.6 to −0.7) −0.46 (−1.51 to 0.58) 0.381 (0.008
  Week 26 3.4 (2.8)‡ −2.6 (−4.0 to −1.2) 3.4 (2.7)‡ −2.5 (−3.8 to −1.1) −0.06 (−0.97 to 1.09) 0.911 (0.001)
  Week 52 3.4 (2.8)‡ −2.6 (−4.0 to −1.2) 2.8 (3.0)‡ −3.0 (−4.5 to −1.6) 0.508 (−0.57 to 1.58) 0.351 (0.009)




  Baseline/1st 
session
7.6 (2.0) 7.5 (2.3)
  2nd session 6.2 (2.3)‡ −1.3 (−2.3 to −0.3) 5.5 (2.9)‡ −2.0 (−3.0 to −0.9) 0.66 (−0.18 to 1.50) 0.122 (0.024)
  3rd session 5.4 (2.6)‡ −2.2 (−3.6 to −0.8) 5.3 (3.1)‡ −2.2 (−3.6 to −0.8) 0.05 (−1.03 to 1.13) 0.926 (0.001)
  4th session 4.9 (2.9)‡ −2.7 (−4.1 to −1.3) 4.5 (3.0)‡ −3.0 (−4.4 to −1.6) 0.31 (−0.76 to 1.39) 0.563 (0.003)
  Week 4 3.6 (3.2)‡ −3.9 (−5.5 to −2.3) 4.9 (3.5)‡ −2.6 (−4.1 to −1.1) −1.28 (−2.53 to −0.04) 0.043 (0.041)§
  Week 8 4.7 (3.4)‡ −2.8 (−4.5 to −1.2) 5.0 (3.1)‡ −2.5 (−3.8 to −1.2) −0.32 (−1.50 to 0.87) 0.599 (0.003)
  Week 12 4.7 (3.3)‡ −2.9 (−4.5 to −1.3) 5.1 (3.1)‡ −2.4 (−3.9 to −1.0) −0.42 (−1.63 to 0.78) 0.487 (0.005)
  Week 26 4.5 (3.2)‡ −3.0 (−4.6 to −1.4) 4.6 (3.1)‡ −2.9 (−4.5 to −1.2) −0.13 (−1.34 to 1.09) 0.838 (0.001)
  Week 52 4.5 (3.2)‡ −3.0 (−4.6 to −1.4) 4.1 (3.4)‡ −3.4 (−5.1 to −1.8) 0.45 (−0.80 to 1.70) 0.480 (0.005)
  Main effect of 
time; p value
<0.001 <0.001
Positive between group differences represent greater change (improvement) in the PNE group compared with the DN group.
*P value after Bonferroni’s correction between group.
†Eta- squared (η²); between groups effect size.
‡P<0.05 after Bonferroni’s correction comparing follow- up against baseline scores within group.
§P<0.05, significant differences between groups.
DN, dry needling; PNE, percutaneous needle electrolysis; VAS, visual analogue scale (0 corresponds to absence of pain; 10, maximum 
tolerable pain).;
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Patients allocated to both groups also had clinically 
important improvements in their mean and maximum 
level of pain since week 1 and during the 52 weeks of 
follow- up.35 There were differences between groups after 
4 weeks of treatment in favour of the DN group; however, 
this difference was not maintained over the time. Both 
groups had similar results to those reported by Cotchett et 
al8 at 4 weeks. However, at 12 weeks, although significant 
improvements were found in both groups, these findings 
differed from the aforementioned study, which we believe 
may be due to a higher number of drop- outs.
Clinical implications
Clinical implications may vary as it is possible that this 
study was underpowered. The sample size necessary to 
avoid this was a total of 78 patients at the end of the study, 
therefore, once we realised that the drop- out rate was 
higher than initially estimated, we increased the recruited 
patients from 94 (considering a 20% of drop- outs) to 102 
(considering a 25% of drop- outs). Despite this, in week 
12 and the following weeks, the number of patients were 
lower than the necessary to avoid underpowering, which 
could result in not detecting the treatment effect in week 
12 or later. For this reason, we carried out a per- protocol 
analysis and compared the results with the intention to 
treat analysis, which was more conservative, revealing 
similar results for both analyses. In addition, we analysed 
whether there were any results in week 8 that were not 
maintained, which was observed in Foot Function and 
QoL, revealing significant improvements at week 8 and 
week 52 for the percutaneous electrolysis group. Although 
it is speculative, either underpowering or the intention to 
treat analysis may explain the inconsistency of the results 
in the percutaneous electrolysis group, possibly leading 
to significant results in weeks 12 and 26.
From a clinical point of view, both groups reported 
similar levels of pain after the treatment, therefore, both 
treatment options should be considered to be equal in 
terms of pain tolerance or sensitisation after treatment. 
Apart from the minimal clinically important difference, 
it is also important to consider the patient acceptable 
symptomatic state (PASS) which provides the basis for 
determining whether the treatment enabled patients to 
achieve a satisfactory state and which may be a clinically 
relevant treatment target. In our study, we found that in 
both groups the average pain, measured using the VAS 
was 5 below points since the first session, which fulfils 
the PASS values determined in populations with similar 
sociocultural characteristics,36 despite the fact that this 
value was found to be unexpectedly high (50 mm) when 
compared with other populations.
The 118 initially selected patients presented MTrPs on 
plantar and calf muscles, as this was part of our inclu-
sion criteria, meaning that MTrPs could be directly or 
indirectly contributing to PHP. However, we were unable 
to find any previous study on the prevalence of MTrPs 
in patients with PHP. Therefore, future studies should 
consider following this line of research.
Strengths and limitations
This study presents several strengths and limitations. One 
of the strengths is that this is the first RCT to analyse 
the effectiveness of PNE and to compare it with DN for 
PHP caused by MTrPs, with a large sample size and a 
long follow- up. Several limitations should be noted. First, 
other sources of pain were not considered, as the study 
was designed to analyse the contribution of MTrPs in PHP. 
Furthermore, we did not measure the number of local 
twitch responses, which is a controversial factor, poten-
tially affecting the treatment effectiveness of MTrPs.37 
Besides, 23 patients (22.5%) dropped out of the study 
during the intervention as they were unable to tolerate 
pain, which is a higher drop- out rate compared with 
other studies.8 38–40 After the intervention period, drop- 
outs increased progressively to 24 at 8 weeks (23.5%), 
26 at 12 weeks (25.5%), 27 at 26 weeks (26.5%) and 34 
at 52 weeks (33.3%) of follow- up, which is similar to the 
study published by Taşoğlu et al,40 with 27.7% of drop- outs 
at 12 weeks. However, these rates differ with other previ-
ously mentioned studies.8 38 39 These differences may be 
due to the cultural behaviours towards pain in the region, 
which constitutes a limitation and an important chal-
lenge that must be addressed by clinicians. It is important 
to note that both treatments were safe with minimal side 
effects, such as haematoma or bruising, which is in line 
with other published studies revealing a low incidence of 
adverse effects.41
Table 5 Localisation and frequency of myofascial trigger 




Quadratus plantae 122 105
Flexor digitorum brevis 106 92
Abductor hallucis 102 93
Values represent the number of myofascial trigger points needled 
per muscle over the course of the study.
DN, dry needling; PNE, percutaneous needle electrolysis.







1st session 3.1 (2.9) 3.5 (2.6) 0.459
2nd session 3.1 (2.8) 3.1 (2.6) 0.968
3rd session 2.9 (2.6) 3.3 (3.2) 0.419
4th session 2.2 (2.7) 2.4 (2.6) 0.792
*P value after independent t- test.
DN, dry needling; PNE, percutaneous needle electrolysis; VAS, 
visual analogue scale (0 corresponds to absence of pain; 10, 
maximum tolerable pain).
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CONCLUSIONS
Both PNE and DN were effective for PHP management, 
with long lasting effects (52 weeks) for Foot Pain and 
the GFH scores, without differences between groups. 
Besides, both treatments were found to be effective for 
reducing mean and maximum pain since the first treat-
ment session, with differences between groups in favour 
of DN group at 4 weeks only.
Although Foot Function and QoL also improved at 
4 weeks for both intervention groups, the PNE group 
showed improvements at 8 weeks and 52 weeks, with 
significant differences between groups in the case of QoL 
at 52 weeks.
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